<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Neuraminidase inhibitors for preventing and treating influenza in adults and children - Jefferson, T - 2014 | Cochrane Library</title> <meta content="Neuraminidase inhibitors for preventing and treating influenza in adults and children - Jefferson, T - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Neuraminidase inhibitors for preventing and treating influenza in adults and children - Jefferson, T - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008965.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Neuraminidase inhibitors for preventing and treating influenza in adults and children" name="citation_title"/> <meta content="Tom Jefferson" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="jefferson.tom@gmail.com" name="citation_author_email"/> <meta content="Mark A Jones" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Peter Doshi" name="citation_author"/> <meta content="University of Maryland School of Pharmacy" name="citation_author_institution"/> <meta content="Chris B Del Mar" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Rokuro Hama" name="citation_author"/> <meta content="Japan Institute of Pharmacovigilance" name="citation_author_institution"/> <meta content="Matthew J Thompson" name="citation_author"/> <meta content="University of Washington" name="citation_author_institution"/> <meta content="Elizabeth A Spencer" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Igho J Onakpoya" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Kamal R Mahtani" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="David Nunan" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Jeremy Howick" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Carl J Heneghan" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD008965.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/04/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiviral Agents [adverse effects, *therapeutic use]; Drug Evaluation; Enzyme Inhibitors [adverse effects, *therapeutic use]; Europe; Health Status; Influenza, Human [*drug therapy, *prevention &amp; control]; Japan; Legislation, Drug; Neuraminidase [*antagonists &amp; inhibitors]; Oseltamivir [adverse effects, *therapeutic use]; Pneumonia [prevention &amp; control]; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008965.pub4&amp;doi=10.1002/14651858.CD008965.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008965\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008965\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ru","pt","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008965.pub4",title:"Neuraminidase inhibitors for preventing and treating influenza in adults and children",firstPublishedDate:"Apr 10, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008965.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008965.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008965.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008965.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008965.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008965.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008965.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008965.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008965.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008965.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>42619 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008965.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0133"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0043"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0054"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0055"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0086"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/appendices#CD008965-sec-0138"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/table_n/CD008965StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/table_n/CD008965StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Neuraminidase inhibitors for preventing and treating influenza in adults and children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Tom Jefferson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0003">Mark A Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0004">Peter Doshi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0005">Chris B Del Mar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0006">Rokuro Hama</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0007">Matthew J Thompson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0008">Elizabeth A Spencer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0009">Igho J Onakpoya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0010">Kamal R Mahtani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0011">David Nunan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0012">Jeremy Howick</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information#CD008965-cr-0013">Carl J Heneghan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information/en#CD008965-sec-0214">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 April 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008965.pub4">https://doi.org/10.1002/14651858.CD008965.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008965-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008965-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008965-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008965-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008965-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008965-abs-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008965-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008965-abs-0001" lang="en"> <section id="CD008965-sec-0001"> <h3 class="title" id="CD008965-sec-0001">Background</h3> <p>Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide. </p> </section> <section id="CD008965-sec-0002"> <h3 class="title" id="CD008965-sec-0002">Objectives</h3> <p>To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all clinical study reports of published and unpublished randomised, placebo‐controlled trials and regulatory comments. </p> </section> <section id="CD008965-sec-0003"> <h3 class="title" id="CD008965-sec-0003">Search methods</h3> <p>We searched trial registries, electronic databases (to 22 July 2013) and regulatory archives, and corresponded with manufacturers to identify all trials. We also requested clinical study reports. We focused on the primary data sources of manufacturers but we checked that there were no published randomised controlled trials (RCTs) from non‐manufacturer sources by running electronic searches in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE (Ovid), EMBASE, Embase.com, PubMed (not MEDLINE), the Database of Reviews of Effects, the NHS Economic Evaluation Database and the Health Economic Evaluations Database. </p> </section> <section id="CD008965-sec-0004"> <h3 class="title" id="CD008965-sec-0004">Selection criteria</h3> <p>Randomised, placebo‐controlled trials on adults and children with confirmed or suspected exposure to naturally occurring influenza. </p> </section> <section id="CD008965-sec-0005"> <h3 class="title" id="CD008965-sec-0005">Data collection and analysis</h3> <p>We extracted clinical study reports and assessed risk of bias using purpose‐built instruments. We analysed the effects of zanamivir and oseltamivir on time to first alleviation of symptoms, influenza outcomes, complications, hospitalisations and adverse events in the intention‐to‐treat (ITT) population. All trials were sponsored by the manufacturers. </p> </section> <section id="CD008965-sec-0006"> <h3 class="title" id="CD008965-sec-0006">Main results</h3> <p>We obtained 107 clinical study reports from the European Medicines Agency (EMA), GlaxoSmithKline and Roche. We accessed comments by the US Food and Drug Administration (FDA), EMA and Japanese regulator. We included 53 trials in Stage 1 (a judgement of appropriate study design) and 46 in Stage 2 (formal analysis), including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628 participants). Inadequate reporting put most of the zanamivir studies and half of the oseltamivir studies at a high risk of selection bias. There were inadequate measures in place to protect 11 studies of oseltamivir from performance bias due to non‐identical presentation of placebo. Attrition bias was high across the oseltamivir studies and there was also evidence of selective reporting for both the zanamivir and oseltamivir studies. The placebo interventions in both sets of trials may have contained active substances. </p> <p><b>Time to first symptom alleviation</b>. For the treatment of adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval (CI) 8.4 to 25.1 hours, P &lt; 0.0001). This represents a reduction in the time to first alleviation of symptoms from 7 to 6.3 days. There was no effect in asthmatic children, but in otherwise healthy children there was (reduction by a mean difference of 29 hours, 95% CI 12 to 47 hours, P = 0.001). Zanamivir reduced the time to first alleviation of symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days, P &lt; 0.00001), equating to a reduction in the mean duration of symptoms from 6.6 to 6.0 days. The effect in children was not significant. In subgroup analysis we found no evidence of a difference in treatment effect for zanamivir on time to first alleviation of symptoms in adults in the influenza‐infected and non‐influenza‐infected subgroups (P = 0.53). </p> <p><b>Hospitalisations</b>. Treatment of adults with oseltamivir had no significant effect on hospitalisations: risk difference (RD) 0.15% (95% CI ‐0.78 to 0.91). There was also no significant effect in children or in prophylaxis. Zanamivir hospitalisation data were unreported. </p> <p><b>Serious influenza complications or those leading to study withdrawal</b>. In adult treatment trials, oseltamivir did not significantly reduce those complications classified as serious or those which led to study withdrawal (RD 0.07%, 95% CI ‐0.78 to 0.44), nor in child treatment trials; neither did zanamivir in the treatment of adults or in prophylaxis. There were insufficient events to compare this outcome for oseltamivir in prophylaxis or zanamivir in the treatment of children. </p> <p><b>Pneumonia</b>. Oseltamivir significantly reduced self reported, investigator‐mediated, unverified pneumonia (RD 1.00%, 95% CI 0.22 to 1.49); number needed to treat to benefit (NNTB) = 100 (95% CI 67 to 451) in the treated population. The effect was not significant in the five trials that used a more detailed diagnostic form for pneumonia. There were no definitions of pneumonia (or other complications) in any trial. No oseltamivir treatment studies reported effects on radiologically confirmed pneumonia. There was no significant effect on unverified pneumonia in children. There was no significant effect of zanamivir on either self reported or radiologically confirmed pneumonia. In prophylaxis, zanamivir significantly reduced the risk of self reported, investigator‐mediated, unverified pneumonia in adults (RD 0.32%, 95% CI 0.09 to 0.41); NNTB = 311 (95% CI 244 to 1086), but not oseltamivir. </p> <p><b>Bronchitis, sinusitis and otitis media</b>. Zanamivir significantly reduced the risk of bronchitis in adult treatment trials (RD 1.80%, 95% CI 0.65 to 2.80); NNTB = 56 (36 to 155), but not oseltamivir. Neither NI significantly reduced the risk of otitis media and sinusitis in both adults and children. </p> <p><b>Harms of treatment</b>. Oseltamivir in the treatment of adults increased the risk of nausea (RD 3.66%, 95% CI 0.90 to 7.39); number needed to treat to harm (NNTH) = 28 (95% CI 14 to 112) and vomiting (RD 4.56%, 95% CI 2.39 to 7.58); NNTH = 22 (14 to 42). The proportion of participants with four‐fold increases in antibody titre was significantly lower in the treated group compared to the control group (RR 0.92, 95% CI 0.86 to 0.97, I<sup>2</sup> statistic = 0%) (5% absolute difference between arms). Oseltamivir significantly decreased the risk of diarrhoea (RD 2.33%, 95% CI 0.14 to 3.81); NNTB = 43 (95% CI 27 to 709) and cardiac events (RD 0.68%, 95% CI 0.04 to 1.0); NNTB = 148 (101 to 2509) compared to placebo during the on‐treatment period. There was a dose‐response effect on psychiatric events in the two oseltamivir "pivotal" treatment trials, WV15670 and WV15671, at 150 mg (standard dose) and 300 mg daily (high dose) (P = 0.038). In the treatment of children, oseltamivir induced vomiting (RD 5.34%, 95% CI 1.75 to 10.29); NNTH = 19 (95% CI 10 to 57). There was a significantly lower proportion of children on oseltamivir with a four‐fold increase in antibodies (RR 0.90, 95% CI 0.80 to 1.00, I<sup>2</sup> = 0%). </p> <p><b>Prophylaxis</b>. In prophylaxis trials, oseltamivir and zanamivir reduced the risk of symptomatic influenza in individuals (oseltamivir: RD 3.05% (95% CI 1.83 to 3.88); NNTB = 33 (26 to 55); zanamivir: RD 1.98% (95% CI 0.98 to 2.54); NNTB = 51 (40 to 103)) and in households (oseltamivir: RD 13.6% (95% CI 9.52 to 15.47); NNTB = 7 (6 to 11); zanamivir: RD 14.84% (95% CI 12.18 to 16.55); NNTB = 7 (7 to 9)). There was no significant effect on asymptomatic influenza (oseltamivir: RR 1.14 (95% CI 0.39 to 3.33); zanamivir: RR 0.97 (95% CI 0.76 to 1.24)). Non‐influenza, influenza‐like illness could not be assessed due to data not being fully reported. In oseltamivir prophylaxis studies, psychiatric adverse events were increased in the combined on‐ and off‐treatment periods (RD 1.06%, 95% CI 0.07 to 2.76); NNTH = 94 (95% CI 36 to 1538) in the study treatment population. Oseltamivir increased the risk of headaches whilst on treatment (RD 3.15%, 95% CI 0.88 to 5.78); NNTH = 32 (95% CI 18 to 115), renal events whilst on treatment (RD 0.67%, 95% CI ‐2.93 to 0.01); NNTH = 150 (NNTH 35 to NNTB &gt; 1000) and nausea whilst on treatment (RD 4.15%, 95% CI 0.86 to 9.51); NNTH = 25 (95% CI 11 to 116). </p> </section> <section id="CD008965-sec-0007"> <h3 class="title" id="CD008965-sec-0007">Authors' conclusions</h3> <p>Oseltamivir and zanamivir have small, non‐specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children. Using either drug as prophylaxis reduces the risk of developing symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question of whether the complications of influenza (such as pneumonia) are reduced, because of a lack of diagnostic definitions. The use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children. The lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir. The balance between benefits and harms should be considered when making decisions about use of both NIs for either the prophylaxis or treatment of influenza. The influenza virus‐specific mechanism of action proposed by the producers does not fit the clinical evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008965-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008965-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008965-abs-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008965-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008965-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008965-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008965-abs-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008965-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008965-abs-0010">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008965-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008965-abs-0009">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008965-abs-0006" lang="en"> <h3>Regulatory information on trials of oseltamivir (Tamiflu) and zanamivir (Relenza) for influenza in adults and children </h3> <p>Oseltamivir and zanamivir have been stockpiled in many countries to treat and prevent seasonal and pandemic influenza, before an influenza vaccine matched to the circulating virus becomes available. Oseltamivir is classified by the World Health Organization as an essential medicine. </p> <p><b>How this review has been approached</b> </p> <p>We have updated and combined our reviews on the antiviral drugs zanamivir and oseltamivir for influenza in adults and children on the basis of the manufacturers' reports to regulators (clinical study reports) and the regulators' comments. We have called these comments and reports 'regulatory information'. Clinical study reports are unpublished, extensive documents with great detail on the trials that formed the basis for market approval. They include the protocols, methods and results. Clinical study reports have until now been confidential, seen only by the manufacturers and regulators. </p> <p><b>Why we have taken this approach</b> </p> <p>In previous versions of this review we identified unresolved discrepancies in the data presented in published trial reports and substantial publication bias. As a consequence, we elected not to use data from journal articles but included the documents generated during licensing processes. We have accessed such data from the UK, USA, European Medicines Agency (EMA), Japanese regulators and clinical study reports from the manufacturers (after a protracted media campaign). This has enabled us to verify information from the randomised, placebo‐controlled trials on adults and children with confirmed or suspected exposure to naturally occurring influenza. </p> <p>Based on our assessments of the regulatory documents (in excess of 160,000 pages), we came to the conclusion that there were substantial problems with the design, conduct, reporting and availability of information from many of the trials. </p> <p><b>What we have found</b> </p> <p>We have used data from 46 trials (20 oseltamivir and 26 zanamivir studies) in this review. We identified problems in the design of many of the studies that we included, which affects our confidence in their results. We found that both drugs shorten the duration of symptoms of influenza‐like illness (unconfirmed influenza or 'the flu') by less than a day. Oseltamivir did not affect the number of hospitalisations, based on the data from all the people enrolled in treatment trials of oseltamivir. Zanamivir trials did not record this outcome. The effects on pneumonia and other complications of influenza, such as bronchitis, middle ear infection (otitis media) and sinusitis, were unreliably reported, as shown by the case report form in the trial documents. Some forms showed limitations in the diagnostic criteria for pneumonia. Regulatory comments noted problems with missing follow‐up diary cards from participants. In children with asthma there was no clear effect on the time to first alleviation of symptoms. </p> <p>Prophylaxis trials showed that oseltamivir and zanamivir reduced the risk of symptomatic influenza in individuals and households. There was no evidence of an effect on asymptomatic influenza or on non‐influenza, influenza‐like illness, but trial conduct problems prevent any definitive conclusion. </p> <p>Oseltamivir use was associated with nausea, vomiting, headaches, renal and psychiatric events; these last three were when it was used to prevent influenza (prophylaxis). Its effect on the heart is unclear: it may reduce cardiac symptoms, but may induce serious heart rhythm problems. In adult treatment trials of zanamivir there was no increased risk of reported adverse events. The evidence on the possible harms associated with the treatment of children with zanamivir was sparse. </p> <p><b>Agreement with other findings</b> </p> <p>The lack of good evidence demonstrating an effect on complications agrees with the conservative conclusions on both drugs drawn by the US Food and Drug Administration (FDA). The FDA only allowed claims of effectiveness of both drugs for the prevention and treatment of symptoms of influenza and not for other effects (including the interruption of person‐to‐person spread of the influenza virus or prevention of pneumonia). The FDA described the overall performance of both drugs as 'modest'. </p> <p><b>Mechanism of action for beneficial effects</b> </p> <p>These findings all suggest that the low immune response with low levels of pro‐inflammatory cytokines, which is induced by the action of oseltamivir carboxylate, may reduce the symptoms of influenza unrelated to an inhibition of influenza virus replication. The potential hypothermic or antipyretic effect of oseltamivir as a central nervous system depressant may also contribute to the apparent reduction of host symptoms. Statements made on the capacity of oseltamivir to interrupt viral transmission and reduce complications are not supported by any data we have been able to access. </p> <p>The mechanism of action proposed by the producers (influenza virus‐specific) does not fit the clinical evidence which suggests a multi‐system and central action. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008965-sec-0133" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008965-sec-0133"></div> <h3 class="title" id="CD008965-sec-0134">Implications for practice</h3> <section id="CD008965-sec-0134"> <p>On the basis of the findings of this review, clinicians and healthcare policy‐makers should urgently revise current recommendations for use of the neuraminidase inhibitors (NIs) for individuals with influenza. Our findings confirm that both oseltamivir and zanamivir reduce the time to symptomatic improvement in adults (but not asthmatic children) with influenza‐like illness. The size of this effect is small, approximately half a day. It is unclear whether this is superior to treatment with commonly used antipyretic medications. However, we did not find any credible evidence that either oseltamivir or zanamivir reduce the risk of complications of influenza, particularly pneumonia, nor reduce risk of hospitalisation or death. Moreover, even in individuals at higher risk of complications, such as children with asthma or the elderly, we found no evidence of a beneficial effect for reducing risks of complications. </p> <p>Based on these findings there appears to be no evidence for patients, clinicians or policy‐makers to use these drugs to prevent serious outcomes, both in annual influenza and pandemic influenza outbreaks. Practice recommendations and drug labelling needs to be changed to reflect these findings. </p> <p>When used as prophylactic agents to prevent the occurrence of influenza in individuals or families, our findings again suggest a minimal effect on prevention. Based on this, there is little support for their use as prophylactic agents, for example, during influenza epidemics. Given that oseltamivir is now recommended as an essential medicine for the treatment of seriously ill patients or those in higher‐risk groups with influenza (H1N1 2009) (<a href="./references#CD008965-bbs2-0301" title="World Health Organization. WHO Model List of Essential Medicines. ADULTS, 18th edition (April 2013). Rev. Oct 2013. http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf 2013 (accessed 25 November 2013). ">WHO 2013a</a>; <a href="./references#CD008965-bbs2-0302" title="World Health Organization. WHO Model List of Essential Medicines for Children. 4th list (April 2013). Rev. Oct 2013. http://apps.who.int/iris/bitstream/10665/93143/1/EMLc_4_eng.pdf 2013 (accessed 25 November 2013). ">WHO 2013b</a>), this is of some concern. </p> <p>Reasons why prophylaxis treatment is not clinically meaningful include: 1) according to modelling studies, for prophylactic treatment to be effective, 80% of the population require at least eight weeks of treatment, which has not been trialled (<a href="./references#CD008965-bbs2-0259" title="LonginiIMJr , HalloranME , NizamA , YangY . Containing pandemic influenza with antiviral agents. Am J Epidemiology2004;159(7):623‐33. ">Longini 2004</a>); 2) models assume the relative risk reduction observed in low risk populations, transfers directly to populations at higher risk (i.e. an absolute treatment effect of 31%, approximately 15‐fold higher than the absolute effects we observed in prophylaxis trials (<a href="./references#CD008965-bbs2-0259" title="LonginiIMJr , HalloranME , NizamA , YangY . Containing pandemic influenza with antiviral agents. Am J Epidemiology2004;159(7):623‐33. ">Longini 2004</a>); 3) A high proportion of people, at least two‐thirds require recognisable influenza symptoms; 4) treatment has to be effective against both asymptomatic and symptomatic infections (which it is not), in modelling studies asymptomatic infections are assumed to be 50% as infectious as symptomatic infections (<a href="./references#CD008965-bbs2-0259" title="LonginiIMJr , HalloranME , NizamA , YangY . Containing pandemic influenza with antiviral agents. Am J Epidemiology2004;159(7):623‐33. ">Longini 2004</a>); 5) because the influenza season can last four to five months, any secondary strategy, such as vaccination, would have to be widely available at the end of the eight week treatment period, and 6) a full understanding of the effect of the treatment in prophylaxis is unknown because symptomatic influenza‐like‐illness without laboratory‐confirmation was only fully reported in one study. This study (NAI30034) showed no difference in proportion of patients with symptomatic influenza‐like‐illness (with or without lab confirmation) (RR 0.90, 95% CI 0.73 to 1.11). </p> <p>The small benefits we noted in symptomatic improvement and the lack of credible evidence for an effect on serious complications needs to be balanced with the adverse effects found with these drugs in meta‐analyses, especially diabetic/hyperglycaemic, renal and neuropsychiatric effects in all those people for whom the World Health Organization (WHO) recommend use. </p> <p>Our results do not discount the potential benefit of using zanamivir and oseltamivir in individuals under particular situations, for example in immunocompromised or in compassionate cases, where few other therapeutic options may exist. However, NIs themselves may be immunosuppressants. Our findings do not support the stockpiling of NIs, nor oseltamivir's inclusion in the WHO's list of essential drugs. </p> <p>The rationale for undertaking the current review and the methods and pressures that needed to be employed to obtain and evaluate the evidence for these drugs has significant implications for the robustness of the scrutiny that new drugs undergo prior to entering widespread clinical use. We believe that several steps now need to be put in place to provide patients, clinicians and policy‐makers with the most transparent assessment of the relative benefits and risks of new drugs. </p> <p>First, our findings imply that numerous national and international bodies appear willing to accept biased or incomplete trial reports seemingly at face value. This ready willingness is in contrast with the considerable time and effort needed to change their recommendations. Second, published trials are unlikely to provide the level of detail to allow the results of a drug trial to be properly evaluated and risk presenting a partial and potentially biased report of trial conduct and findings. This has implications not only for the reporting of trials but also the weight that can be applied to published studies alone. Third, clinicians and policy‐makers should be cautious in interpreting and using the findings of systematic reviews including only published studies, particularly those that comprise only a portion of an entire drug trial programme, or which contain only a portion of the results of trials. There have been many systematic reviews of NIs, none assessing the full trial programme or full trial results, thus limiting their validity. We suspect a similar situation exists for other drugs. Fourth, clinical policy‐makers at the national and international level should raise the level of scrutiny needed in the cases of drugs that are likely to be used by large numbers of people who are either asymptomatic or have short, self limiting illnesses such as influenza ('public health drugs') and where the potential for benefit (and harm) is vital. Given the weight of these decisions (with serious implications for both correct and incorrect decisions), policy‐makers should not face the barrier of being denied access to what sponsors regard as commercially sensitive information. </p> <p>Without concerted efforts from multiple stakeholders to put the above measures in place, it is not possible to provide objective assessment of the benefits and risks of new drugs. This risks not only patients potentially missing out on effective treatments, but also patients being exposed to either ineffective (or harmful) treatments. </p> </section> <h3 class="title" id="CD008965-sec-0135">Implications for research</h3> <section id="CD008965-sec-0135"> <p>Our findings have implications for research on the mechanism of action of NIs, with special regard to any direct central action of oseltamivir and the inhibitory effect of the host endogenous neuraminidase of various organs and systems. We could not reach a consensus on whether further trials are warranted and whether current trials should be discontinued. </p> <p>The considerable body of evidence from randomised controlled trials (RCTs) included in this review indicates either no effect or a relatively small absolute effect size against the complications of influenza. Such an effect, even if statistically significant, would be too small to warrant treatment with NIs in a primary care setting, especially since effective diagnosis and treatments for rare complications (such as pneumonia) are available. Lack of evidence of an effect on hospitalisations probably indicates lack of severity in the first place. Assuming an influenza incidence rate of 2% (similar to that in the control arms of oseltamivir treatment trials), to detect a 25%, clinically significant reduction in pneumonia, 21,500 participants would have to be enrolled in a clinical trial. </p> <p>Our calculation is likely to underestimate population size, as the 2% incidence rate was derived from trials that used enhanced ad hoc surveillance systems. Any trial design would have to ensure that the presence of complications is ascertained using objective diagnostic criteria (for example, with confirmation using imaging or laboratory testing for pneumonia). Such trials would also have to consider the ethical implications of conducting studies where the estimate of benefit (based on 11 RCTs) in otherwise healthy people is likely to be small, and would have to be balanced against the apparent risks of adverse effects from NIs. We think research should be aimed at more effective preventive measures and early identification of complications. </p> <p>Based on the length of time it has taken to provide a definitive answer on the efficacy of the NIs, the challenges in obtaining the full information and the methods that we needed to develop to conduct the evidence synthesis, we believe the main implication of our review is the need for reform of multiple components of the research and development, regulatory and assessment pathway of new drugs. </p> <p>Pharmaceutical sponsors of drug trials should follow a data access and sharing procedure similar to that of the European Medicines Agency (EMA) and sponsors should make all full clinical study reports available to be downloaded from their websites and shared freely once a regulatory decision has been made. Redactions should be kept to the minimum. Part of this process needs to include a full list of the entire drug development programme, to avoid assessment of an incomplete set of trials. Researchers and industry employees who are listed in trial documents should be considered to have legal responsibility for the conduct and reporting of a trial. </p> <p>Regulators should post an inventory of their documentary holdings on their websites with a brief description of the main content and size of each file. They should make all information available shortly after making a registration decision on a drug and within a reasonable time period. The information should be in electronic format and anonymised (i.e. participants' details should be removed to prevent each person being identified but no further). </p> <p>Trial registries have improved the reporting of new trials. However, on their own they will not be adequate to resolve the problems we encountered. The completeness of trial registries needs to tested with a random sampling procedure. Clear instructions for the reporting and updating of their content should be promulgated and penalties imposed on breaches of these procedures. Trial registration should include the original and final versions of a trial protocol, with a full declaration of dated amendments. Procedures for trial unblinding and dates of unblinding should be routinely reported. Registration should be made compulsory for all studies in which human beings are randomly assigned to experimental arms. Ethical and consent procedures for all trials should include obligations of the trial sponsor to ensure results are made public. Failure to report the existence of a trial on humans and to make results available should be considered as an ethical breach of conduct and subject to appropriate penalties. </p> <p>The methods used to conduct our evidence synthesis need to be repeated across further interventions and by other researchers and may need to be refined further. Given the considerable resources involved in using these methods, a system is needed to prioritise reviews of important drugs so that such methods are reserved for drugs that meet certain conditions. Priority could perhaps be given to first drugs of a new family, drugs considered to be innovative or those that are likely to have a big market impact. Such reviews should be publicly funded and be independent from both regulators and manufacturers. Researchers who conduct these 'high scrutiny' reviews need to be free of recent ties to either government or the pharmaceutical industry. Systematic review groups such as The Cochrane Collaboration should consider both adopting these methods for other drugs and whether perhaps to scrutinise the published reviews of prioritised drugs. </p> <p>Finally, all documentary evidence relating to a trial on humans (including clinical study reports, regulatory documents, evidence syntheses) should be archived electronically with no statute of limitations. </p> <p><b>Authors' note</b>: in reviewing over 2 GB of data there is the possibility of mistakes. The authors would be grateful if readers could identify these. We promise that if we concur the record will be amended accordingly. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008965-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008965-sec-0043"></div> <p>This review (known as A159) reports our efforts to get to the bottom of the issue of the effects of NIs by appraising evidence from unpublished clinical study reports (see Glossary, <a href="./appendices#CD008965-sec-0139">Appendix 1</a>) and regulatory documents containing comments and reviews. We have called the body of clinical studies and regulatory comments 'regulatory information'. For the history and evolution of the review see <a href="./appendices#CD008965-sec-0140">Appendix 2</a>. </p> <section id="CD008965-sec-0044"> <h3 class="title" id="CD008965-sec-0044">Description of the condition</h3> <p>Influenza is mostly a mild, self limiting infection of the upper airways with local symptoms, including sniffles, nasal discharge, dry cough and sore throat, and systemic symptoms such as fever, headache, aches and pains, malaise and tiredness. </p> <p>Occasionally patients with influenza develop complications such as pneumonia, otitis media and dehydration or encephalopathy with or without liver failure, which may be due to the effects of the influenza virus itself or associated secondary bacterial infections and/or adverse effects of drugs such as antipyretics (including salicylates and other non‐steroidal anti‐inflammatory drugs) (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>). </p> <p>Influenza is not clinically distinguishable from influenza‐like illness (ILI) (<a href="./references#CD008965-bbs2-0194" title="CallSA , VollenweiderMA , HornungCA , SimelDL , McKinneyWP . Does this patient have influenza?. JAMA2005;8:987‐97. ">Call 2005</a>). Epidemic influenza in humans is caused by influenza A and B viruses. Currently, influenza A/H1N1, influenza A/H3N2 and influenza B cause most influenza infections worldwide (<a href="./references#CD008965-bbs2-0197" title="U.S. Centers for Disease Control and Prevention. Influenza activity — United States, 2012–13 season and composition of the 2013–14 influenza vaccine. Morbidity and Mortality Weekly Report2013;62(23):473‐9. ">CDC 2013</a>). </p> </section> <section id="CD008965-sec-0045"> <h3 class="title" id="CD008965-sec-0045">Description of the intervention</h3> <p>Neuraminidase inhibitors (NIs) comprise inhaled zanamivir (Relenza, GlaxoSmithKline), oral oseltamivir (Tamiflu, Gilead Sciences and F. Hoffman‐La Roche), parenteral peramivir (BioCryst Ltd), inhaled laninamivir (Daiichi Sankyo Co. Ltd) (<a href="./references#CD008965-bbs2-0285" title="SugayaN , OhashiY . Long‐acting neuraminidase inhibitor laninamivir octanoate (CS‐8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrobial Agents and Chemotherapy2010;54(6):2575‐82. ">Sugaya 2010</a>) and others still under development (<a href="./references#CD008965-bbs2-0238" title="HaydenF . Developing new antiviral agents for influenza treatment: what does the future hold?. Clinical Infectious Diseases2009;48(Suppl 1):3‐13. ">Hayden 2009</a>). The use of NIs has increased dramatically since the outbreak of A/H1N1 in April 2009, partly because of the rise in amantadine/rimantadine resistance and, in the early stages of the outbreak, the lack of a vaccine, which meant that NIs became a widespread public health intervention. The World Health Organization (WHO) had previously encouraged member states to stockpile and gain experience of using NIs (<a href="./references#CD008965-bbs2-0296" title="World Health Organization. Global agenda on influenza‐‐adopted version. Part I. Releve Epidemiologique Hebdomadaire/Section d'Hygiene du Secretariat de la Societé des Nations = Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations2002;77(22):179‐82. [PUBMED: 12061030] ">WHO 2002a</a>; <a href="./references#CD008965-bbs2-0297" title="World Health Organization. Adoption of global agenda on influenza ‐ Part II. Releve Epidemiologique Hebdomadaire/Section d'Hygiene du Secretariat de la Societé des Nations = Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations2002;77(23):191‐5. [PUBMED: 12073536] ">WHO 2002b</a>; <a href="./references#CD008965-bbs2-0298" title="World Health Organization. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. http://www.who.int/csr/resources/publications/influenza/11_29_01_A.pdf 2009 (accessed 30 November 2009). ">WHO 2004</a>). </p> </section> <section id="CD008965-sec-0046"> <h3 class="title" id="CD008965-sec-0046">How the intervention might work</h3> <p>Although NIs may reduce the ability of the virus to penetrate the mucus in the very early stage of infection (<a href="./references#CD008965-bbs2-0190" title="BhatiaA , KastRE . How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency (Letter). Cellular and Molecular Biology2007;12(1):111‐9. ">Bhatia 2007</a>; <a href="./references#CD008965-bbs2-0263" title="MatrosovichMN , MatrosovichTY , GrayT , RobertsNA , KlenkH . Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Journal of Virology2004;78(22):12665‐7. ">Matrosovich 2004</a>; <a href="./references#CD008965-bbs2-0268" title="MosconaA . Neuraminidase inhibitors for influenza. New England Journal of Medicine2005;353(13):1363‐73. ">Moscona 2005</a>; <a href="./references#CD008965-bbs2-0274" title="OhuchiM , AsaokaN , SakaiT , OhuchiR . Roles of neuraminidase in the initial stage of influenza virus infection. Microbes and Infection2006;8(5):1287‐93. ">Ohuchi 2006</a>), their main mechanism of action is thought to lie in their ability to inhibit influenza viruses from exiting host cells (<a href="./references#CD008965-bbs2-0258" title="LiuC , EichelbergerMC , CompansRW , AirGM . Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. Journal of Virology 69;2:1099‐106. ">Liu 1995</a>; <a href="./references#CD008965-bbs2-0268" title="MosconaA . Neuraminidase inhibitors for influenza. New England Journal of Medicine2005;353(13):1363‐73. ">Moscona 2005</a>). The manufacturers state that oseltamivir does not prevent infection, nor affect antibody production (<a href="./references#CD008965-bbs2-0284" title="SmithJ , DutkowskiR , WardP . Antivirals for influenza in healthy adults. Lancet2006;367(9522):1571; author reply 1573. [PUBMED: 16698402] ">Smith 2006</a>), but it reduces symptom duration probably by reducing viral load, spread and release of cytokines (<a href="./references#CD008965-bbs2-0237" title="HaydenFG , TreanorJJ , FritzRS , LoboM , BettsRF , MillerM , et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA1999;282(13):1240‐6. ">Hayden 1999</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>), diminishing the chance of complications and interrupting person‐to‐person viral spread. </p> <p>Oseltamivir phosphate (Tamiflu) is the pro‐drug of oseltamivir carboxylate, the effective form. Oseltamivir phosphate dissociates in the gastrointestinal tract to form oseltamivir, which is absorbed and metabolised into oseltamivir carboxylate by hepatic carboxylesterase (h‐CE). Oseltamivir may have a central depressant action (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>) and may also inhibit human sialidase (<a href="./references#CD008965-bbs2-0257" title="LiC , YuQ , YeZ , SunY , HeQ , LiX , et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Research2007;17(4):357‐62. ">Li 2007</a>), causing abnormal behaviour. </p> <p>Inhaled zanamivir reaches a far lower plasma concentration compared to its intravenous administration (<a href="./references#CD008965-bbs2-0195" title="CassLM , EfthymiopoulosC , ByeA . Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clinical Pharmacokinetics1999;36(Suppl 1):1‐11. ">Cass 1999</a>). </p> <p>Any treatment that reduces the complications of influenza (for example, pneumonia) and the excretion of the virus from infected people might be a useful public health measure to contain an epidemic by limiting the impact and spread of the virus. In addition to symptomatic treatment, prophylactic use for interrupting the spread of disease has informed pandemic planning over the past decade. </p> </section> <section id="CD008965-sec-0047"> <h3 class="title" id="CD008965-sec-0047">Why it is important to do this review</h3> <p>There are three major reasons for conducting this review, in addition to questions of efficacy associated with the clinical use of NIs for influenza: </p> <p> <ol id="CD008965-list-0001"> <li> <p>Influenza antivirals are a commonly used and stockpiled drug against past and future pandemics on the basis of international and national recommendations. These recommendations are based on the claimed and assumed ability of the drug to reduce complications and transmission (<a href="./references#CD008965-bbs2-0240" title="U.S. Department of Health and Human Services. HHS pandemic influenza plan. http://www.hhs.gov/pandemicflu/plan/pdf/HHSPandemicInfluenzaPlan.pdf 2005 (accessed 9 June 2009). ">HHS 2005</a>; <a href="./references#CD008965-bbs2-0299" title="World Health Organization. WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. http://www.who.int/influenza/resources/documents/RapidContProtOct15.pdf October 2007 (accessed 17 May 2011). ">WHO 2007</a>). In theory, containing the spread of influenza allows time for an organised response with longer‐term interventions (such as vaccines), which take time to produce (<a href="./references#CD008965-bbs2-0299" title="World Health Organization. WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. http://www.who.int/influenza/resources/documents/RapidContProtOct15.pdf October 2007 (accessed 17 May 2011). ">WHO 2007</a>). </p> </li> <li> <p>There are legitimate reasons to doubt these claims and the results of previous Cochrane reviews of NIs in adults (<a href="./references#CD008965-bbs2-0248" title="JeffersonTO , DemicheliV , DiPietrantonjC , JonesM , RivettiD . Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001265.pub2] ">Jefferson 2006</a>; <a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>) and children (<a href="./references#CD008965-bbs2-0283" title="Shun‐ShinM , ThompsonM , HeneghanC , PereraR , HarndenA , MantD . Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta‐analysis of randomised controlled trials. BMJ2009;339:b3172. ">Shun‐Shin 2009</a>), due to the risk of reporting bias, including the certainty of publication bias (<a href="./references#CD008965-bbs2-0204" title="DoshiP , JeffersonT , DelMarC . The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med2012;9(4):e1001201. [DOI: 10.1371/journal.pmed.1001201] ">Doshi 2012a</a>; <a href="./references#CD008965-bbs2-0205" title="DoshiP , JonesMA , JeffersonT . Rethinking credible evidence synthesis. BMJ2012;344:d7898. [DOI: 10.1136/bmj.d7898] ">Doshi 2012b</a>). </p> </li> <li> <p>Oseltamivir is now on the list of WHO essential drugs (<a href="./references#CD008965-bbs2-0301" title="World Health Organization. WHO Model List of Essential Medicines. ADULTS, 18th edition (April 2013). Rev. Oct 2013. http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf 2013 (accessed 25 November 2013). ">WHO 2013a</a>; <a href="./references#CD008965-bbs2-0302" title="World Health Organization. WHO Model List of Essential Medicines for Children. 4th list (April 2013). Rev. Oct 2013. http://apps.who.int/iris/bitstream/10665/93143/1/EMLc_4_eng.pdf 2013 (accessed 25 November 2013). ">WHO 2013b</a>). </p> </li> </ol> </p> <section id="CD008965-sec-0048"> <h4 class="title">Process</h4> <p>A159 is an amalgamation of two long‐standing Cochrane reviews on the effects of NIs for influenza in healthy adults (<a href="./references#CD008965-bbs2-0250" title="JeffersonT , JonesM , DoshiP , DelMarC , DooleyL , FoxleeR . Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD001265.pub2] ">Jefferson 2010a</a>, also published as <a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>) and children (<a href="./references#CD008965-bbs2-0262" title="MathesonNJ , HarndenAR , PereraR , SheikhA , Symmonds‐AbrahamsM . Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002744.pub2] ">Matheson 2007</a>), and it is based on the assessment of trials through their clinical study reports and other regulatory information: a decision we made after finding substantial reporting bias in the journal publications of the relevant trials. </p> <p>For the rationale for this process see <a href="./appendices#CD008965-sec-0140">Appendix 2</a>. </p> </section> <section id="CD008965-sec-0049"> <h4 class="title">Examples of discrepancies and reporting bias</h4> <p>We identified that 60% (3145/5267) of patient data from randomised, placebo‐controlled, phase III treatment trials of oseltamivir have never been published. This includes <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>, the biggest treatment trial ever undertaken on oseltamivir (with just over 1400 people of all ages). Exclusion of unpublished data changed our previous findings regarding the ability of oseltamivir to reduce the complications of influenza (<a href="./references#CD008965-bbs2-0203" title="DoshiP . Neuraminidase inhibitors ‐ the story behind the Cochrane review. BMJ2009;339:b5164. ">Doshi 2009</a>; <a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>). In some cases, mistakes in the attribution of adverse events were only discovered through matching summary tables with individual participant listings (<a href="./references#CD008965-bbs2-0233" title="GravensteinS , PetersP . Erratum. Journal of the American Geriatrics Society2013;61:478. ">Gravenstein 2013</a>; <a href="./references#CD008965-bbs2-0278" title="PetersPHJr , GravensteinS , NorwoodP , DeBockV , VanCouterA , GibbensM , et al. Long‐term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatrics Society2001;49(8):1025‐31. [PUBMED: 11555062] ">Peters 2001</a>; <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>). </p> </section> <section id="CD008965-sec-0050"> <h4 class="title">A modified approach</h4> <p>We have modified the routine Cochrane processes to improve our previous methods, which we now consider inadequate. To resolve inconsistencies and under‐reporting, we changed our approach by no longer including trial data as reported in papers published in biomedical journals. Instead, we treated clinical study reports as our basic unit of analysis. Clinical study reports are often sent to national drug regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (formerly EMEA), which require far more stringent standards for completeness and accuracy of reporting than biomedical journals. Journal articles can be regarded as a very succinct synthesis of a clinical study report. In addition to seeking clinical study reports, we decided to read and review regulatory documentation. The FDA in particular (and the EMA to a far lesser extent) make many of its scientific reviews available on its website. Unlike Cochrane review authors, regulators can have access to the whole data set and their comments can provide useful insight, helping to achieve a better understanding of trial programmes. </p> <p>Clinical study reports generally remain hidden from public view and are not readily available for wider scientific scrutiny, despite the wealth of information they contain for those willing and able to spend the time reading them and despite calls to make all relevant trial data public (<a href="./references#CD008965-bbs2-0206" title="DoshiP , JeffersonT . Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open2013;3:e002496. [DOI: 10.1136/bmjopen‐2012‐002496] ">Doshi 2013</a>; <a href="./references#CD008965-bbs2-0230" title="GodleeF , ClarkeM . Why don't we have all the evidence on oseltamivir?. BMJ2009;339:b5351. ">Godlee 2009</a>), as well as the known problems with reporting biases (<a href="./references#CD008965-bbs2-0265" title="McGauranN , WieselerB , KreisJ , SchulerY , KolschH , KaiserT . Reporting bias in medical research ‐ a narrative review. Trials2010;11(1):37. ">McGauran 2010</a>; <a href="./references#CD008965-bbs2-0303" title="WieselerB , WolframN , McGauranN , KerekesMF , VervölgyiV , KohleppP , et al. Completeness of reporting of patient‐relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Medicine2013;10(10):e1001526. ">Wieseler 2013</a>). </p> </section> <section id="CD008965-sec-0051"> <h4 class="title">Implications</h4> <p>This modified approach to a Cochrane review aims to provide patients, clinicians and policy‐makers with the most transparent and independent information possible about NIs for influenza. In addition, it should contribute to improving a European regulatory and pharmacovigilance legal framework, which commentators consider weak (<a href="./references#CD008965-bbs2-0200" title="CohenD . Complications: tracking down the data on oseltamivir. BMJ2009;339:b5387. ">Cohen 2009</a>; <a href="./references#CD008965-bbs2-0230" title="GodleeF , ClarkeM . Why don't we have all the evidence on oseltamivir?. BMJ2009;339:b5351. ">Godlee 2009</a>). We believe that as NIs have become public health drugs, recommended and stockpiled globally, independent scrutiny of all the evidence relating to harms and effects on complications is necessary to provide patients, policy‐makers and physicians with a complete and unbiased view of their risks and benefits. </p> </section> <section id="CD008965-sec-0052"> <h4 class="title">Implication for A/H1N1 (2009) influenza</h4> <p>In response to our 2010 review (<a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>; <a href="./references#CD008965-bbs2-0250" title="JeffersonT , JonesM , DoshiP , DelMarC , DooleyL , FoxleeR . Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD001265.pub2] ">Jefferson 2010a</a>), some have argued that its findings cannot be applied to the 2009 A/H1N1, suggesting that it is a new virus and thus we need new evidence (<a href="./references#CD008965-bbs2-0247" title='Japanese Association for Infectious Diseases. Question and answers on the Japanese Association for Infectious Diseases urgent recommendation "Handling pandemic influenza in routine care institutions". http://www.kansensho.or.jp/topics/090525influenza_qanda.html 2010 (accessed 9 May 2010). '>JAID 2010</a>; <a href="./references#CD008965-bbs2-0264" title="MaughTHII . British Medical Journal questions efficacy of Tamiflu for swine flu ‐ or any flu. http://latimesblogs.latimes.com/booster_shots/2009/12/british‐medical‐journal‐questions‐efficacy‐of‐tamiflu‐for‐swine‐flu‐or‐any‐flu.html 2009 (accessed 8 December 2009). ">Maugh 2009</a>; <a href="./references#CD008965-bbs2-0269" title="NebehayS . WHO backs findings on Tamiflu for seasonal flu. http://www.reuters.com/article/idUSGEE5BA0UY20091211?type=marketsNews 2009 (accessed 11 December 2009). ">Nebehay 2009</a>; <a href="./references#CD008965-bbs2-0270" title="National Health Service. NHS choices. Antivirals and swine flu. http://www.nhs.uk/news/2009/12December/Pages/Antivirals‐and‐swine‐flu.aspx 2009 (accessed 17 May 2010). ">NHS 2009</a>; <a href="./references#CD008965-bbs2-0271" title="National Health Service. NHS Choices. Swine flu ‐ questions and answers. http://www.nhs.uk/Conditions/Pandemic‐flu/Pages/QA.aspx 2010 (accessed 17 May 2010). ">NHS 2010</a>). Novel A/H1N1 is a new strain of a subtype that has been circulating since 1977, but it also resembles the A/H1N1 strain that has been circulating since before 1957 (<a href="./references#CD008965-bbs2-0196" title="U.S. Centers for Disease Control and Prevention. Serum cross‐reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morbidity and Mortality Weekly Report2009;58(19):521‐4. ">CDC 2009</a>) or before the 1918 pandemic (<a href="./references#CD008965-bbs2-0245" title="ItohY , ShinyaK , KisoM , WatanabeT , SakodaY , HattaM , et al. In vitro and in vivo characterization of new swine‐origin H1N1 influenza viruses. Nature2009;460(7258):1021‐5. ">Itoh 2009</a>). Influenza subtype A/H1N1 was indeed circulating in the clinical trials we have included in our previous reviews. In addition, oseltamivir and zanamivir were approved by regulators worldwide for the treatment and prevention of influenza types A and B, not specific subtypes or strains of influenza A and B. The expectation of regulatory approval is thus that the effects of these drugs demonstrated in clinical trials will apply to future strains of influenza A and B. Use of these drugs during the pandemic was not off‐label. It was approved use because of the assumption that the clinical trial evidence underpinning regulatory approval applied to novel A/H1N1. We reviewed the clinical trial evidence with the expectation that our results, similar to regulators, will apply to all influenza viruses. </p> </section> <section id="CD008965-sec-0053"> <h4 class="title">Wider implications</h4> <p>The modified approach in this Cochrane review grew out of a realisation that prior methods employed to review NIs were inadequate. There seems to be no compelling reason to think that the lessons learned are limited to these particular drugs (<a href="./references#CD008965-bbs2-0230" title="GodleeF , ClarkeM . Why don't we have all the evidence on oseltamivir?. BMJ2009;339:b5351. ">Godlee 2009</a>; <a href="./references#CD008965-bbs2-0280" title="RodgersMA , BrownJVE , HeirsMK , HigginsJPT , MannionRJ , SimmondsMC , et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP‐2 for spinal fusion. BMJ2013;346:f3981. ">Rodgers 2013</a>; <a href="./references#CD008965-bbs2-0293" title="VedulaSS , BeroL , SchererRW , DickersinK . Outcome reporting in industry‐sponsored trials of gabapentin for off‐label use. New England Journal of Medicine2009;361(20):1963–71. ">Vedula 2009</a>; <a href="./references#CD008965-bbs2-0294" title="VedulaSS , LiT , DickersinK . Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry‐sponsored trials in off‐label uses of gabapentin. PLoS Medicine2013;10(1):e1001378. ">Vedula 2013</a>; <a href="./references#CD008965-bbs2-0303" title="WieselerB , WolframN , McGauranN , KerekesMF , VervölgyiV , KohleppP , et al. Completeness of reporting of patient‐relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Medicine2013;10(10):e1001526. ">Wieseler 2013</a>). For this reason, our independent scrutiny, using all possible trial information, may inform both the wider debate on the adequacy of existing regulatory frameworks in the adoption of new drugs and the question of whether other systematic reviews should move to this new, more rigorous, approach, which focuses on trial programmes rather than single trials (<a href="./references#CD008965-bbs2-0211" title="EydingD , LelgemannM , GrouvenU , HarterM , KrompM , KaiserT , et al. Reboxetine for acute treatment of major depression: systematic review and meta‐analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ2010;341:c4737. ">Eyding 2010</a>; <a href="./references#CD008965-bbs2-0244" title="IoannidisJPA , KarassaFB . The need to consider the wider agenda in systematic reviews and meta‐analyses: breadth, timing, and depth of the evidence. BMJ2010;341:c4875. ">Ioannidis 2010</a>) (see Glossary, <a href="./appendices#CD008965-sec-0139">Appendix 1</a>). Although there is substantial evidence for the effects of reporting bias in estimates of effectiveness, less is known of its impact on the evidence of harms (<a href="./references#CD008965-bbs2-0198" title="ChouR , HelfandM . Challenges in systematic reviews that assess treatment harms. Annals of Internal Medicine2005;142(2 Pt 2):1090‐9. ">Chou 2005</a>). We decided to quantify the additional resources required to follow our modified methodological approach to assess the feasibility of other systematic reviews proceeding in a similar fashion. </p> <p>See the <a href="#CD008965-sec-0218">Differences between protocol and review</a> section for the previous version of the objectives of this review. </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008965-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008965-sec-0054"></div> <p>To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all clinical study reports of published and unpublished randomised, placebo‐controlled trials and regulatory comments. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008965-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008965-sec-0055"></div> <section id="CD008965-sec-0056"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008965-sec-0057"> <h4 class="title">Types of studies</h4> <p>We included evidence from randomised controlled trials (RCTs) testing the effects of NIs for prophylaxis, post‐exposure prophylaxis (PEP) and treatment of influenza. Prophylaxis is the mode of use of NIs when there is expectation of possible near‐future exposure to influenza. PEP is the use of NIs following probable exposure to influenza but before symptoms develop. Treatment is the use of NIs in persons showing probable signs of influenza. </p> <p>Due to discrepancies between published and unpublished reports of the same trials, we decided to include only those trials for which we had unabridged clinical study reports (for example, with consecutively numbered pages), even though they may be parts of clinical study reports (i.e. Module 1 only) and information on reports of trials that were considered "pivotal" (i.e. first or second‐line evidence to regulators in support of the registration application). </p> </section> <section id="CD008965-sec-0058"> <h4 class="title">Types of participants</h4> <p>We included previously healthy people (children and adults). 'Previously healthy' includes people with chronic illness (such as asthma, diabetes, hypertension), but excludes people with illnesses with more significant effects on the immune system (such as malignancy or HIV infection). We included only trials on people exposed to naturally occurring influenza with or without symptoms. We targeted the intention‐to‐treat (ITT) and safety populations as our prior review discovered compelling evidence that the intention‐to‐treat‐influenza‐infected (ITTI), the sub‐population deemed to be influenza‐infected, were not balanced between treatment groups in the Roche oseltamivir trials. In addition, estimates from the ITT population will be more generalisable to clinical practice, where routine testing for influenza is not common in many countries (and even where used, remains of variable accuracy). </p> </section> <section id="CD008965-sec-0059"> <h4 class="title">Types of interventions</h4> <p>NIs administered by any route compared with placebo during the period in which medication was assumed and during the follow‐up (on‐ and off‐treatment: on‐t and off‐t) periods. </p> </section> <section id="CD008965-sec-0060"> <h4 class="title">Types of outcome measures</h4> <section id="CD008965-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD008965-sec-0062"> <h6 class="title">Primary outcome measures for treatment studies</h6> <p> <ol id="CD008965-list-0002"> <li> <p>Symptom relief</p> </li> <li> <p>Hospitalisation and complications</p> </li> <li> <p>Harms</p> </li> </ol> </p> </section> <section id="CD008965-sec-0063"> <h6 class="title">Primary outcome measures for prophylaxis studies</h6> <p> <ol id="CD008965-list-0003"> <li> <p>Influenza (symptomatic and asymptomatic, always with laboratory confirmation) and influenza‐like illness (ILI) </p> </li> <li> <p>Hospitalisation and complications</p> </li> <li> <p>Interruption of transmission (in its two components, reduction of viral spread from index cases and prevention of onset of influenza in contacts) </p> </li> <li> <p>Harms</p> </li> </ol> </p> </section> </section> <section id="CD008965-sec-0064"> <h5 class="title">Secondary outcomes</h5> <section id="CD008965-sec-0065"> <h6 class="title">Secondary outcome measures for treatment studies</h6> <p> <ol id="CD008965-list-0004"> <li> <p>Symptom relapse after finishing treatment</p> </li> <li> <p>Drug resistance</p> </li> <li> <p>Viral excretion</p> </li> <li> <p>Mortality</p> </li> </ol> </p> </section> <section id="CD008965-sec-0066"> <h6 class="title">Secondary outcome measures for prophylaxis studies</h6> <p> <ol id="CD008965-list-0005"> <li> <p>Drug resistance</p> </li> <li> <p>Viral excretion</p> </li> <li> <p>Mortality</p> </li> </ol> </p> <p>Whilst overall symptom reduction is well documented, our interest was particularly focused on complications and adverse events, as this is where evidence is currently scarce or inconclusive (<a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>; <a href="./references#CD008965-bbs2-0283" title="Shun‐ShinM , ThompsonM , HeneghanC , PereraR , HarndenA , MantD . Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta‐analysis of randomised controlled trials. BMJ2009;339:b3172. ">Shun‐Shin 2009</a>). Our preliminary examination of some regulatory documents and some published versions of the studies had identified that some symptoms and sequelae of influenza (such as pneumonia) had been classified as either a 'complication of influenza' or as an 'adverse event of the treatment', or both. This is somewhat confusing and we intended to analyse 'compliharms' (see Glossary, <a href="./appendices#CD008965-sec-0139">Appendix 1</a>) irrespective of the classification as a 'complication of influenza' or as an 'adverse event of the treatment' (<a href="./appendices#CD008965-sec-0141">Appendix 3</a>) in oseltamivir trials. Complications of particular interest included pneumonia, bronchitis, otitis media and sinusitis as these were the secondary illnesses often collected in the Roche oseltamivir trials and we agreed that these events are clinically important. Initially we constructed a table to illustrate the design methodology used for each complication by study (<a href="#CD008965-tbl-0001">Table 1</a>). The table included the following variables: definition of which events are termed complications; where complications are first defined in the clinical study report; diagnosis method; and availability of data. We then stratified our analysis by method of diagnosis with three possible criteria: (1) laboratory‐confirmed diagnosis (e.g. based on radiologically or microbiologically confirmed evidence of infection); (2) clinical diagnosis without laboratory confirmation (diagnosed by a doctor after a clinical examination); (3) other type of diagnosis such as self reported by patient. We conducted analysis of any complication (pneumonia, bronchitis, otitis media and sinusitis) that was classified as serious or led to study withdrawal. </p> <div class="table" id="CD008965-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blank case report forms' data capture for secondary illnesses in oseltamivir trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Where in CRF (PDF pg #)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data captured</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Person reporting</b> </p> <p><b>(participant/investigator)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Where reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific field for recording confirmatory assessment (e.g. CXR)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confirmation (including px)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/no answer to question: "Is this event a secondary illness related to influenza?"</p> <p>Secondary illness is defined: sinusitis, otitis, bronchitis, pneumonia + other chest infections that are not diagnosed as bronchitis and/or pneumonia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In form for "Adverse events or intercurrent illness"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV16871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361, 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Form states:</p> <p>Have there been any changes in the patient’s health including any new conditions or worsening of existing conditions since day 1 (please include secondary illnesses)? </p> <p>Yes/No. If "Yes", please record the details on the "Adverse events or secondary illness" form in the Additional Forms section of the CRF on pg 30.0. All serious adverse events must be reported within 1 working day of occurrence to Roche </p> <p>Pg 30.0 of CRF (PDF pg 389) defines secondary illnesses as sinusitis, otitis media, bronchitis and pneumonia, and asks additional questions such as relationship to test drug and outcome, and leaves space for investigator's comments on the adverse event </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not listed as efficacy outcomes</p> <p>Recording of secondary illnesses was to occur in a form titled "Adverse event or secondary illness" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>732, 754, 791, 832</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRF form (PDF pg 732) states:</p> <p>Secondary illness reminder</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [ ] Complete secondary illness page (not the adverse event page)</p> <p>no [ ]</p> <p>Secondary illness page CRF (PDF pg 754) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose, and start/end date of treatment or medical procedure </p> <p>In addition, participants could fill in information related to a secondary illness in their diary card in the free‐text box called "Notes" which prompts participants: "Please can you record below any extra information about your flu which may be of interest to us, (for example: did your flu symptoms re‐occur, and if so when?), and have you taken any other treatments. If so please record the treatment name and the dates you took it." (PDF pg 791) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For investigators, on "Secondary illness" form</p> <p>For participants, on "Notes" section of diary card</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15671</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740, 889, 1018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRF form (PDF pg 740) states:</p> <p>Secondary illness reminder</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [ ] Complete secondary illness page (not the adverse event page)</p> <p>no [ ]</p> <p>Secondary illness page CRF (PDF pg 889) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose and start/end date of treatment or medical procedure </p> <p>Secondary illnesses are listed as sinusitis, otitis, bronchitis, pneumonia and other chest infections that are not diagnosed as bronchitis and/or pneumonia </p> <p>In addition, participants could fill in information related to a secondary illness in their diary card in the free‐text box called "Notes" which prompts participants: "Please can you record below any extra information about your flu which may be of interest to us, (for example: did your flu symptoms re‐occur, and if so when?), and have you taken any other treatments. If so please record the treatment name and the dates you took it." (PDF pg 1018) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mentioned in M1 and RAP as tertiary outcomes not mentioned in protocol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673/WV15697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 483</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No mention of pneumonia, secondary illness, complications in the CRFs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illnesses not listed in protocol as endpoints. They are listed as safety endpoints in the RAP which states that "pre‐defined" secondary illnesses were "sinusitis, otitis, bronchitis, pneumonia, and other chest infections that are not diagnosed as bronchitis and/or pneumonia, plus recurrence of symptoms from the diary card once alleviation had occurred." (PDF pg 479) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pg 117 Secondary illness reminder: Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [] ‐ Complete secondary illness page (not the adverse event page)</p> <p>no []</p> <p>Pg 131: <b>Diagnostic procedures</b> </p> <p>1) Were there any diagnostic procedures or tests carried out since day 1 as a result of influenza or secondary illness that were not scheduled as part of protocol?<br/> Yes </p> <p>Type of diagnostic procedure or test</p> <p>1 Chest X‐rays, 2 ECG, 3 Bacterial culture, 4 Bronchoscopy, 5 Pulmonary function test, 6 Viral culture (other than influenza), 7 Blood tests (other than antibody sample), 8 Other <i>specify</i> </p> <p>No</p> <p>Secondary illness page CRF (PDF pg 158) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose and start/end date of treatment or medical procedure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mentioned in RAP as tertiary endpoints pg 57‐8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 460</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness reminder at pg 474:</p> <p>Has the patient reported any new episodes of sinusitis, otitis, bronchitis, other chest infection or pneumonia since screening? </p> <p>yes [] ... <i>Complete adverse event page</i> </p> <p>no []</p> <p>"Adverse events" CRF collected data on date of onset, initial intensity, test drug adjustment, whether treatment was given (if so, what), most extreme intensity, relationship to test drug, outcome, whether it led to hospitalisation and a free‐text line for recording "Comments on AE" (e.g. PDF pg 479) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not mentioned in protocol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15730</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 340</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness reminder:</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [] ... <i>Complete secondary illness page (not the adverse event page)</i> </p> <p>no []</p> <p>The secondary illness page is descriptive of dates and px</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as tertiary endpoints in RAP at pg 297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15758</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 637</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses and secondary illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>Diagnostic confirmation of otitis media from pg 648 onwards</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as secondary illnesses in core report Module 1‐2 (pg 36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15759/871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 665</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the subject reported any adverse events including secondary and intercurrent illnesses?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illnesses not mentioned in protocol, but secondary outcome in core report</p> <p>Note: worth looking at comparisons 1.49 to 1.51 in RM5. No effect but in bronchitis this study has a more conservative effect than NV 16871 which has no definitions and no diagnostics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 642</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness defined as in M76001. There is a generic physical examination form at pg 704 including "lungs" normal/abnormal specify_______ </p> <p>At pg 709 has the patient reported any new AE including intercurrent or secondary illnesses yes/no. If y record the adverse events/intercurrent illness section of the CRF (noted at pf 746 on to be at the back of the CRF) with FULL HISTORY, PHYSICAL EXAMINATION AND DIAGNOSTIC WORK UP QUESTIONS FOR BRON+PNUM+LRTI+SIN+OM including questions about CXR, MRI, sputum etc. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of contacts who are classified as having a secondary illness subsequent to a confirmed episode of influenza listed as tertiary endpoints </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15812/872</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 285</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses and secondary illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>At pg 450‐74 is <b>DIAGNOSIS OF SECONDARY ILLNESS</b> page which is very similar to the one at serial 10 </p> <p>EXHAUSTIVE list of diagnostic procedures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as secondary tertiary in protocol at pg 252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15819/978/876</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pg 437 (adverse event reminder):</p> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>In CRF pg 447 and 443 usual secondary illness reminder</p> <p>From pg 471 <b>DIAGNOSTIC OF SECONDARY ILLNESS. This is a one page list of diagnostics similar to that at serial 10.</b> The question is: "Were there any diagnostic procedures or tests carried out since day 1 as a result of influenza or secondary illness that were not scheduled as part of protocol?" If yes list per serial 10 </p> <p>From pg 486 is a list of diagnostic tests</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness listed as secondary (required antibiotics) and tertiary outcomes in core report and as an addition in protocol amendment at pg 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is a usual note: please go to diagnosis of secondary illness at back of CRF. Pg 487: </p> <p>Is this event a secondary illness related to influenza?</p> <p><b>DIAGNOSTIC OF SECONDARY ILLNESS</b> </p> <p>From pg 510‐40 with exhaustive list of diagnostics as per serial 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness listed as secondary outcomes in protocol pg 346</p> <p>Secondary illnesses recorded on "Adverse events" CRF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV16277</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not found</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not found</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not listed as efficacy outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>#Events within the first 2 days of the study were excluded<br/> *Note that some events are reported as secondary illness and adverse event (AE) but some events are reported as secondary illness only and some events are reported as adverse event only<br/> BRON = bronchitis<br/> CRF = case report form<br/> CXR = chest x‐ray<br/> ECG = electrocardiogram<br/> LRTI = lower respiratory tract infection<br/> MRI = magnetic resonance imaging<br/> OM = otitis media<br/> PNUM = pneumonia<br/> px = prescription<br/> ˜RAP = reporting analysis plan<br/> SIN = sinusitis </p> </div> </div> <p>In all cases of influenza complications reporting (pneumonia, bronchitis, sinusitis, otitis media) there is a variable degree of participant self reporting, of investigator mediation (for example, in writing down the details in the case report form) and lack of verification with investigations such as culture or imaging. The 'self reported, investigator‐mediated, unverified' title is relevant to all complications but for brevity we use it as sparingly as possible. </p> <p>For harms we were limited by the frequency of occurrence of the adverse events collected in the trials. Consequently we meta‐analysed (1) all serious adverse events; (2) all adverse events leading to study withdrawal; (3) all withdrawals; (4) all adverse events within a clinical study report's defined body system; as well as (5) a small group of common adverse events as defined in the FDA drug label for oseltamivir. There were too few events to meta‐analyse (1) deaths; (2) serious adverse events by body system; and (3) any events that had an overall incidence of less than 0.5%. We did not meta‐analyse outcomes with fewer than 10 events in total. We conducted analyses separately for on‐treatment and off‐treatment periods. However, in two cases where (on‐treatment) treatment effects were borderline statistically significant (prophylaxis with oseltamivir: renal body system on‐treatment and psychiatric body system on‐treatment), we conducted additional analysis combining on‐ and off‐treatment periods to maximise statistical power. We conducted dose‐response harms analysis for two treatment trials (<a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a> and <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>) combined and one prophylaxis study (<a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>), as these trials investigated the active agent at multiple doses. These studies included standard‐dose and high‐dose oseltamivir arms. For these analyses we used logistic regression, adjusting for study effects if appropriate (i.e. for the two treatment trials) and testing for trend using a likelihood ratio test. We tested the hypothesis that increased dose of drug leads to increased incidence of adverse effects. </p> </section> </section> </section> </section> <section id="CD008965-sec-0067"> <h3 class="title">Search methods for identification of studies</h3> <p>To identify trials in the manufacturer‐funded clinical trial programmes for NIs, as well as non‐manufacturer‐funded clinical trials of NIs, we used a variety of methods applied to a variety of sources from the literature, manufacturers and from regulatory bodies. These methods, as well as our methodology for identifying and obtaining relevant clinical study reports, are detailed in <a href="./appendices#CD008965-sec-0142">Appendix 4</a>, <a href="./appendices#CD008965-sec-0143">Appendix 5</a> and <a href="./appendices#CD008965-sec-0146">Appendix 6</a>. </p> <section id="CD008965-sec-0068"> <h4 class="title">Electronic searches</h4> <p>We used electronic searches to identify trials not identified by the methods outlined in <a href="./appendices#CD008965-sec-0142">Appendix 4</a>, particularly for non‐manufacturer‐funded clinical trials. See <a href="./appendices#CD008965-sec-0143">Appendix 5</a> for details. For the 2012 review, we updated our searches of the electronic databases of published studies that were previously carried out for the Cochrane reviews on NIs in children (<a href="http://Matheson+2007" target="_blank">Matheson 2007</a>) and healthy adults (<a href="http://Jefferson+2010a" target="_blank">Jefferson 2010a</a>), and then updated the searches again on 22 July 2013. </p> </section> <section id="CD008965-sec-0069"> <h4 class="title">Searching other resources</h4> <p>For the description of our searches for regulatory information (FDA, EMA, Roche, GlaxoSmithKline (GSK), Japanese Pharmaceuticals and Medical Devices Agency (PMDA)), see <a href="./appendices#CD008965-sec-0146">Appendix 6</a>. </p> </section> </section> <section id="CD008965-sec-0070"> <h3 class="title" id="CD008965-sec-0070">Data collection and analysis</h3> <p>Collection and inventory of the evidence base was facilitated by the tools specifically developed for the review (<a href="./appendices#CD008965-sec-0147">Appendix 7</a>). The overall risk of bias is presented graphically in <a href="#CD008965-fig-0001">Figure 1</a> and summarised in <a href="#CD008965-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008965-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.  'Other bias' includes potentially active placebos." data-id="CD008965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.<br/> 'Other bias' includes potentially active placebos. </p> </div> </div> </div> <div class="figure" id="CD008965-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.  'Other bias' includes potentially active placebos." data-id="CD008965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.<br/> 'Other bias' includes potentially active placebos. </p> </div> </div> </div> <section id="CD008965-sec-0071"> <h4 class="title">Selection of studies</h4> <p>For this 2013 review, two authors (PD, TJ) reapplied the inclusion criteria for the oseltamivir clinical study reports and resolved disagreements by discussion. Two review authors (ES, IO) applied the criteria for the zanamivir clinical study reports while one review author (CH) arbitrated. </p> <p>For the procedures followed in the 2012 review, see <a href="./appendices#CD008965-sec-0148">Appendix 8</a> and <a href="./appendices#CD008965-sec-0149">Appendix 9</a>. </p> </section> <section id="CD008965-sec-0072"> <h4 class="title">Data extraction and management</h4> <p>The sizeable quantity of available data led us to subdivide the extraction, appraisal and analysis of the data into a two‐stage exercise. In Stage 1 we assessed the reliability and completeness of the identified trial data. We decided to include in Stage 2 of the review (full analysis following standard Cochrane methods) only data that satisfied the following three criteria. </p> <p> <ol id="CD008965-list-0006"> <li> <p>Completeness. Clinical study reports/unpublished reports include both identifiable CONSORT statement‐specified methods to enable replication of the study. Identifiable CONSORT statement‐specified results (primary outcomes, tables, appendices) must be available. </p> </li> <li> <p>Internal consistency. All parts (for example, denominators) of the same clinical study reports/unpublished report are broadly consistent. </p> </li> <li> <p>External consistency. Consistency of data as reported in regulatory documents, other versions of the same clinical study reports/unpublished reports and other references, to be established by cross‐checking. </p> </li> </ol> </p> <p>This was a different approach to that used in the previous version of the current review (<a href="./references#CD008965-bbs2-0305" title="JeffersonT , JonesMA , DoshiP , DelMarCB , HeneghanCJ , HamaR , et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD008965.pub3] ">Jefferson 2012</a>), since we only had incomplete information at that time and only applied the second and third criteria. </p> <section id="CD008965-sec-0073"> <h5 class="title">Stage 1</h5> <p>For details of the use of the CONSORT‐based extraction template and the assessment for Stage 1 inclusion in the A159 (<a href="./references#CD008965-bbs2-0305" title="JeffersonT , JonesMA , DoshiP , DelMarCB , HeneghanCJ , HamaR , et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD008965.pub3] ">Jefferson 2012</a>) review, see <a href="./appendices#CD008965-sec-0147">Appendix 7</a>. In this review assessment for inclusion in Stage 1 was part of the inclusion procedure. </p> </section> <section id="CD008965-sec-0074"> <h5 class="title">Stage 2</h5> <p>In Stage 2, one review author extracted data and a second review author checked it. We extracted data onto standard forms, checked and recorded it. </p> </section> <section id="CD008965-sec-0075"> <h5 class="title">Use of regulatory information</h5> <p>We used regulatory information to assess the possible correlation between citation frequency of oseltamivir treatment trials in the FDA regulatory documents and trial size. </p> </section> <section id="CD008965-sec-0076"> <h5 class="title">Post‐protocol analyses</h5> <p>After publication of the A159 protocol in December 2010, but before validation of our CONSORT‐based extractions in the Northern Hemisphere spring of 2011, we decided to carry out analyses (which we called post‐protocol analyses) to test five null hypotheses that we had formulated while reading, summarising and reconstructing the clinical study reports. The hypotheses originated from our observations of discrepancies and other unexpected observations in the clinical study reports' data and were informed by reading regulatory information. <a href="./appendices#CD008965-sec-0150">Appendix 10</a> reports the rationale, methods to formulate and test, and the results of the hypotheses. </p> <p>The hypotheses reflect the uncertainty prevailing in the evidence base at a time when full clinical study reports were not available for all studies. </p> </section> </section> <section id="CD008965-sec-0077"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Previous studies comparing regulatory with published or internal company sources of evidence have reported a variety of different biases that affect medical knowledge (<a href="./references#CD008965-bbs2-0198" title="ChouR , HelfandM . Challenges in systematic reviews that assess treatment harms. Annals of Internal Medicine2005;142(2 Pt 2):1090‐9. ">Chou 2005</a>; <a href="./references#CD008965-bbs2-0261" title="MacLeanCH , MortonSC , OfmanJJ , RothEA , ShekellePG . How useful are unpublished data from the Food and Drug Administration in meta‐analysis?. Journal of Clinical Epidemiology2003;56(1):44‐51. ">MacLean 2003</a>; <a href="./references#CD008965-bbs2-0265" title="McGauranN , WieselerB , KreisJ , SchulerY , KolschH , KaiserT . Reporting bias in medical research ‐ a narrative review. Trials2010;11(1):37. ">McGauran 2010</a>; <a href="./references#CD008965-bbs2-0303" title="WieselerB , WolframN , McGauranN , KerekesMF , VervölgyiV , KohleppP , et al. Completeness of reporting of patient‐relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Medicine2013;10(10):e1001526. ">Wieseler 2013</a>). We will report in detail elsewhere our comments on using the Cochrane 'Risk of bias' tool (<a href="./references#CD008965-bbs2-0241" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.cochrane‐handbook.org. ">Higgins 2011</a>) to appraise clinical study reports and for trial programmes, and our efforts to construct an instrument for assessing risk of bias in complete clinical study reports. A full description of the methods used to quantify biases will be published in another paper. </p> </section> <section id="CD008965-sec-0078"> <h4 class="title">Measures of treatment effect</h4> <p>To estimate treatment effects we first calculated the risk ratios (RRs) and used the average (mean) control event rate and the pooled RRs reported in the figures to calculate the risk differences (RD). For consistency we adopted this method for both the 'Summary of findings' tables and for the RDs reported in the text. For the analysis we chose to report the RRs as they are more consistent across the studies, and we have reported the heterogeneity for the pooled RR. We reinterpreted the results using the RD as this result is applicable to clinical decision‐making. We calculated mean differences (MDs) for time to first alleviation of symptoms. For time to first alleviation of symptoms we also estimated the treatment effect as the percentage reduction in the average time to first alleviation of symptoms in the placebo group. Most zanamivir clinical study reports only reported treatment effects in terms of medians in each treatment group as well as P values from a hypothesis test comparing the time‐to‐event distributions. These data are insufficient for conducting meta‐analysis. However, often sufficient time‐to‐event data were reported to allow us to estimate restricted means and standard deviations. Restricted means are based on the maximum time reported where alleviation occurred. There were some patients where alleviation was censored at the maximum follow‐up time, therefore restricted means are under‐estimates of the true means. However, the proportion of patients censored was generally low and similar in both treatment arms, hence this limitation is unlikely to have led to bias. The length of follow‐up varied across trials and this has led to high variation in the estimated means and standard deviations (SDs) across trials. </p> <p>A post hoc analysis was undertaken after we discovered seven zanamivir trials provided data on time to first alleviation of symptoms with and without relief medication. Each patient in the studies may or may not have taken relief medication during the trial. Alleviation of symptoms may have occurred while the patient was taking relief medication and the "standard" comparison was made using this scenario. However, an additional analysis used a stricter definition where alleviation of symptoms could only be achieved without the use of relief medication. For example, a patient may have achieved alleviation using relief medication after five days but took seven days to achieve alleviation without the use of relief medication. The comparison we reported is for all patients where we used the stricter definition for the zanamivir group (alleviation without relief medication) and the less strict definition for the placebo group (alleviation with relief medication). </p> <p>We planned to use the tri‐dimensional dose‐relatedness, timing and patient susceptibility (DoTS) methodology to assess the likelihood of harms causality (<a href="./references#CD008965-bbs2-0189" title="AronsonJK , FernerRE . Joining the DoTS: new approach to classifying adverse drug reactions. BMJ2003;327(7425):1222‐5. ">Aronson 2003</a>), but the quality of the data available did not allow for this. </p> </section> <section id="CD008965-sec-0079"> <h4 class="title">Unit of analysis issues</h4> <p>Problems with unit of analysis are described in the 'Risk of bias' and 'Post‐protocol hypotheses' sections. </p> </section> <section id="CD008965-sec-0080"> <h4 class="title">Dealing with missing data</h4> <p>We developed a comprehensive strategy for dealing with data that we know are missing at the trial level, i.e. unpublished trials (see <a href="#CD008965-sec-0067">Search methods for identification of studies</a> section and <a href="./appendices#CD008965-sec-0142">Appendix 4</a>, <a href="./appendices#CD008965-sec-0143">Appendix 5</a> and <a href="./appendices#CD008965-sec-0146">Appendix 6</a>) and unreliable published records, which are a very concentrated summary of clinical study reports. For example, in the oseltamivir trial programme, some trials' clinical study reports (e.g. <a href="./references#CD008965-bbs2-0159" title="A randomized, double blind, parallel group, placebo controlled study of the effect of oseltamivir on ECG intervals in healthy subjects. Data on file. ">WP16263</a>) consist of 8545 pages. This has a 1000‐fold greater length compared to its published version (<a href="./references#CD008965-bbs2-0207" title="DutkowskiR , SmithJR , DaviesBE . Safety and pharmacokinetics of oseltamivir at standard and high dosages. International Journal of Antimicrobial Agents2010;35:461–7. ">Dutkowski 2010</a>), which consists of seven pages. The purpose of this review is to provide as complete a picture as possible of trial programmes, without reliance on the published literature. <a href="./appendices#CD008965-sec-0151">Appendix 11</a> reports an example of the content of a typical Roche clinical study report. </p> </section> <section id="CD008965-sec-0081"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used Tau<sup>2</sup> (inverse variance method) and the I<sup>2</sup> statistic to estimate between‐study variance as measures of the level of statistical heterogeneity and the Chi<sup>2</sup> test to test for heterogeneity. </p> </section> <section id="CD008965-sec-0082"> <h4 class="title">Assessment of reporting biases</h4> <p>We carried out assessment of reporting biases (comparing clinical study report with the relevant publication) only in the first publication of A159. For this version, as we had complete clinical study reports for the trial programmes of the two drugs, we expected to find all relevant information in these documents and adopted a binary assessment (high risk, low risk or unclear bias). </p> </section> <section id="CD008965-sec-0083"> <h4 class="title">Data synthesis</h4> <p>We used the random‐effects approach of DerSimonian and Laird based on MDs for analysis of time to first alleviation of symptoms. For all other outcomes we used the random‐effects approach for binary data of DerSimonian and Laird, where Tau<sup>2</sup> was estimated using the inverse variance method. </p> <p>Whilst overall symptom reduction is well documented, our interest was particularly focused on complications and adverse events, as this is where evidence is currently scarce or inconclusive (<a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>; <a href="./references#CD008965-bbs2-0262" title="MathesonNJ , HarndenAR , PereraR , SheikhA , Symmonds‐AbrahamsM . Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002744.pub2] ">Matheson 2007</a>; <a href="./references#CD008965-bbs2-0283" title="Shun‐ShinM , ThompsonM , HeneghanC , PereraR , HarndenA , MantD . Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta‐analysis of randomised controlled trials. BMJ2009;339:b3172. ">Shun‐Shin 2009</a>). Our preliminary examination of clinical study reports identified that some symptoms and sequelae of influenza (such as “pneumonia”) had been classified as either a ‘complication of influenza’ or as an 'adverse event of the treatment’ or both. We called this somewhat confusing classification 'compliharms'. We decided to deal with compliharms as follows. We identified complications of particular clinical interest as “pneumonia”, bronchitis, otitis media and sinusitis. We tabulated the type of data capture used for each complication (“secondary illness”) by study including the following variables: definition of what events are termed complications, which part of the clinical study report captured data on complications, who reported and captured the data, which diagnostic method was used, whether and where the diagnostic pathway was (usually a form) and whether prescription for treatment were captured. We then aimed to stratify our analysis by method of diagnosis with three possible criteria: (1) laboratory‐confirmed diagnosis (e.g. based on radiological‐ or microbiologically‐confirmed evidence of infection); (2) clinical diagnosis without laboratory‐confirmation (diagnosed by a doctor/investigator after a clinical examination); (3) other type of diagnosis such as self‐reported by patient. We also conducted analysis of any complication (such as “pneumonia”, bronchitis, otitis media and sinusitis) that was classified as serious or led to study withdrawal. </p> <p>We tested the effects of oseltamivir in prophylaxis of influenza and influenza‐like illness. However the clinical study reports of prophylaxis trials do not define influenza‐like illness but report eight different definitions for influenza with laboratory‐confirmation (see web extra influenza definitions). </p> <p>This is a complex and confusing set of definitions where, for example, the definition for Upper Respiratory Tract Infection (URTI) with systemic disturbance is the same as one of the definitions for asymptomatic influenza. After discovering the absence of a definition for influenza‐like illness and the complex and confusing definitions for laboratory‐confirmed influenza, we classified influenza‐like illness as two or more symptoms from the following: nasal congestion, headache, chills/sweats, sore throat, cough, fatigue, myalgia and fever. These were the symptoms reported in the efficacy listing of individual patients in Module 3 of the prophylaxis trials clinical study reports. </p> <p>In two oseltamivir treatment trials (<a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>) and one prophylaxis study (<a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>) there were three treatment arms comparing placebo, standard dose and high dose. For time to first alleviation of symptoms we restricted comparison to placebo versus standard dose (as this is how it was reported in the original report). However, for all other outcomes we combined the standard and high‐dose treatment arms. There was little apparent difference in the incidence of outcomes between the standard and high‐dose arms and combining the arms did not appear to cause heterogeneity. However, in two cases there was some evidence of a dose‐response effect. These cases are described more fully in the <a href="./full#CD008965-sec-0086">Results</a> section under 'Analysis of harms'. </p> <p>The majority of zanamivir trials compared placebo with inhaled zanamivir. However, some trials also included an intranasal zanamivir treatment arm and a combined arm of inhaled and intranasal treatment. The multiple zanamivir arms were generally combined for meta‐analysis as effects appeared similar and did not appear to cause heterogeneity. </p> </section> <section id="CD008965-sec-0084"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated the robustness of complications outcomes using subgroup analysis by method of diagnosis. We investigated high estimates of heterogeneity, where possible, using subgroup analysis. For example, we conducted subgroup analysis of time to first alleviation of symptoms in studies of oseltamivir treatment in children by partitioning studies into those of otherwise healthy children and those of children with chronic illness (asthma). Based on a referee's comment, we conducted a subgroup analysis on time to first alleviation of symptoms by infection status for zanamivir. We could not do a similar analysis for oseltamivir because we did not have data on the non‐influenza‐infected patients and we could not correctly identify the patients with influenza infection due to the effect of oseltamivir on antibodies. </p> <p>In the trial programmes for both oseltamivir and zanamivir there was large variation in treatment effects for pneumonia across the populations studied (i.e. adults and children as well as treatment and prophylaxis), hence we conducted meta‐regression to investigate this heterogeneity. We included all studies that reported pneumonia (32 studies in total) and investigated the four binary factors: age group (adults versus children); drug (oseltamivir versus zanamivir); indication (treatment versus prophylaxis) and method of diagnosis. For oseltamivir studies, the method of diagnosis was either based on data collected on non‐specific adverse events or secondary/intercurrent illness forms or data collected on specific "diagnosis of secondary illness" forms that included objective criteria such as X‐ray confirmation. For zanamivir, two trials included X‐ray confirmation of pneumonia. We conducted meta‐regression in Stata/SE, version 13 for Windows using the <i>metareg</i> command. There were some studies where one treatment group had zero events, therefore we added 0.5 events to all treatment groups for all studies prior to analysis. The dependent variable in the regression was log relative risk. A further post hoc analysis was undertaken after we discovered seven trials provided data on time to first alleviation of symptoms with and without relief medication. Each patient in the studies may or may not have taken relief medication during the trial. Alleviation of symptoms may have occurred while the patient was taking relief medication and the "standard" comparison was made using this scenario. However, an additional analysis used a stricter definition where alleviation of symptoms could only be achieved without the use of relief medication. For example, a patient may have achieved alleviation using relief medication after five days but took seven days to achieve alleviation without the use of relief medication. The comparison we reported is for all patients where we used the stricter definition for the zanamivir group (alleviation without relief medication) and the less strict definition for the placebo group (alleviation with relief medication). </p> </section> <section id="CD008965-sec-0085"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses applicable to our post‐protocol analyses have been covered earlier in the Methods section of this review. We used the fixed‐effect method of Mantel and Haenszel as a sensitivity analysis to supplement our primary analyses using the random‐effects method of DerSimonian and Laird. Random‐effects meta‐analysis is known to be overly conservative with sparse data. Hence we conducted sensitivity analysis using Peto's method on two occasions where we had sparse data and borderline statistically significant results (prophylaxis with oseltamivir: renal body system on‐treatment and psychiatric body system on‐treatment). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008965-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008965-sec-0086"></div> <section id="CD008965-sec-0087"> <h3 class="title">Description of studies</h3> <p>We searched trial registries, electronic databases and regulatory archives, corresponded with manufacturers to identify all trials and requested clinical study reports. Although this review focuses on the primary data sources of manufacturers, we checked that there were no published randomised controlled trials (RCTs) from non‐manufacturer sources by running electronic searches in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 6), limited to year published 2010 to 2013 (20 search results); MEDLINE (January 2011 to July week 2, 2013) (56 search results) and MEDLINE (Ovid) from 1 January 2011 to July week 2, 2013 (56 search results); EMBASE (January 2011 to July 2013) (90 search results) and Embase.com from 1 January 2011 to July 2013 (90 search results); and PubMed (not MEDLINE) with no date limit (21 records). We searched PubMed to identify publisher‐submitted records that will never be indexed in MEDLINE and the most recently added records not yet indexed in MEDLINE. To identify reviews that may possibly have referenced further trials we searched: the Database of Reviews of Effects (DARE) (2013, Issue 2 of 4 April) (four search results); the NHS Economic Evaluation Database (NHSEED) (Issue 2 of 4 April 2013) (two search results), both resources part of <i>The Cochrane Library</i> (accessed 22 July 2013), and the Health Economic Evaluations Database (HEED) (searched 22 July 2013) (three search results). </p> <section id="CD008965-sec-0088"> <h4 class="title">Results of the search</h4> <section id="CD008965-sec-0089"> <h5 class="title">Use of regulatory information</h5> <p>We were able to download 2673 pages from the FDA website. The table of contents is in <a href="#CD008965-tbl-0002">Table 2</a>, <a href="#CD008965-tbl-0003">Table 3</a>, <a href="#CD008965-tbl-0004">Table 4</a> and <a href="#CD008965-tbl-0005">Table 5</a>. We used these pages to identify all trials that had been conducted within a drug's trial programme. There was no correlation between citation frequency of oseltamivir treatment trials in the FDA regulatory documents and trial size. The biggest treatment trial (<a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>) is cited only four times in three documents, while other contemporary treatment trials are cited far more (<a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>; <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>; <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>; <a href="./references#CD008965-bbs2-0037" title="GrosseM . A multi‐center, randomized, double‐blind, placebo‐controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Data on file. ">WV15707</a>). <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>, for example, is cited 46 times in the FDA documents. However, the combined enrolled denominator of the four treatment trials completed at the time (<a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>; <a href="./references#CD008965-bbs2-0037" title="GrosseM . A multi‐center, randomized, double‐blind, placebo‐controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Data on file. ">WV15707</a>; <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>) was 1442, smaller than <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a> (1459). This suggested that the FDA's regulatory evaluation of Roche's New Drug Application was based predominantly on what Roche had offered them as "pivotal" or trials that best demonstrated the properties of oseltamivir, not the complete evidence base of all oseltamivir trials. One possible alternative explanation for this observation could have been the interval between trial completion, generation of the report and New Drug Applications (NDA) submission. This explanation is supported by the relatively brief interval between completion of the <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a> trial (19 February 1999) and submission (on 30 April 1999) of NDA 021087 to the FDA. However, the core part of the submission (the clinical development programme) contains data from two (at the time) ongoing trials (<a href="./references#CD008965-bbs2-0044" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza infection in elderly patients. Data on file. ">WV15819/WV15876/WV15978</a>; <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>). </p> <div class="table" id="CD008965-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from the FDA (USA)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mentioned study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113502</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113625</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113678</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI108166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105934</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI106784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107485</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112311</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GCP/95/045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10902</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 14 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19, 19, 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 3, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/21036ltr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 110 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 10, 12, 13, 13, 14, 14, 17, 29, 42, 61, 62, 64, 64, 65, 65, 68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 34, 36, 43, 43, 43, 43, 52, 52, 52, 53, 53, 56, 57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 5, 6, 6, 8, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 3, 3, 3, 3, 4, 4, 5, 8, 9, 9, 10, 10, 11, 11, 11, 14, 14, 15, 16, 17, 19, 19, 19, 20, 20, 22, 23, 23, 23, 24, 24, 24, 25, 25, 25, 25, 25, 25, 26, 26, 26, 27, 27, 28, 28, 28, 29, 29, 31, 31, 31, 31 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MICROBR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 4, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 2, 4, 7, 12, 18, 18, 18, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 65 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 12, 13, 14, 14, 15, 17, 62, 62, 62, 64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34, 34, 36, 43, 53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 3, 3, 4, 5, 18, 19, 21, 21, 22, 23, 23, 23, 23, 24, 25, 25, 25, 26, 26, 26, 26, 27, 27, 27, 28, 28, 29, 29, 29, 30, 31, 31, 31, 32 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 13, 13, 13, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30028</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30034</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI40012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIA1009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 17 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 48, 49, 52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 6, 7, 20, 31, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>NAIA3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 documents with 122 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 7, 7, 14, 15, 22, 22, 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 4, 4, 12, 12, 12, 12, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 14, 14, 14, 14, 14, 15, 15, 15, 15, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 2, 3, 4, 4, 5, 6, 6, 6, 8, 8, 9, 9, 9, 12, 12, 15, 16, 16, 16, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9, 9, 10, 11, 12, 13, 13, 14, 15, 15, 17, 18, 18, 19, 20, 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 1, 2, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 2, 2, 2, 2, 3, 3, 4, 4, 5, 5, 7, 8, 10, 11, 12, 14, 16, 16, 16, 16, 16, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 6, 6, 8, 8, 9, 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐stats.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIA3003</p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17, 17, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NAIA3004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 18, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NAIA3005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12, 12, 12, 13, 14, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 documents with 99 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 14, 14, 14, 14, 14, 14, 14, 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9, 9, 9, 9, 9, 9, 10, 11, 12, 12, 12, 12, 13, 13, 13, 14, 14, 14, 15, 15, 16, 16, 16, 17 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 6, 6, 6, 7, 7, 7, 8, 8, 8, 9, 9, 11, 12, 12, 13, 13, 14, 15, 17, 18, 18, 19, 20, 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 1, 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 3, 7, 8, 10, 11, 14, 15, 16, 16, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 8, 8, 8, 9, 9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐stats.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAIB2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 18 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15, 16, 16, 17, 17, 17, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8, 10, 10, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C94‐085</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NAIB1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIA2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 44 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 17, 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 3, 3, 3, 3, 5, 6, 6, 6, 6, 8, 8, 8, 9, 11, 12, 12, 13, 14, 14, 14, 14, 14, 15, 18 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 9, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐microbiology.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIB2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 43 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17, 20, 20, 22, 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 7, 8, 8, 8, 9, 10, 11, 11, 11, 11, 11, 12, 12, 12, 13, 14, 14, 14, 14, 14, 14, 14, 15 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 9, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐microbiology.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA/B2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA/B2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PE‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167T3‐11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Zanamivir trials citation by trial ID and source FDA file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which regulatory file. Blank spaces indicate no citation for known trials. </p> <p>All the studies have been searched in the folder "Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036". File name is left blank when the study was not present in that folder. </p> </div> </div> <div class="table" id="CD008965-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from the FDA (USA)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Referenced study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NP15717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 13 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 8, 10, 13, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15718</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NP15728 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45, 46, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92, 93, 104, 122, 126, 131, 144, 144, 145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NP15826 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 26 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 5, 8, 8, 8, 10, 17, 29, 30, 30, 30, 30, 30, 31, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NP15827 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 7 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15525 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21, 25, 26, 27, 27, 27, 27, 42, 42, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 document with 13 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WP15647</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 27, 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15648 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94, 128, 153, 153, 154</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15676 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15670 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 44, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 45 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 19, 37, 38, 39, 39, 39, 39, 40, 41, 41, 42, 43, 44, 48, 48, 49, 49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 25, 25, 35, 35, 39, 39, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 4, 4, 5, 5, 5, 8, 9, 10, 17, 17, 21, 22,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15671 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 44, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 50 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 16, 19, 24, 24, 25, 25, 26, 27, 27, 28, 32, 34, 35, 36, 37, 38, 39, 39, 39, 40, 41, 46, 49, 49 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 25, 25, 35, 38, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 4, 5, 5, 5, 5, 9, 10, 10, 15, 17, 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15673 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 50 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 18, 18, 20, 21, 21, 21, 22, 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58, 59, 71, 71, 71, 71, 71, 72, 72, 73, 73, 76, 76, 76, 76, 76, 77, 77, 79, 82, 83, 83, 84, 122, 124, 125, 126, 128, 131, 131, 132, 133, 134, 134, 145, 145, 156, 169, 177, 189 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15697 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 40 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58, 59, 71, 71, 71, 71, 71, 72, 72, 73, 73, 76, 76, 76, 76, 76, 77, 77, 79, 82, 83, 83, 84, 122, 126, 128, 131, 131, 131, 132, 133, 134, 145, 145, 152, 153, 156, 162, 189 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15708 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 39 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23, 35, 39, 41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71, 71, 71, 71, 71, 72, 72, 72, 72, 75, 75, 75, 75, 77, 77, 78, 79, 79, 82, 82, 122, 125, 125, 126, 131, 134, 134, 135, 135, 149, 151, 152, 152, 153 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15708D </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>WV15730 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 15 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 9, 19, 49, 50, 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 25, 25, 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15731 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 30, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 30, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>WV15758 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12, 19, 19, 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 92 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 8, 17, 39, 39, 57, 57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 5, 5, 5, 8, 10, 17, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Corres.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 9, 9, 10, 11, 12, 12, 16, 18, 18, 18, 19, 19, 31, 31, 31, 33, 33, 35, 36, 37, 37, 37, 37, 37, 37, 37, 40, 43 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 9, 9, 10, 11, 12, 12, 16, 18, 18, 18, 19, 19, 31, 31, 31, 33, 33, 35, 36, 37, 37, 37, 37, 37, 37, 37, 40, 43 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15759 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 44 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 10, 30, 30, 30, 30, 31, 32, 32, 33, 34, 37, 37, 37, 40, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 4, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 10, 30, 30, 30, 30, 31, 32, 32, 33, 34, 37, 37, 37, 40, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15799 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 28, 28, 28, 29, 29, 30, 30, 30, 30, 30, 31, 31, 31, 31, 32, 32, 32, 32, 32, 33, 33, 34, 34, 35, 35, 35, 36, 37, 37, 37, 37, 37, 38, 38, 38, 39, 39, 40, 40, 40, 40, 40, 58, 60, 71, 71, 71, 71, 71, 72, 72, 73, 76, 76, 76, 77, 78, 79, 84, 85, 122, 125, 125, 126, 126, 128, 131, 140, 140, 140, 143, 147, 149, 156, 162, 169, 175, 187, 203, 208, 208 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 89 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15812 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 8, 10, 25, 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15819 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 10, 12, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 6, 6, 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41, 41, 41, 41, 42, 42, 42, 42, 42, 42, 43, 44, 58, 59, 71, 71, 71, 71, 71, 72, 72, 72, 72, 73, 73, 75, 75, 77, 77, 78, 79, 79, 79, 80, 80, 80, 81, 82, 85, 125, 125, 126, 126, 128, 131, 134, 134, 135, 135, 137, 137, 138, 145, 150, 151, 152, 152, 155, 156, 162, 169, 180, 204, 211 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 64 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15871 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 42 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 11, 30, 31, 31, 32, 32, 32, 33, 34, 37, 37, 37, 37, 37, 37, 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 11, 30, 31, 31, 32, 32, 32, 33, 34, 37, 37, 37, 37, 37, 37, 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15872 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Oseltamivir trials citation by trial ID and source FDA file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which regulatory file. Blank spaces indicate no citation for known trials. </p> <p>Search strategy:<br/> WV15758 OR WV 15758 OR Trial 15758 OR Trial15758 OR Trials 15758 OR Trials15758 OR 15758 OR study 15758 OR study15758 </p> </div> </div> <div class="table" id="CD008965-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from NICE (UK)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mentioned study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI106784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107485</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112311</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GCP/95/045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10902</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission executive summary.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 10 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 26, 146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 461 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\suptables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\tables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 19, 27, 30, 31,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 19, 27, 30, 31, 76, 128, 130, 132, 134, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report\Final NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 399 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\NAI30010 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\suptables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\tables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 8, 11, 12, 19, 20, 21, 23, 24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 27, 30, 31, 76, 135, 137, 139, 141, 143, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission executive summary.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30028</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30031</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30034</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI40012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NAIA1009</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIA3002</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 513 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 supporting tables 2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 47, 49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31, 63, 63, 63, 76, 106, 106, 107, 107, 109, 109, 112, 112, 114, 114, 115, 115, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NAIA3005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 94, 94, 94, 95, 96, 96, 101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 310 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\NAI30010 HO FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\TABS.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 6, 12, 13, 13, 15, 15, 16, 16, 17, 17, 18, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>NAIB3001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34, 50, 95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 documents with 374 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf \NAI30010 HO FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 supporting tables 1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 27, 30, 31, 32, 63, 63, 63, 76, 99, 99, 101, 101, 103, 103, 105, 105, 144, 162 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 27, 30, 31, 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 579 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 48, 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002supporting tables 1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002supporting tables 2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31, 63, 63, 63, 76, 117, 117, 117, 118, 118, 120, 120, 122, 122, 124, 124, 125, 125, 127, 127, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIB2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 379 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\TABLES.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 19, 27, 30, 31, 76, 91, 91, 92, 92, 94, 94, 96, 96, 98, 98, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NAIA2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38, 73, 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIB2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐085</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB_1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>NAIA2005</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 documents with 895 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\APPS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\TBS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 48, 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\b2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 7, 22, 25, 26, 34, 34, 42, 71, 72, 72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 47, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30, 76, 77, 77, 77, 79, 79, 79, 80, 80, 82, 82, 84, 84, 85, 144, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>NAIB2005</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 documents with 838 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 8, 8, 24, 24, 25, 43, 70, 74, 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 48, 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\APPSNEW.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\b2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\TBS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 47, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30, 76, 77, 79, 79, 85, 85, 85, 86, 86, 88, 88, 90, 90, 144, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NAIA/B2008</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 16 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25, 26, 26, 26, 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIA/B2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PE‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167T3‐11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Zanamivir trials citation by trial ID and source NICE file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which file. Blank spaces indicate no citation for known trials </p> </div> </div> <div class="table" id="CD008965-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from NICE (UK)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Referenced study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name volume*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS97‐802</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS‐97‐801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JP15734</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JP15735</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV15823</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV15824</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV16284</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 67, 68, 94, 95, 224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML20910</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML22789</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML22879</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MV21118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MV22841</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00298233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00555893</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00707941</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00799760</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00830323</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML25018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00867139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00873886</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01002729</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NP15717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32, 75, 76, 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15718</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15728</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15826</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32, 75, 75, 75, 76, 76, 77, 78, 79, 80, 98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 11 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15827</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP22770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP25138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP25139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV16871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20234</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20235 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20237</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV22155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV25118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV25182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PP16351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15517</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.245</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15525</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.245</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15647</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15648</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15676</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP22849</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV144181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>WV15670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 48, 48, 49, 49, 50, 53, 54, 54, 55, 163, 171, 188, 207, 209, 224, 245, 245, 252, 253, 253 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 1193 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20, 20, 20, 20, 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15671</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 48, 49, 49, 50, 53, 54, 54, 55, 163, 171, 188, 207, 209, 224, 245, 245 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 1222 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15697D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 67, 68, 224, 245, 245, 245, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15730</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 53, 54, 55, 186, 207, 224, 245, 245, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 22 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15731</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15758</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 82, 83, 84, 85, 86, 92, 94, 95, 97, 106, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 424 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15759</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 94, 95, 95, 109, 113, 114, 121, 122, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137, 139, 139, 232, 233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 499 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15812</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107, 107, 108, 108, 121, 121, 122, 123, 224, 246 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 197 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15819</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 58, 58, 59, 59, 60, 61, 62, 62, 65, 65, 67, 68, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 173 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66, 66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15872</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107, 108, 108, 121, 121, 122, 123, 224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 18 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15876</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15978</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67, 70, 175, 246, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV16193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML16369</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Oseltamivir trials citation by trial ID and source NICE file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which file. Blank spaces indicate no citation for known trials. </p> <p>All the studies have been searched in the folder "Roche submission".</p> <p>When there is the number of the volume but no pages are mentioned, it means that the code of the study is cited more than 100 times. </p> <p>*Number of the volume of the Tamiflu NICE submission.</p> </div> </div> <p>The basis of the selection of trials to regulators is therefore unclear but appears to be dictated by criteria other than availability and size. The importance of trials (to manufacturers and possibly to regulators) may not be based on the same criteria that systematic reviewers would use (i.e. the capability of the trial to answer questions). </p> <p>Due to the vast size of FDA documents, sometimes hundreds of pages long, it was difficult to determine important emerging themes solely by reading. To identify items of interest in the FDA comments we used word clouds (<a href="./references#CD008965-bbs2-0225" title="FeinbergJ . Wordle. http://www.wordle.net/ 2009 (accessed 15 September 2010). ">Feinberg 2009</a>). Word clouds give greater prominence to words that appear more frequently in the source document. The resulting graphic representation showed words such as 'diary' and 'baseline' to be heavily mentioned in the relevant (abridged) text from the FDA's Medical Officer Review (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>, PDF page 19). Examining the 'diary' entry in more detail, we found the following FDA comment: </p> <p>"The majority of subjects participating in the treatment trials had only used the first diary card. The second diary card was issued in 15% to 20% of participants. In response to FDA's request, the applicant provided a summary of diary card dispensing in the 8/6/99 submission. It became apparent that instructions on when to start a second diary card were not uniformly followed in <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>, <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>, and <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a> trials. There were examples of patients who had alleviated symptoms yet also received a second diary card. Conversely, there were also examples of patients who did not alleviate all symptoms but did not receive a second diary card. Thus the second diary card was used inconsistently which is viewed as a flaw of these trials. The lack of consistency in collecting symptom information after alleviation precluded a complete documentation of symptom fluctuation. Also missing second diary cards in subjects who had not alleviated symptoms were responsible for the majority of censored data which may have potentially influenced the results of efficacy analysis. In order to address the impact of censoring, the applicant performed several sensitivity analyses which will be summarized in the Integrated Summary of Efficacy". </p> <p>This comment highlights problems with the follow‐up procedure of treatments trials, which may have impaired the regulator's ability to draw conclusions on the duration of effect of oseltamivir. It also provides a good example of how graphic methods can help identify crucial comments in vast regulatory files. </p> <p>Several other experiments with text from the same FDA document showed that the choice of text to be represented as a Word cloud heavily influenced cloud construction, visibility of words and hence our ability to detect important comments. It is for this reason that we decided to adopt a mixed approach: mapping citations while reading FDA comments and integrating such comments in our appraisal of the evidence. Regulatory comments were all the more important, because at the time we developed this method we had few clinical study reports and comments helped to identify the gaps in our knowledge of the trial programmes. </p> <p>Once the table of contents had been constructed, we postulated that given the huge work involved in reviewing lots of regulatory files, our new instrument could also help us by indicating which parts were more important than others, thus focusing our efforts. We experimented with a variety of methods reported in the <a href="#CD008965-sec-0070">Data collection and analysis</a> section. </p> </section> <section id="CD008965-sec-0090"> <h5 class="title">Clinical study reports</h5> <p>After prolonged correspondence and media pressure (<a href="./appendices#CD008965-sec-0140">Appendix 2</a>), we were able to access the trial programmes for both oseltamivir and zanamivir without clauses restricting their accessibility to third parties. </p> </section> <section id="CD008965-sec-0091"> <h5 class="title">Electronic searches</h5> <p>Two review authors (CDM, MT) independently scanned the titles and abstracts of the electronic searches. Three identified studies (<a href="./references#CD008965-bbs2-0186" title="AnekthananonT , PukritayakameeS , RatanasuwanW , JittamalaP , WerarakP , CharunwatthanaP , et al. Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: A randomized, double‐blind, placebo‐controlled safety trial over 16 weeks. Journal of Antimicrobial Chemotherapy2013;68:697‐707. [NCT00980109 ] ">NCT00980109</a>; <a href="./references#CD008965-bbs2-0187" title="DharanNJ , FryAM , KiekeBA , ColemanL , MeeceJ , VandermauseM , et al. Clinical and virologic outcomes in patients with oseltamivir‐resistant seasonal influenza A (H1N1) infections: results from a clinical trial. Influenza and Other Respiratory Viruses2012;6:153‐8. ">NCT01032837</a>; <a href="./references#CD008965-bbs2-0170" title="KashiwagiS , WatanabeA , IkematsuH , AwamuraS , OkamotoT , UemoriM , et al. Laninamivir octanoate for post‐exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. Journal of Infection and Chemotherapy2013;19:740‐9. ">JPRN‐JapicCTI‐111647</a>) were published versions of trials possibly unknown to us. We wrote to the first trial author to ask for clinical study reports or equivalent on 12 November 2013 who confirmed that the trials had not been completed. </p> </section> </section> <section id="CD008965-sec-0092"> <h4 class="title">Included studies</h4> <p>The absence of documentation of trial programmes for both drugs, listing all sponsored trials completed or underway, meant we had to rely on a variety of sources for the reconstruction of the trial programmes and identification of relevant clinical study reports. This complexity is reflected in the flowchart presented in <a href="#CD008965-fig-0003">Figure 3</a>, illustrating the study selection process for this review. The two main pathways were the spontaneous release of 77 full clinical study reports by Roche (long after our request for 36 of them) and the requests to regulatory authorities and GSK for all the relevant reports. </p> <div class="figure" id="CD008965-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Flow diagram describing the number of studies identified, inclusion, exclusion and progression from identification to stage 1 to stage 2 of the review.NB Because of the absence of trial programmes for both drugs listing all sponsored trials completed or underway, we had to rely on a variety of sources for the reconstruction of the trial programmes and retrieval of relevant clinical study reports. This complexity is reflected in the flowchart, illustrating the study selection process for this review. The two main pathways were the spontaneous release of 77 clinical full clinical study reports by Roche and the requests to regulatory authorities and GSK for all the relevant reports. There was overlap in trial reports retrieved following the different pathways" data-id="CD008965-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram describing the number of studies identified, inclusion, exclusion and progression from identification to stage 1 to stage 2 of the review. </p> <p><b>NB</b> Because of the absence of trial programmes for both drugs listing all sponsored trials completed or underway, we had to rely on a variety of sources for the reconstruction of the trial programmes and retrieval of relevant clinical study reports. This complexity is reflected in the flowchart, illustrating the study selection process for this review. The two main pathways were the spontaneous release of 77 clinical full clinical study reports by Roche and the requests to regulatory authorities and GSK for all the relevant reports. There was overlap in trial reports retrieved following the different pathways </p> </div> </div> </div> <p>We carried out the inclusion into Stage 1 using the clinical study reports, titles, abstracts and any other relevant information. Through this process we identified 208 potentially relevant studies (139 oseltamivir trials, 61 zanamivir trials and eight peramivir trials). We excluded 123 studies (listed in the <a href="./references#CD008965-sec-0222" title="">Characteristics of excluded studies</a> table) as clearly ineligible. A further 19 studies are awaiting classification (see <a href="./references#CD008965-sec-0223" title="">Characteristics of studies awaiting classification</a>). We requested 66 trials from study sponsors, the EMA and the FDA. From these different methods the total number of trials available for assessment for inclusion in our review at Stage 1 was 53. </p> <p>Twenty three studies of oseltamivir (<a href="./references#CD008965-bbs2-0005" title="No authorslisted . A randomized, placebo‐controlled, multicenter study of oseltamivir (Ro 64‐0796) in the treatment of influenza in Japanese subjects (Translation of summary Japanese report ‐ of 29 pages). Data on file. ">JV15823</a>; <a href="./references#CD008965-bbs2-0006" title="No authorslisted . Phase 3 study for prophylaxis of influenza with Ro64‐0796 (15 page summary from Japanese). Data on file. ">JV15824</a>; <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>; <a href="./references#CD008965-bbs2-0008" title="No authorslisted . A double‐blind, randomized, placebo‐controlled multicenter study of oseltamivir phosphate in the treatment of influenza infection in China. Data on file. ">ML16369</a>; <a href="./references#CD008965-bbs2-0032" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza in children with asthma. Data on file. ">NV16871</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>; <a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>; <a href="./references#CD008965-bbs2-0037" title="GrosseM . A multi‐center, randomized, double‐blind, placebo‐controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Data on file. ">WV15707</a>; <a href="./references#CD008965-bbs2-0038" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Data on file. ">WV15708</a>; <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>; <a href="./references#CD008965-bbs2-0040" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS 4104) in the treatment of children with influenza. Data on file. ">WV15758</a>; <a href="./references#CD008965-bbs2-0041" title="GersterT . A double‐blind, randomized, stratified, placebo‐controlled study of oseltamivir phosphate (Ro 64‐0796, also known as GS 4104) in the treatment of influenza in children with chronic asthma. Data on file. ">WV15759/WV15871</a>; <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a>; <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>; <a href="./references#CD008965-bbs2-0044" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza infection in elderly patients. Data on file. ">WV15819/WV15876/WV15978</a>; <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>; <a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>) and 28 of zanamivir (<a href="./references#CD008965-bbs2-0001" title="GSK . Investigation of the efficacy of GG167 (zanamivir) in the treatment of influenza viral infections (late Phase II study: dose comparison study). Data on file. ">167‐101</a>; <a href="./references#CD008965-bbs2-0002" title="GSK . Investigation of the efficacy of CG167 in the treatment of influenza viral infections (phase II study) (Protocol NoJNAI‐01). Double blind, double dummy, randomized, placebo controlled, parallel group, multicenter study to investigate safety and route of administration of CG167 when inhaled, CG167 10 mg, or the combination of inhaled CG167 10 mg plus intranasal CG167 6.4 mg, administered twice daily for 5 days in the treatment of influenza A and B viral infections. Data on file. ">JNAI‐01</a>; <a href="./references#CD008965-bbs2-0003" title="GSK . A multicenter two way layout randomized placebo‐controlled double‐blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No. JNAI‐04). Data on file. ">JNAI‐04</a>; <a href="./references#CD008965-bbs2-0004" title="GSK . A multicenter two way layout randomized placebo‐controlled double‐blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No.JNAI‐07). Data on file. ">JNAI‐07</a>; <a href="./references#CD008965-bbs2-0009" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of influenza in patients 12 years or over diagnosed with asthma or chronic obstructive pulmonary disease. Data on file. ">NAI30008</a>; <a href="./references#CD008965-bbs2-0010" title="AlforsS , KeeneO , GriceR , HammondJ , HendricksV , MartinN , et al. A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5‐12. Data on file. ">NAI30009</a>; <a href="./references#CD008965-bbs2-0011" title="HunterS , ReillyL , SharpS , WestM , AlforsS , HammondJ , et al. A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Data on file. ">NAI30010</a>; <a href="./references#CD008965-bbs2-0012" title="No authorslisted . A randomised, double‐blind, placebo‐controlled study to evaluate the impact of inhaled zanamivir treatment on workplace attendance due to influenza A and B infections. Data on file. ">NAI30011</a>; <a href="./references#CD008965-bbs2-0013" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in subjects aged over 65 years. Data on file. ">NAI30012</a>; <a href="./references#CD008965-bbs2-0014" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Data on file. ">NAI30015</a>; <a href="./references#CD008965-bbs2-0015" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd. via Diskhaler), for 5 days, in high risk patients with symptomatic influenza A and / or B infection. Data on file Synopsis only available. ">NAI30020</a>; <a href="./references#CD008965-bbs2-0016" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic influenza A and / or B infection. Data on file. ">NAI30028</a>; <a href="./references#CD008965-bbs2-0017" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within households. Data on file. ">NAI30031</a>; <a href="./references#CD008965-bbs2-0018" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community‐dwelling high‐risk populations. Data on file. ">NAI30034</a>; <a href="./references#CD008965-bbs2-0019" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, multicenter, parallel‐group study to investigate the efficacy and safety of zanamivir administered twice or four times a day for the treatment of influenza A and B viral infections. Data on file. ">NAIA/B2008</a>; <a href="./references#CD008965-bbs2-0020" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicentre, parallel‐group study to demonstrate the efficacy and safety of zanamivir in the prevention and/or progression of influenza A and B viral infections. Data on file. ">NAIA/B2009</a>; <a href="./references#CD008965-bbs2-0021" title="MacLeodA , GummerM , RanigaK , HirstH , KeeneO , OssiM , et al. A double‐blind, randomised, placebo‐controlled multi‐centre study to investigate the efficacy and safety of inhaled and intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIA2005</a>; <a href="./references#CD008965-bbs2-0022" title="No authorslisted . A double‐blind, randomised, placebo‐controlled multicentre study to investigate the efficacy and safety of zanamivir therapy in the prevention of progression of influenza A and B viral infections. Data on file. ">NAIA2006</a>; <a href="./references#CD008965-bbs2-0023" title="ElliottM , FlackN , KeeneO , SzymborskiP , Vega R (PharmaResearch, Inc) . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIA3002</a>; <a href="./references#CD008965-bbs2-0024" title="No authorslisted . A double‐blind, randomized, parallel‐group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day compared to the standard of care in controlling nursing home influenza outbreaks. Data on file. ">NAIA3003</a>; <a href="./references#CD008965-bbs2-0025" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. Data on file. ">NAIA3004</a>; <a href="./references#CD008965-bbs2-0026" title="ElliottM , HunterS , FlackN , CrispA , SzymborskiP , VegaR . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. Data on file. ">NAIA3005</a>; <a href="./references#CD008965-bbs2-0027" title="LeongJ , BrennanJ , GummerM , KeeneO , WightmanK . A double‐blind, randomised, placebo‐controlled, parallel‐group, multi‐centre study to investigate the efficacy and safety of inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIB2005</a>; <a href="./references#CD008965-bbs2-0028" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir in preventing progression of influenza A and B viral infections. Data on file. ">NAIB2006</a>; <a href="./references#CD008965-bbs2-0029" title="PerichR , SolterbeckA , KeeneO , LeongJ , RanigaK , MacLeodA . A double‐blind, randomised, placebo‐controlled, parallel‐group, multi‐centre study to investigate the efficacy and safety of inhaled and inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIB2007</a>; <a href="./references#CD008965-bbs2-0030" title="CampionK , GummerM , KeeneO . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Data on file. ">NAIB3001</a>; <a href="./references#CD008965-bbs2-0031" title="ManCY , KeeneON , ChallonerT (Challoner Associates) . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIB3002</a>; <a href="./references#CD008965-bbs2-0033" title="No authorslisted . A trial to investigate efficacy to reduce development of influenza symptoms in influenza infected patients treated with GG167 (protocol number PE‐01 phase II clinical trial). A double‐blind double‐dummy, randomized, placebo‐controlled, parallel group, multicenter study to investigate the efficacy reducing development of influenza symptoms and, safety and rout of administration of GG 157 when orally inhaled GG 167 10 mg, 6.4 mg nebulized intranasally or the combination of inhaled GG167 10 mg plus intranasal GG167 6.4 mg was administered twice day for 5 days in the treatment of influenza A and B viral infections. Data on file. ">PE‐01</a>) were included in Stage 1. It was not uncommon for more than one trial to be reported in the same clinical study reports. This was either due to the amalgamation of two or more trials because of low influenza virus circulation and difficulties in recruitment (for example, <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>), or because the trials bore different ID numbers when in reality they followed the same protocol, albeit in two different hemispheres (for example, <a href="./references#CD008965-bbs2-0041" title="GersterT . A double‐blind, randomized, stratified, placebo‐controlled study of oseltamivir phosphate (Ro 64‐0796, also known as GS 4104) in the treatment of influenza in children with chronic asthma. Data on file. ">WV15759/WV15871</a>). </p> <p>We also identified six completed or ongoing studies of peramivir in dose‐response or placebo‐controlled studies (<a href="./references#CD008965-bbs2-0179" title="A phase II, multicenter, randomized, double‐mask, placebo‐controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza. Data on file. ">NCT00419263</a>; <a href="./references#CD008965-bbs2-0180" title="A phase II, multicenter, randomized, double‐mask, double‐dummy study comparing the efficacy and safety of peramivir administered intravenously once daily versus oseltamivir administered orally twice daily in adults with acute serious or potentially life‐threatening influenza. Data on file. ">NCT00453999</a>; <a href="./references#CD008965-bbs2-0181" title="A phase 3 multicenter, randomized, double blind, placebo‐controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza. Data on file. ">NCT00486980</a>; <a href="./references#CD008965-bbs2-0183" title="A phase 3 multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza. Data on file. ">NCT00610935</a>; <a href="./references#CD008965-bbs2-0184" title="A phase II, multicenter, randomized, placebo‐controlled, study to evaluate the efficacy and safety of intramuscular peramivir 600 mg in subjects with uncomplicated acute influenza. Data on file. ">NCT00705406</a>; <a href="./references#CD008965-bbs2-0185" title="A phase 3, multicenter, randomized, double‐blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza. Data on file. ">NCT00958776</a>). </p> <p>The included trials were predominantly conducted in adults during influenza seasons in both hemispheres. A small number of studies were conducted in older people residing in care homes and in people with underlying respiratory diseases. All trials were sponsored by the manufacturers. </p> <p><b>Oseltamivir</b> </p> <p>Of the 23 oseltamivir trials in Stage 1, 15 were multicentre trials conducted in both the Northern and Southern Hemispheres, while eight were done in only one country (USA five, Japan two and China one). In total 9623 participants were included (6574 in treatment trials and 3049 in prophylaxis trials). The age of the participants ranged from 1 to 82 years and the duration of follow‐up varied from 6 to 42 days. </p> <p>Two of the trials were conducted within nursing homes; 20 were within free‐living populations; one was performed in in‐ and out‐patient departments. Three trials were conducted in children, while participants in 20 trials were adults. In some trials the eligible population included participants at increased risk of influenza complications, or with diagnoses of asthma or chronic obstructive pulmonary disease, but the majority included only otherwise healthy adults. In one trial (<a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>), participants were stratified by smoking status, while those in another trial were stratified by the presence or absence of otitis media (<a href="./references#CD008965-bbs2-0040" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS 4104) in the treatment of children with influenza. Data on file. ">WV15758</a>). </p> <p>All trials compared orally administered oseltamivir (either as capsules or reconstituted powder) with placebo. </p> <p>Of the 23 trials, we included 20 RCTs for the analysis examining the use of oseltamivir compared with placebo. Two were excluded from the meta‐analysis because they were only synopsis reports (<a href="./references#CD008965-bbs2-0005" title="No authorslisted . A randomized, placebo‐controlled, multicenter study of oseltamivir (Ro 64‐0796) in the treatment of influenza in Japanese subjects (Translation of summary Japanese report ‐ of 29 pages). Data on file. ">JV15823</a>; <a href="./references#CD008965-bbs2-0006" title="No authorslisted . Phase 3 study for prophylaxis of influenza with Ro64‐0796 (15 page summary from Japanese). Data on file. ">JV15824</a>) and another because it was not a full clinical study report (<a href="./references#CD008965-bbs2-0008" title="No authorslisted . A double‐blind, randomized, placebo‐controlled multicenter study of oseltamivir phosphate in the treatment of influenza infection in China. Data on file. ">ML16369</a>). </p> <p>We finally included 20 oseltamivir trials into Stage 2: 11 on treatment in adults (<a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>; <a href="./references#CD008965-bbs2-0037" title="GrosseM . A multi‐center, randomized, double‐blind, placebo‐controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Data on file. ">WV15707</a>, <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>; <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>; <a href="./references#CD008965-bbs2-0044" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza infection in elderly patients. Data on file. ">WV15819/WV15876/WV15978</a><a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>), four in children (<a href="./references#CD008965-bbs2-0032" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza in children with asthma. Data on file. ">NV16871</a>; <a href="./references#CD008965-bbs2-0040" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS 4104) in the treatment of children with influenza. Data on file. ">WV15758</a>; <a href="./references#CD008965-bbs2-0041" title="GersterT . A double‐blind, randomized, stratified, placebo‐controlled study of oseltamivir phosphate (Ro 64‐0796, also known as GS 4104) in the treatment of influenza in children with chronic asthma. Data on file. ">WV15759/WV15871</a>), and five on prophylaxis: two in adults (<a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>), two in the elderly (<a href="./references#CD008965-bbs2-0038" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Data on file. ">WV15708</a>; <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>) and one in households (<a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a>). Of the 15 included treatment trials of oseltamivir only three (<a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0040" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS 4104) in the treatment of children with influenza. Data on file. ">WV15758</a>) were successful in recruiting the a priori planned sample size. </p> <p><b>Zanamivir</b> </p> <p>Of the 28 included zanamivir trials, 18 were multicentre trials done in both the Northern and Southern Hemisphere and 10 were done in only one country (Japan five, USA three, Finland and Germany one each). In total 14,628 participants were included (7678 in treatment trials and 6950 in prophylaxis trials). Participants' age ranged from 5 to 12 years to over 65 and duration of follow‐up varied from 5 to 35 days.   </p> <p>Two of the trials were performed within nursing homes; several were within free‐living populations; one was performed within a university student population. In some trials the eligible population included participants at increased risk of influenza complications, or with diagnoses of asthma or chronic obstructive pulmonary disease, but the majority included only adults who were otherwise healthy. </p> <p>Zanamivir was administered as an intranasal spray, an inhalation or a combination of both and placebos were designed to match. Administration was by the participant in the majority of trials and by nursing staff in the trials within nursing homes. Twenty‐two trials compared inhaled zanamivir with placebo and six trials compared inhaled zanamivir, or intranasal zanamivir, with placebo or usual care. </p> <p>Of the 28 trials we included 26 RCTs for the analysis examining the use of zanamivir compared with placebo. Two were excluded from the meta‐analysis because one was only a synopsis (<a href="./references#CD008965-bbs2-0015" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd. via Diskhaler), for 5 days, in high risk patients with symptomatic influenza A and / or B infection. Data on file Synopsis only available. ">NAI30020</a>) and one compared zanamivir to usual care and not placebo (<a href="./references#CD008965-bbs2-0024" title="No authorslisted . A double‐blind, randomized, parallel‐group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day compared to the standard of care in controlling nursing home influenza outbreaks. Data on file. ">NAIA3003</a>).  </p> <p>We finally included 26 zanamivir trials: 14 on treatment in adults (<a href="./references#CD008965-bbs2-0002" title="GSK . Investigation of the efficacy of CG167 in the treatment of influenza viral infections (phase II study) (Protocol NoJNAI‐01). Double blind, double dummy, randomized, placebo controlled, parallel group, multicenter study to investigate safety and route of administration of CG167 when inhaled, CG167 10 mg, or the combination of inhaled CG167 10 mg plus intranasal CG167 6.4 mg, administered twice daily for 5 days in the treatment of influenza A and B viral infections. Data on file. ">JNAI‐01</a>; <a href="./references#CD008965-bbs2-0003" title="GSK . A multicenter two way layout randomized placebo‐controlled double‐blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No. JNAI‐04). Data on file. ">JNAI‐04</a>; <a href="./references#CD008965-bbs2-0004" title="GSK . A multicenter two way layout randomized placebo‐controlled double‐blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No.JNAI‐07). Data on file. ">JNAI‐07</a>, <a href="./references#CD008965-bbs2-0009" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of influenza in patients 12 years or over diagnosed with asthma or chronic obstructive pulmonary disease. Data on file. ">NAI30008</a>; <a href="./references#CD008965-bbs2-0012" title="No authorslisted . A randomised, double‐blind, placebo‐controlled study to evaluate the impact of inhaled zanamivir treatment on workplace attendance due to influenza A and B infections. Data on file. ">NAI30011</a>; <a href="./references#CD008965-bbs2-0013" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in subjects aged over 65 years. Data on file. ">NAI30012</a>; <a href="./references#CD008965-bbs2-0014" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Data on file. ">NAI30015</a>; <a href="./references#CD008965-bbs2-0019" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, multicenter, parallel‐group study to investigate the efficacy and safety of zanamivir administered twice or four times a day for the treatment of influenza A and B viral infections. Data on file. ">NAIA/B2008</a>; <a href="./references#CD008965-bbs2-0021" title="MacLeodA , GummerM , RanigaK , HirstH , KeeneO , OssiM , et al. A double‐blind, randomised, placebo‐controlled multi‐centre study to investigate the efficacy and safety of inhaled and intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIA2005</a>; <a href="./references#CD008965-bbs2-0023" title="ElliottM , FlackN , KeeneO , SzymborskiP , Vega R (PharmaResearch, Inc) . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIA3002</a>; <a href="./references#CD008965-bbs2-0027" title="LeongJ , BrennanJ , GummerM , KeeneO , WightmanK . A double‐blind, randomised, placebo‐controlled, parallel‐group, multi‐centre study to investigate the efficacy and safety of inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIB2005</a>; <a href="./references#CD008965-bbs2-0029" title="PerichR , SolterbeckA , KeeneO , LeongJ , RanigaK , MacLeodA . A double‐blind, randomised, placebo‐controlled, parallel‐group, multi‐centre study to investigate the efficacy and safety of inhaled and inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIB2007</a>; <a href="./references#CD008965-bbs2-0030" title="CampionK , GummerM , KeeneO . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Data on file. ">NAIB3001</a>; <a href="./references#CD008965-bbs2-0031" title="ManCY , KeeneON , ChallonerT (Challoner Associates) . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIB3002</a>), two in children (<a href="./references#CD008965-bbs2-0010" title="AlforsS , KeeneO , GriceR , HammondJ , HendricksV , MartinN , et al. A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5‐12. Data on file. ">NAI30009</a>; <a href="./references#CD008965-bbs2-0016" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic influenza A and / or B infection. Data on file. ">NAI30028</a>) and 10 trials in prophylaxis (<a href="./references#CD008965-bbs2-0001" title="GSK . Investigation of the efficacy of GG167 (zanamivir) in the treatment of influenza viral infections (late Phase II study: dose comparison study). Data on file. ">167‐101</a>; <a href="./references#CD008965-bbs2-0018" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community‐dwelling high‐risk populations. Data on file. ">NAI30034</a>; <a href="./references#CD008965-bbs2-0020" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicentre, parallel‐group study to demonstrate the efficacy and safety of zanamivir in the prevention and/or progression of influenza A and B viral infections. Data on file. ">NAIA/B2009</a>; <a href="./references#CD008965-bbs2-0022" title="No authorslisted . A double‐blind, randomised, placebo‐controlled multicentre study to investigate the efficacy and safety of zanamivir therapy in the prevention of progression of influenza A and B viral infections. Data on file. ">NAIA2006</a>; <a href="./references#CD008965-bbs2-0025" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. Data on file. ">NAIA3004</a>; <a href="./references#CD008965-bbs2-0026" title="ElliottM , HunterS , FlackN , CrispA , SzymborskiP , VegaR . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. Data on file. ">NAIA3005</a>; <a href="./references#CD008965-bbs2-0028" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir in preventing progression of influenza A and B viral infections. Data on file. ">NAIB2006</a>; <a href="./references#CD008965-bbs2-0033" title="No authorslisted . A trial to investigate efficacy to reduce development of influenza symptoms in influenza infected patients treated with GG167 (protocol number PE‐01 phase II clinical trial). A double‐blind double‐dummy, randomized, placebo‐controlled, parallel group, multicenter study to investigate the efficacy reducing development of influenza symptoms and, safety and rout of administration of GG 157 when orally inhaled GG 167 10 mg, 6.4 mg nebulized intranasally or the combination of inhaled GG167 10 mg plus intranasal GG167 6.4 mg was administered twice day for 5 days in the treatment of influenza A and B viral infections. Data on file. ">PE‐01</a>; <a href="./references#CD008965-bbs2-0011" title="HunterS , ReillyL , SharpS , WestM , AlforsS , HammondJ , et al. A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Data on file. ">NAI30010</a>; <a href="./references#CD008965-bbs2-0017" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within households. Data on file. ">NAI30031</a>). </p> <p>Our attempt at collecting sufficient information from regulatory files to reconstruct missing clinical study reports also failed because the information appeared insufficient for a reliable reconstruction. </p> </section> <section id="CD008965-sec-0093"> <h4 class="title">Excluded studies</h4> <p>We excluded 123 studies from entering Stage 1 for various reasons. Some were pharmacokinetic studies, or had an active comparator, or compared higher‐ versus lower‐dose schedules, or were ongoing trials. A further 19 trials are awaiting assessment (<a href="./references#CD008965-sec-0223" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> <section id="CD008965-sec-0094"> <h3 class="title">Risk of bias in included studies</h3> <p>Study level assessments are reported in the 'Risk of bias' tables. To address the problem of reporting bias, we ignored published trial reports and directed our attention to clinical study reports and regulatory information. Our problems in reviewing the copious material at our disposal were how to identify and analyse important details in the midst of thousands of pages of information and how to construct a coherent appraisal of large and complex trial programmes. </p> <p>In addition, since we gained unrestricted access to the full clinical study reports (apart from personal de‐identifying redactions) we took the view that all information needed to judge risk of bias should be present. Therefore when this information was not available, we judged the corresponding risk of bias element as at 'high' risk of bias. For example, when details of the random sequence generation are missing from journal publications of clinical trials, it is customary to record this as "unknown" risk of bias. This judgment usually carries the assumption that the random sequence generation details are available in more detailed reports. But when these details were still missing in even full clinical study reports, we chose to rate this risk of bias element at "high" risk of bias. </p> <p>In the following paragraphs we report some of the salient findings using the current Cochrane format but applying the logic of reviewing regulatory data. </p> <section id="CD008965-sec-0095"> <h4 class="title">Allocation</h4> <p>In 10 of the 20 oseltamivir studies included in Stage 2 the description of random sequence generation is missing. The reporting of all zanamivir trials but one (<a href="./references#CD008965-bbs2-0016" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic influenza A and / or B infection. Data on file. ">NAI30028</a>) was biased by the absence of description of random sequence generation. </p> </section> <section id="CD008965-sec-0096"> <h4 class="title">Blinding</h4> <p>The placebo and active drug capsule cap were not identical in 11 of the 20 trials of oseltamivir. This may have compromised blinding of participants. For all but one of the zanamivir trials we did not have the certificates of analysis to enable us to reconstruct the appearance, taste and texture of the two principles. </p> </section> <section id="CD008965-sec-0097"> <h4 class="title">Incomplete outcome data</h4> <p>In addition to the missing diary cards in three treatment trials (see <a href="#CD008965-sec-0088">Results of the search</a> section), we were unable to identify all data for all outcomes in all oseltamivir trials and in eight of the zanamivir trials. For example, hospitalisations were not reported in zanamivir trials and inconsistently reported in oseltamivir trials. The relevant data in this review come from a table of hospitalisations sent to us by Roche in late 2013. In addition, in some trials we were unable to track individual participants through tables, narratives and individual listings. The issue of compliharms impeded the ascertainment of harms in oseltamivir treatment trials (<a href="./appendices#CD008965-sec-0139">Appendix 1</a>). We had difficulty in following the logic of compliharms, even with access to full clinical study reports. The definition of adverse events in the RCTs of oseltamivir and zanamivir is different from the ordinary definition of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E2D guideline, which is as follows: "An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product". (<a href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf" target="_blank">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf</a> accessed 27 December 2013). </p> <p>As an example, the definition of adverse events in the <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a> study is as follows (PDF page 35): "following the alleviation of influenza‐like symptoms, the recurrence of a single respiratory or constitutional symptom was recorded as an adverse event, however, the reappearance of more than one symptom was recorded as influenza‐like syndrome (i.e. secondary illness) and therefore do not appear as adverse events" and <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>: "<b>any adverse change from the subject</b> '<b>s baseline (pre‐treatment) condition</b> , which occurred during the course of the study after treatment had started, whether considered related to treatment or not". Treatment included <b>all</b> investigational agents (including placebo and comparative agents) administered during the course of the study)" (our emphasis). As a consequence, adverse events that are similar to the symptoms of influenza (such as headache and mild gastrointestinal adverse events) tend to be excluded from the treatment trials. </p> <p>We identified a report of a site inspection for the adult prophylaxis trial <a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>. The FDA carried out the inspection in September 2000 at various trial sites in the US including the West Virginia site (which was responsible for enrolling many hundreds of participants). An FDA official letter reported several violations including failure to report serious harms to the sponsor (Roche) as the protocol required and in addition stated: "... we view the statement in the payment section of the consent form used in the study that subjects '...will receive $300.00 for participating in and completing the study. No payment will be made to you if you withdraw from the study for personal reasons...' to be an improper procedure. When subjects are to be paid for participating in a study, the payment should be prorated for the subject's actual participation in the study in order to avoid the possibility of coercion" (<a href="./references#CD008965-bbs2-0220" title="Food , DrugAdministration . Site inspection report in Review. Tamiflu (oseltamivir). NDA 021087 Supplement 002. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21‐087SE1‐002_review.pdf 2000 (accessed 26 August 2009):177. ">FDA 2000e</a>, PDF page 177). However, the FDA allowed the data (which had been published a year earlier in a prime journal) to stand in support of Roche's application for the prophylaxis indication. We do not know whether the participant contract was standard (i.e. whether the observation of possible improper procedures could be generalised to other sites and other trials), but the document cited by the FDA inspector is the subject of one of our (as yet unfulfilled) Freedom of Information (FOI) requests. The possibility of financial pressure, if confirmed, could seriously confound drop‐out rates because of harms or any other causes in prophylaxis trials. </p> <p>The significantly higher incidence of diarrhoea in placebo recipients of treatment trial <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a> was identified by the FDA reviewers who remarked "Diarrhea was reported more frequently among subjects receiving placebo than among subjects receiving Ro 64‐0796 [oseltamivir]. Diarrhoea, although not specified as an inclusion criterion, has been documented to be a clinical manifestation of influenza infection. The reduction in the incidence of diarrhoea for the treatment groups compared with the placebo group could be considered as a possible treatment effect of Ro 64‐0796" (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>). However, according to the Japanese Summary Basis for Approval (JSBA) of oseltamivir capsules for prophylaxis, diarrhoea was reported more frequently in the oseltamivir arm (49/986) than in the placebo group (38/973) in the summarised table of adverse events from three trials (<a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>; <a href="./references#CD008965-bbs2-0038" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Data on file. ">WV15708</a>; <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>). Our findings are inconsistent with the explanation by the FDA. </p> </section> <section id="CD008965-sec-0098"> <h4 class="title">Selective reporting</h4> <p>All oseltamivir trials and almost half of the zanamivir trials had selected reporting. The oseltamivir trials showed a consistent trend of missing original protocols (except for <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>), changing outcome definitions while the trial was running, protocol amendments even after the trial had been completed, inconsistent approaches to outcome data collection, missing statistical analysis plans, missing date of unblinding and the use of self reported outcomes such as pneumonia (<a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>; <a href="./references#CD008965-bbs2-0037" title="GrosseM . A multi‐center, randomized, double‐blind, placebo‐controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Data on file. ">WV15707</a>; <a href="./references#CD008965-bbs2-0039" title="DorkingsJ . A double‐blind, stratified, randomized, placebo controlled study of Ro 64‐0796 (GS4104) in the treatment of influenza infection in adults. Data on file. ">WV15730</a>; <a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>). This represent 55% of pneumonia event data. As an example, in trial <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>, secondary illnesses were patient reported. The body of the clinical study report states that complications requiring antibiotic treatment were specified a priori but even in the final version of the protocol, for which we have the full text, there is no predefined list of secondary illnesses (i.e. no mention of pneumonia, bronchitis, sinusitis or otitis in the protocol), nor did complications have anything to do with antibiotic treatment according to the protocol, nor does the Case Report Form mention specific secondary illnesses by name. Zanamivir trials reported outcomes not specified in the protocol provided. </p> <p>We found evidence of possible selective reporting bias when we analysed the JSBA data on prophylaxis. The regulatory data reports tables for individual trials as well as 10 pages of summarised tables for three trials of prophylaxis (<a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>; <a href="./references#CD008965-bbs2-0038" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Data on file. ">WV15708</a>; <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>). Tables for individual trials include data for high‐dose arms but report few psychiatric adverse events overall. However, the summarised tables list a variety of psychiatric adverse events including psychotic and suicidal adverse events, but not adverse events from the high‐dose group. As a preliminary exploratory analysis, we combined the following suspected serious adverse events collectively: hallucination and delusion that are classified grade 3 (serious) by the National Cancer Institute‐Common Toxicity Criteria Version 2.0 (NCI‐CTC V2.0), psychosis (hallucination and delusion are the two major symptoms of this disease), suicidal attempt that is classified grade 3 (serious) by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (CTCAE V4.0) and hostility that includes aggression, hostility, violence, murder and commonly considered as serious events though not listed in the NCI‐CTC V2.0 or CTCAE V4.0. Numbers of suspected serious psychotic/suicidal adverse events (including hallucination, psychosis, schizophrenia, paranoia, aggression/hostility and attempted suicide) were five in the oseltamivir group and zero in the placebo group during the on‐treatment period. When the off‐treatment period data are added the total was eight versus one. The prophylaxis programme is crucial in understanding the harms profile of the drug as the potential for harms witnessed to be confounded by the apparently numerous symptoms and signs of influenza infection is far less, as many participants do not become infected with influenza. This makes a causality assessment more straightforward. </p> </section> <section id="CD008965-sec-0099"> <h4 class="title">Other potential sources of bias</h4> <p>All but three of the oseltamivir treatment trials were under‐recruited. Several of the zanamivir trials were also under‐recruited. We noted the use of different relief medication across different centres within the same trial and in one zanamivir trial (<a href="./references#CD008965-bbs2-0017" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within households. Data on file. ">NAI30031</a>), according to the protocol participants receiving antibiotics for bacterial respiratory tract infection should have been excluded but in the trial this did not happen. In the zanamivir trial <a href="./references#CD008965-bbs2-0018" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community‐dwelling high‐risk populations. Data on file. ">NAI30034</a>, the definition of "confirmed influenza" was amended after protocol closure. </p> <p>We also noted several other items that were not included in all full clinical study reports: </p> <p> <ul id="CD008965-list-0007"> <li> <p>Study protocols dated prior to participant enrolment (missing for many oseltamivir trials). </p> </li> <li> <p>Certificates of analysis for the intervention/placebo preparations.</p> </li> <li> <p>Patient enrolment dates explicitly reported (only trial inception and cessation dates are given; in zanamivir trials these are partially redacted). </p> </li> <li> <p>Explicitly reported date of trial unblinding. We frequently noted the statement "the database was authorized on xxxx" to identify the unblinding date but an explicit date is important to report. In some cases, the date of unblinding was reported but the actual date within the month was redacted. This practice also applied to zanamivir protocol amendments. </p> </li> <li> <p>Authorship and accountability for the writing of the clinical study reports.</p> </li> <li> <p>Statistical analysis plans in some cases.</p> </li> <li> <p>Patient consent forms (missing from most zanamivir trials).</p> </li> <li> <p>Patient information form (missing from most zanamivir trials).</p> </li> <li> <p>List of randomisation codes (variably included).</p> </li> <li> <p>Case report form templates in zanamivir trials do not allow for determining who completes the form (patient or clinician). </p> </li> <li> <p>Core data sheet.</p> </li> </ul> </p> <p>Other important documents that we did not have included:</p> <p> <ul id="CD008965-list-0008"> <li> <p>Study manual of procedures.</p> </li> <li> <p>Minutes of safety data monitoring committee meetings.</p> </li> </ul> </p> <p>The placebo interventions in both sets of trials may have contained active substances. The placebo for zanamivir trials contained lactose powder, which can potentially cause bronchospasm, while the placebo for oseltamivir trials contained dehydrocholic acid and dibasic calcium phosphate dehydrate, which can cause gastrointestinal symptoms. </p> <p>Data on participants by influenza‐infected status (in treatment trials) and for participants with influenza‐like illness (in prophylaxis trials) were not reported in the oseltamivir clinical study reports. </p> <p>Finally, data on the effects of rescue or relief medication (mainly paracetamol/acetaminophen) were incomplete in clinical study reports of oseltamivir trials and not reported separately in all zanamivir trials. </p> </section> </section> <section id="CD008965-sec-0100"> <h3 class="title" id="CD008965-sec-0100">Effects of interventions</h3> <section id="CD008965-sec-0101"> <h4 class="title">Analysis of time to first symptom alleviation</h4> <p>In adult treatment, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval (CI) 8.4 to 25.1 hours, I<sup>2</sup> statistic = 0%), representing a 10% reduction from 7 days to 6.3 days (<a href="./references#CD008965-fig-0016" title="">Analysis 1.1</a>; <a href="#CD008965-fig-0004">Figure 4</a>). There was no significant effect in asthmatic children: increased by 5.2 hours (95% CI 11.1 hours lower to 21.4 hours higher, I<sup>2</sup> statistic = 0%). But there was an effect in otherwise healthy children, based on one trial: 29 hours, 95% CI: 12 to 47 hours, P = 0.001). (<a href="./references#CD008965-fig-0061" title="">Analysis 1.46</a>). Zanamivir reduced time to first alleviation of symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days, I<sup>2</sup> statistic = 9%), which equates to a 14.4 hours (10%) reduction in symptoms from 6.6 days to 6.0 days (<a href="./references#CD008965-fig-0153" title="">Analysis 3.1</a>; <a href="#CD008965-fig-0005">Figure 5</a>). There was no significant effect in children: time to first alleviation of symptoms was 1.08 days lower in the zanamivir group (95% CI 2.32 lower to 0.15 days higher, I<sup>2</sup> statistic = 72%) (<a href="./references#CD008965-fig-0166" title="">Analysis 3.14</a>). </p> <div class="figure" id="CD008965-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.1 Time to first alleviation of symptoms in adult treatment (ITT population) [hours]." data-id="CD008965-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.1 Time to first alleviation of symptoms in adult treatment (ITT population) [hours]. </p> </div> </div> </div> <div class="figure" id="CD008965-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.1 Time to first alleviation of symptoms in adult treatment (days)." data-id="CD008965-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.1 Time to first alleviation of symptoms in adult treatment (days). </p> </div> </div> </div> <p>In eight zanamivir trials that reported on use of relief medication, in all participants the median days to alleviation in both the placebo and the treatment arms was less when compared to those who did not use relief medications (<a href="#CD008965-tbl-0006">Table 6</a>). In seven zanamivir trials, time to first alleviation of symptoms was also reported with and without rescue medication. Using these data we were able to compare zanamivir without rescue medication with placebo with rescue medication. Overall there was a non‐significant 0.41 day decrease (95% CI 0.47 days lower to 1.29 days higher, I<sup>2</sup> statistic = 67%) in time to first alleviation of symptoms in the placebo with rescue medication group, suggesting that zanamivir itself is no better than rescue medication and possibly even less effective, although the varying levels of use of rescue medication in the seven trials did give rise to large heterogeneity (<a href="./references#CD008965-fig-0220" title="">Analysis 3.68</a>; <a href="#CD008965-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008965-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.68 Time to first alleviation of symptoms in adults with/without relief medication [days]." data-id="CD008965-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.68 Time to first alleviation of symptoms in adults with/without relief medication [days]. </p> </div> </div> </div> <div class="table" id="CD008965-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to alleviation* of clinically significant symptoms of influenza‐like illness (in all participants and participants with no use of relief medication)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Sample size </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Median days to alleviation for all participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference in days </b> </p> <p><b>(P value)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Median days to alleviation and no use of relief medication</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference in days (P value)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.123)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> <p>(0.037)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.011)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.002)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.033)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25</p> <p>(0.150)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> <p>(0.495)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> <p>(0.623)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.159)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.131)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.166)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> <p>(0.058)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.228)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.054)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> <p>(&lt; 0.001)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 (&lt; 0.001)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Alleviation defined as no fever (temperature &lt; 37.8 °C), cough recorded as none or mild and muscle/joint aches and pains, sore throat, feverishness/chills and headache recorded as absent/minimal </p> </div> </div> <p>In subgroup analysis of time to first alleviation of symptoms in adults by infection status, we found no evidence of a difference in treatment effect for zanamivir on the influenza‐infected subgroup compared to the non‐influenza‐infected subgroup (P = 0.53). The treatment effect was 0.67 days (95% CI 0.35 to 0.99 days, I<sup>2</sup> statistic = 17%) for influenza‐infected patients and 0.52 days (95% CI 0.18 to 0.86 days, I<sup>2</sup> statistic = 0%) for non‐influenza‐infected patients (<a href="./references#CD008965-fig-0221" title="">Analysis 3.69</a>). </p> </section> <section id="CD008965-sec-0102"> <h4 class="title">Analysis of hospitalisations</h4> <p>In oseltamivir treatment of adults, there was no significant difference in hospitalisation rate between treatment groups (risk ratio (RR) 0.92, 95% CI 0.57 to 1.50, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0017" title="">Analysis 1.2</a>), or in treatment of children (RR 1.92, 95% CI 0.70 to 5.23, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0062" title="">Analysis 1.47</a> ), with wide CIs; or in prophylaxis (RR 1.14, 95% CI 0.66 to 1.94, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0104" title="">Analysis 2.7</a>). Data on hospitalisations for the zanamivir studies were not reported. </p> </section> <section id="CD008965-sec-0103"> <h4 class="title">Analysis of influenza complications</h4> <section id="CD008965-sec-0104"> <h5 class="title">Pneumonia</h5> <p>In adult treatment trials, oseltamivir significantly reduced self reported, investigator‐mediated, unverified pneumonia (RR 0.55, 95% CI 0.33 to 0.90, I<sup>2</sup> statistic = 0%; risk difference (RD) 1.00%, 95% CI 0.22 to 1.49; number needed to treat to benefit (NNTB) = 100, 95% CI 67 to 451) in the treated population. The effect was significant in the six trials that collected data on non‐specific adverse events or secondary/intercurrent illness forms (RR 0.44, 95% CI 0.22 to 0.88, I<sup>2</sup> statistic = 0%; RD 0.99%, 95% CI 0.21 to 1.38; NNTB = 101, 95% CI 73 to 470). However, it was not significant in the five trials (two clinical study reports) that used more detailed diagnostic data collection forms, and in no studies that reported on radiological confirmation of pneumonia (<a href="#CD008965-fig-0007">Figure 7</a>; <a href="./references#CD008965-fig-0032" title="">Analysis 1.17</a>). There was no significant effect on pneumonia in children (RR 1.06, 95% CI 0.62 to 1.83, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0067" title="">Analysis 1.52</a>). In two zanamivir adult trials (<a href="./references#CD008965-bbs2-0013" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in subjects aged over 65 years. Data on file. ">NAI30012</a>; <a href="./references#CD008965-bbs2-0014" title="No authorslisted . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Data on file. ">NAI30015</a>), pneumonia reporting was based on a stricter definition of X‐ray confirmation and there was also no significant treatment effect (RR 1.02, 95% CI 0.35 to 3.02, I<sup>2</sup> = 39%) (<a href="./references#CD008965-fig-0155" title="">Analysis 3.3</a>). In nine zanamivir trials (<a href="./references#CD008965-bbs2-0009" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel group, multi‐center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of influenza in patients 12 years or over diagnosed with asthma or chronic obstructive pulmonary disease. Data on file. ">NAI30008</a>; <a href="./references#CD008965-bbs2-0011" title="HunterS , ReillyL , SharpS , WestM , AlforsS , HammondJ , et al. A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Data on file. ">NAI30010</a>; <a href="./references#CD008965-bbs2-0012" title="No authorslisted . A randomised, double‐blind, placebo‐controlled study to evaluate the impact of inhaled zanamivir treatment on workplace attendance due to influenza A and B infections. Data on file. ">NAI30011</a>; <a href="./references#CD008965-bbs2-0019" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, multicenter, parallel‐group study to investigate the efficacy and safety of zanamivir administered twice or four times a day for the treatment of influenza A and B viral infections. Data on file. ">NAIA/B2008</a>; <a href="./references#CD008965-bbs2-0021" title="MacLeodA , GummerM , RanigaK , HirstH , KeeneO , OssiM , et al. A double‐blind, randomised, placebo‐controlled multi‐centre study to investigate the efficacy and safety of inhaled and intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIA2005</a>; <a href="./references#CD008965-bbs2-0023" title="ElliottM , FlackN , KeeneO , SzymborskiP , Vega R (PharmaResearch, Inc) . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIA3002</a>; <a href="./references#CD008965-bbs2-0029" title="PerichR , SolterbeckA , KeeneO , LeongJ , RanigaK , MacLeodA . A double‐blind, randomised, placebo‐controlled, parallel‐group, multi‐centre study to investigate the efficacy and safety of inhaled and inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Data on file. ">NAIB2007</a>; <a href="./references#CD008965-bbs2-0030" title="CampionK , GummerM , KeeneO . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Data on file. ">NAIB3001</a>; <a href="./references#CD008965-bbs2-0031" title="ManCY , KeeneON , ChallonerT (Challoner Associates) . A double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Data on file. ">NAIB3002</a>), pneumonia was a self reported, investigator‐mediated, unverified outcome (<a href="#CD008965-fig-0008">Figure 8</a>; <a href="#CD008965-fig-0009">Figure 9</a>). Overall, there was no significant effect of zanamivir on mixed verified and unverified pneumonia in adult treatment (RR 0.90, 95% CI 0.58 to 1.40, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0154" title="">Analysis 3.2</a>). <a href="./references#CD008965-fig-0226" title="">Analysis 4.5</a> shows that in prophylaxis trials, zanamivir reduced the risk of self reported, investigator‐mediated, unverified pneumonia in adults (RR 0.30, 95% CI 0.11 to 0.80, I<sup>2</sup> statistic = 0%; RD 0.32%, 95% CI 0.09 to 0.41; NNTB = 311, 95% CI 244 to 1086). </p> <div class="figure" id="CD008965-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.17 Complications: pneumonia in adult treatment." data-id="CD008965-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.17 Complications: pneumonia in adult treatment. </p> </div> </div> </div> <div class="figure" id="CD008965-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Example Diary card from case‐report form for Zanamivir trial" data-id="CD008965-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Example Diary card from case‐report form for Zanamivir trial</p> </div> </div> </div> <div class="figure" id="CD008965-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Example Diary card from case‐report form for Zanamivir trial (cont)" data-id="CD008965-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Example Diary card from case‐report form for Zanamivir trial (cont)</p> </div> </div> </div> <p>In meta‐regression of 'pneumonia' based on 32 studies, treatment effects were not statistically different by age group (P = 0.22), drug (P = 0.89) or indication (P = 0.14). However, treatment effects were statistically different by method of diagnosis (P = 0.025). For unclear objective diagnosis of pneumonia, the treatment effect was RR 0.51 (95% CI 0.35 to 0.75, I<sup>2</sup> statistic = 0%), whereas for objective diagnosis data collection of pneumonia, the treatment effect was 1.01 (95% CI 0.69 to 1.47, I<sup>2</sup> statistic = 0%). A subgroup analysis of pneumonia for all 32 studies by method of diagnosis is shown in <a href="./references#CD008965-fig-0268" title="">Analysis 5.1</a>. Please note that estimates in the subgroup analysis are slightly different to those obtained in meta‐regression due to the different methodologies. </p> </section> <section id="CD008965-sec-0105"> <h5 class="title">Serious complications and study withdrawals</h5> <p>In oseltamivir trials, treatment did not significantly affect complications classified as serious or those that led to withdrawal from the trial in adults (RR 0.91, 95% CI 0.40 to 2.06, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0035" title="">Analysis 1.20</a>) or in children (RR 1.98, 95% CI 0.58 to 6.72, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0070" title="">Analysis 1.55</a>). This outcome could not be assessed in oseltamivir prophylaxis due to an insufficient number of events. There was no significant effect of zanamivir, in adult treatment, in reducing the risk of any complication classified as serious or which led to study withdrawal (RR 1.10, 95% CI 0.46 to 2.63, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0159" title="">Analysis 3.7</a>) or in prophylaxis (RR 1.09, 95% CI 0.36 to 3.26, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0229" title="">Analysis 4.8</a>). This outcome could not be assessed in children due to an insufficient number of events. </p> </section> <section id="CD008965-sec-0106"> <h5 class="title">Bronchitis, sinusitis and otitis media</h5> <p>Neither zanamivir (<a href="./references#CD008965-fig-0227" title="">Analysis 4.6</a>; <a href="./references#CD008965-fig-0228" title="">Analysis 4.7</a>) nor oseltamivir (<a href="./references#CD008965-fig-0105" title="">Analysis 2.8</a>; <a href="./references#CD008965-fig-0106" title="">Analysis 2.9</a>) significantly reduced the risk of bronchitis or sinusitis in prophylaxis trials. In adults, treatment with oseltamivir did not significantly reduce the risk of bronchitis (RR 0.75, 95% CI 0.56 to 1.01, I<sup>2</sup> statistic = 36%) (<a href="./references#CD008965-fig-0031" title="">Analysis 1.16</a>), sinusitis (RR 1.03, 95% CI 0.76 to 1.40, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0033" title="">Analysis 1.18</a>) or otitis media (RR 1.11, 95% CI 0.57 to 2.15, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0034" title="">Analysis 1.19</a>). The result for bronchitis was sensitive to the methods used, as a fixed‐effect analysis showed a significant effect (P = 0.02). Oseltamivir did not significantly affect complications in treatment of children (<a href="./references#CD008965-fig-0067" title="">Analysis 1.52</a> ; <a href="./references#CD008965-fig-0065" title="">Analysis 1.50</a>; <a href="./references#CD008965-fig-0068" title="">Analysis 1.53</a>), including otitis media (RR 0.80, 95% CI 0.62 to 1.02, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0066" title="">Analysis 1.51</a>). </p> <p>Treatment with zanamivir significantly reduced the risk of bronchitis in adults (RR 0.75, 95% CI 0.61 to 0.91, I<sup>2</sup> statistic = 0%; RD 1.80%, 95% CI 0.65 to 2.80; NNTB = 56, 95% CI 36 to 155) (<a href="./references#CD008965-fig-0156" title="">Analysis 3.4</a>), but did not reduce the risk of sinusitis (<a href="./references#CD008965-fig-0157" title="">Analysis 3.5</a>) or otitis media (<a href="./references#CD008965-fig-0158" title="">Analysis 3.6</a>). In children, zanamivir treatment did not significantly reduce the risk of sinusitis (RR 0.87, 95% CI 0.12 to 6.45, I<sup>2</sup> statistic = 40%) (<a href="./references#CD008965-fig-0169" title="">Analysis 3.17</a>) or otitis media (RR 1.00, 95% CI 0.59 to 1.72, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0170" title="">Analysis 3.18</a>). </p> <p>See <a href="#CD008965-tbl-0001">Table 1</a> for a summary of the methodology used for collecting and assessing complications in oseltamivir treatment trials. See <a href="#CD008965-tbl-0007">Table 7</a> for the overall results for oseltamivir in adults and <a href="#CD008965-tbl-0008">Table 8</a> for children. See <a href="#CD008965-tbl-0009">Table 9</a> for the overall results for zanamivir in adults and <a href="#CD008965-tbl-0010">Table 10</a> for children. </p> <div class="table" id="CD008965-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treating influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults with influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> oseltamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in adult treatment (ITT population) (hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (hours) to first alleviation of symptoms adults in the intervention groups was<br/> <b>16.76 lower</b><br/> (25.1 to 8.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 hours (8.4 to 25.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3954<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (1.14 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐3.66% (‐7.39 to ‐0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 28 (14 to 112)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/> (73 to 138) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.43</b> <br/> (1.75 to 3.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐4.56% (‐7.58 to ‐2.39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 22 (14 to 42)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/> (56 to 108) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: diarrhoea in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> <br/> (0.46 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2.33% (0.14 to 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 43 (27 to 709)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/> (32 to 69) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: self reported, investigator‐mediated, unverified pneumonia in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b> <br/> (0.33 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.00% (0.22 to 1.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 100 (67 to 451)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>(7 to 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: cardiac body system in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> <br/> (0.25 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3943<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.68% (0.04 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 148 (101 to 2509)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/> (3 to 13) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: hospital admission in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.57 to 1.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4394</p> <p>(7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.15% (‐0.78 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 687 (NNTB 110 to ∞ to NNTH 128)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> <p>(11 to 28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treating influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children with influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> oseltamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in child treatment (hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (hours) to first alleviation of symptoms in children in the intervention groups was<br/> <b>8.04 lower</b><br/> (33.34 lower to 17.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1329<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospital admission in child treatment (safety population)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b> <br/> (0.7 to 5.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.81% (‐3.72 to 0.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 124 (NNTB 379 to ∞ to NNTH 27)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/> (6 to 46) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b> <br/> (0.27 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.08% (‐1.69 to 2.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 93 (NNTB 45 to ∞ to NNTH 59)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (8 to 48) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: otitis media in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.8</b> <br/> (0.62 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3.26% (‐0.33 to 6.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 31 (NNTB 17 to ∞ to NNTH 308)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/> (101 to 166) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> <br/> (0.62 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.22% (‐3.07 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 450 (NNTB 71 to ∞ to NNTH 33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/> (23 to 68) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: diarrhoea in child treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b> <br/> (0.58 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1358<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.93% (‐2.01 to 3.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB 108 (NNTB 34 to ∞ to NNTH 50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><br/> (42 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in child treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.7</b> <br/> (1.23 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1358<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5.34% (1.75 to 10.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 19 (10 to 57)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/> (94 to 179) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harm; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treating influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults with influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> zanamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in adult treatment (days)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (days) to first alleviation of symptoms in adults in the intervention groups was<br/> <b>0.60 lower</b><br/> (0.81 to 0.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 days (0.39 to 0.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5411<br/> (13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia confirmed with X‐ray in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.35 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>946<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.06% (‐6.56 to 2.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 1540 (NNTB 48 to ∞ to NNTH 16)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (11 to 98) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea/vomiting in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.6</b> <br/> (0.39 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6553<br/> (15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.63% (0.24 to 2.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 62 (41 to 411)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/> (16 to 38) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: psychiatric body system in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/> (0.57 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4732<br/> (10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.09% (‐0.76 to 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH 1132 (NNTB 421 to ∞ to NNTH 132)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (3 to 13) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.61 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6072</p> <p>(12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.80% (0.65 to 2.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB 56 (36 to 155)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> <p>(44 to 65)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treating influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children with influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> zanamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in children (days)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (days) to first alleviation of symptoms in children in the intervention groups was<br/> <b>1.08 lower</b><br/> (2.32 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: sinusitis in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b> <br/> (0.12 to 6.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>737<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.19% (‐8.09 to 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 519 (NNTB 13 to ∞ to NNTH 77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/> (2 to 96) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: otitis media in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> <br/> (0.59 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>737<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.00% (‐5.13 to 2.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = &gt; 1000 (NNTB 35 to ∞ to NNTH 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (42 to 122) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD008965-sec-0107"> <h4 class="title">Analysis of influenza outcomes in prophylaxis studies</h4> <p>Symptomatic influenza was lower in the oseltamivir arms compared to placebo in studies of prophylaxis (RR 0.45, 95% CI 0.30 to 0.67, I<sup>2</sup> statistic = 0%; RD 3.05%, 95% CI 1.83 to 3.88; NNTB = 33, 95% CI 26 to 55) (<a href="./references#CD008965-fig-0098" title="">Analysis 2.1</a>); but there were no differences for all other influenza outcomes including overall influenza‐like‐illness reported as an adverse event on‐treatment. In household prophylaxis, one small study with missing outcome data and selective reporting, including 405 participants, showed a significant reduction of symptomatic influenza in the oseltamivir arm compared to placebo (RR 0.20, 95% CI 0.09 to 0.44; RD 13.6%, 95% CI 9.52 to 15.47) (<a href="./references#CD008965-fig-0100" title="">Analysis 2.3</a>), but in the same study there was no significant reduction in asymptomatic influenza (RR 1.14, 95% CI 0.39 to 3.33) (<a href="./references#CD008965-fig-0101" title="">Analysis 2.4</a>). Asymptomatic influenza was not significantly reduced and there was no non‐influenza, influenza‐like illness reported throughout the study period. </p> <p>In prophylaxis trials we could not analyse effects on influenza‐like illness because of a lack of definition in the clinical study reports. However, using our definition (see methods), oseltamivir did not reduce influenza‐like illness in participants (RR 0.95, 95% CI 0.86 to 1.06). </p> <p>The Roche trial programme assessing the effects of oseltamivir in post‐exposure prophylaxis (PEP) submitted to the FDA on 22 May 2000 consisted of two trials: <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> and <a href="./references#CD008965-bbs2-0168" title="(Oseltamivir trial. Title unknown). Data on file. [Mentioned in EMA EPAR dated 23 March 2006 pdf page 14 but possibly same trial as WV 16193] ">WV16139</a>. We included only trial <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> because <a href="./references#CD008965-bbs2-0168" title="(Oseltamivir trial. Title unknown). Data on file. [Mentioned in EMA EPAR dated 23 March 2006 pdf page 14 but possibly same trial as WV 16193] ">WV16139</a> was not placebo‐controlled. <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> was a double‐blind, cluster‐randomised trial in which contact clusters of index cases were randomised to oseltamivir 75 mg a day or placebo for seven days. The manufacturer concluded that the trial proved that oseltamivir could prevent influenza in contacts by interrupting transmission from index cases. Interruption of transmission has two components: reduction of viral spread from index cases (measured by nasal shedding of influenza viruses) and prevention of onset of influenza in contacts measured with a mixture of symptoms and signs and 'laboratory confirmation' (i.e. viral culture from the upper airways and/or at least a four‐fold rise in antibody titres measured between baseline and two to three weeks later). The design of the <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> is weak. All index cases were left untreated except for a paracetamol rescue pack, making it impossible to assess the effect of oseltamivir on nasal voidance of index cases. Nasal viral voidance was measured only in symptomatic participants thereby missing out on potential asymptomatic infected people. </p> <p>Zanamivir similarly significantly reduced the risk of symptomatic influenza for individuals (RR 0.39, 95% CI 0.22 to 0.70, I<sup>2</sup> statistic = 45%; RD = 1.98%, 95% CI: 0.98 to 2.54; NNTB = 51, 95% CI 40 to 103) (<a href="./references#CD008965-fig-0222" title="">Analysis 4.1</a>), as well as households (RR 0.33, 95% CI 0.18 to 0.58, I<sup>2</sup> statistic = 40%; RD = 14.84%, 95% CI 12.18 to 16.55, NNTB = 7, 95% CI 6 to 9) (<a href="./references#CD008965-fig-0224" title="">Analysis 4.3</a>). However, it did not reduce the risk of asymptomatic influenza in the prophylaxis of individuals (RR 0.97, 0.76 to 1.24, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0223" title="">Analysis 4.2</a>) or asymptomatic individuals in post‐exposure prophylaxis of households (RR 0.88, 95% CI 0.65 to 1.20, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0225" title="">Analysis 4.4</a>). See <a href="#CD008965-tbl-0011">Table 11</a> for the overall results for oseltamivir in adults and <a href="#CD008965-tbl-0009">Table 9</a> for children. See <a href="#CD008965-tbl-0012">Table 12</a> and <a href="#CD008965-tbl-0013">Table 13</a> for the overall results for zanamivir in adults and <a href="#CD008965-tbl-0014">Table 14</a> for children. </p> <div class="table" id="CD008965-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for preventing influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children without influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> oseltamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; RR: risk ratio </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for preventing influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults without influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> zanamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for prophylaxis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in prophylaxis of individuals</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.39</b> </p> <p>(0.22 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5275</p> <p>(4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.98% (0.98 to 2.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 51 (40 to 103)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/> (7 to 23) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic influenza in prophylaxis of individuals</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/> (0.76 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5275<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.14% (‐1.1 to 1.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 729 (NNTB 91 to ∞ to NNTH 91)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><br/> (38 to 60) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in household prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.22</b> <br/> (0.13 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>824<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14.84% (12.18 to 16.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 7 (6 to 9)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (25 to 68) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic influenza in household prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/> (0.6 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>824<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.32% (‐2.2 to 3.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 76 (NNTB 26 to ∞ to NNTH 46)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>107 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b><br/> (64 to 145) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia in adult prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.30</b> <br/> (0.11 to 0.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7662<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.32% (0.09 to 0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 311 (244 to 1086)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.5 per 1000</b><br/> (1 to 4) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in adult prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> </p> <p>(0.02 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7662</p> <p>(6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.79% (‐0.29 to 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 127 (to NNTB 81 to ∞ to NNTH 341)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> <p>(3 to 18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for preventing influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults without influenza <br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> oseltamivir for prophylaxis<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for prophylaxis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in adult prophylaxis of individuals</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.45</b> <br/> (0.30 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2479<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3.05% (1.83 to 3.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 33 (26 to 55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (17 to 37) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in household prophylaxis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.2</b> <br/> (0.09 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>405<br/> (1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13.6% (9.52 to 15.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 7 (6 to 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (15 to 75) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: psychiatric body systems in adult prophylaxis (all events on‐ and off‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.80</b> <br/> (1.05 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐1.06% (‐2.76 to ‐0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 94 (36 to 1538)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (14 to 40) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: headache in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.18</b> <br/> (1.05 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐3.15% (‐5.78 to ‐0.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 32 (18 to 115)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b><br/> (184 to 233) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.96</b> <br/> (1.2 to 3.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐4.15% (‐9.51 to ‐0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 25 (11 to 116)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (52 to 138) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.91</b> <br/> (0.7 to 5.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.95% (‐4.41 to 0.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 106 (NNTB 319 to ∞ to NNTH 23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (7 to 55) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: headache in adult prophylaxis (off‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> <br/> (0.63 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.44% (‐0.89 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 226 (NNTB 74 to ∞ to NNTH 113)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (23 to 46) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD008965-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for preventing influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children without influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> zanamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; RR: risk ratio </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008965-sec-0108"> <h4 class="title">Analysis of harms</h4> <section id="CD008965-sec-0109"> <h5 class="title">Oseltamivir treatment</h5> <section id="CD008965-sec-0110"> <h6 class="title">Nausea, vomiting and diarrhoea</h6> <p>Oseltamivir in the treatment of adults is associated with increased risk of nausea (RR 1.57, 95% CI 1.14 to 2.15, I<sup>2</sup> statistic = 43%; RD 3.66%, 95% CI 0.90 to 7.39; number needed to treat to harm (NNTH) = 28, 95% CI 14 to 112) (<a href="./references#CD008965-fig-0020" title="">Analysis 1.5</a>) and vomiting (RR 2.43, 95% CI 1.75 to 3.38, I<sup>2</sup> statistic = 12%; RD 4.56%, 95% CI 2.39 to 7.58; NNTH = 22, 95% CI 14 to 42) (<a href="./references#CD008965-fig-0021" title="">Analysis 1.6</a>). It is associated with a decreased risk of diarrhoea (RR 0.67, 95% CI 0.46 to 0.98, I<sup>2</sup> statistic = 44%; RD 2.33%, 95% CI 0.14 to 3.81; NNTB = 43, 95% CI 27 to 709) (<a href="./references#CD008965-fig-0022" title="">Analysis 1.7</a>) when compared to placebo during on‐treatment periods. Both nausea and vomiting were associated with significant heterogeneity where treatment effects appeared larger in otherwise healthy adults compared to the elderly and the chronically ill. However, one trial of otherwise healthy adults also showed smaller effects (<a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>). Vomiting was more common in those children on oseltamivir treatment compared to those on placebo (RR 1.70, 95% CI 1.23 to 2.35, I<sup>2</sup> statistic = 0%; RD 5.34%, 95% CI 1.75 to 10.29; NNTH = 19, 95% CI 10 to 57) (<a href="./references#CD008965-fig-0078" title="">Analysis 1.63</a>). </p> </section> <section id="CD008965-sec-0111"> <h6 class="title">Cardiac effects</h6> <p>The cardiac effects of oseltamivir are unclear. Exposure to oseltamivir may reduce cardiac general events compared to placebo (RR 0.49, 95% CI 0.25 to 0.97, I<sup>2</sup> statistic = 0%; RD 0.68%, 95% CI 0.04 to 1.00; NNTB = 148, 95% CI 101 to 2509), excluding <a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a> in which ECG was included in the safety parameters (<a href="./references#CD008965-fig-0042" title="">Analysis 1.27</a>). However, exposure to oseltamivir may increase QTc prolongation (including borderline) as reported in trial <a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a> (RD 4.0%, 95% CI 0.71 to 7.30; NNTH = 25, 95% CI 14 to 140) compared to placebo during on‐treatment periods. </p> </section> <section id="CD008965-sec-0112"> <h6 class="title">Psychiatric effects</h6> <p>In treatment trials, there was no significant increase in risk between oseltamivir and on‐treatment psychiatric adverse events overall (<a href="./references#CD008965-fig-0047" title="">Analysis 1.32</a>). However, there was a dose‐response effect in the two "pivotal" treatment trials. In the identically designed trials <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a> and <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a> there were two active treatment groups: 150 mg (standard dose) and 300 mg (high dose) oseltamivir per day. In the dose‐response analysis there was an increased risk of psychiatric body system adverse events over the entire follow‐up period (P = 0.038 based on likelihood ratio test). In trial <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>, the event rates were: 1/204, 1/206 and 4/205 in the placebo, 75 mg and 150 mg arms respectively, whereas trial <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a> had rates of 2/235, 0/242 and 5/242, respectively. </p> </section> <section id="CD008965-sec-0113"> <h6 class="title">Effect on antibodies (post‐protocol hypotheses)</h6> <p>The proportion of patients being diagnosed as influenza‐infected in oseltamivir treatment of adults was significantly lower in the treated compared to the control group (RR 0.95, 95% CI 0.91 to 0.99, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0018" title="">Analysis 1.3</a>). The proportion of patients with four‐fold increases in antibody titre was significantly lower in the treated group compared to the control group (RR 0.92, 95% CI 0.86 to 0.97, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0019" title="">Analysis 1.4</a>). This represents an absolute difference of 5% between treatment groups. There was a lower proportion of children on oseltamivir with a four‐fold increase in antibodies (RR 0.90, 95% CI 0.80 to 1.00, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0064" title="">Analysis 1.49</a>). </p> </section> </section> <section id="CD008965-sec-0114"> <h5 class="title">Oseltamivir prophylaxis</h5> <section id="CD008965-sec-0115"> <h6 class="title">Headaches and nausea</h6> <p>In oseltamivir prophylaxis, there was an increased risk of headaches on‐treatment (RR 1.18, 95% CI 1.05 to 1.33, I<sup>2</sup> statistic = 0%; RD 3.15%, 95% CI 0.88 to 5.78; NNTH = 32, (95% CI 18 to 115) (<a href="./references#CD008965-fig-0116" title="">Analysis 2.19</a>; <a href="#CD008965-fig-0010">Figure 10</a>) and nausea on‐treatment (RR 1.96, 95% CI 1.20 to 3.20, I<sup>2</sup> statistic = 49%; RD 4.15%, 95% CI 0.86 to 9.51; NNTH = 25, 95% CI 11 to 116) (<a href="./references#CD008965-fig-0117" title="">Analysis 2.20</a>). There was also a dose‐response effect for headaches in study <a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a> (P = 0.013 based on likelihood ratio test), where on‐treatment rates were: 202/519, 225/520 and 242/520 in the placebo, standard‐dose and high‐dose arms, respectively. </p> <div class="figure" id="CD008965-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.19 Adverse events: headache in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.19 Adverse events: headache in adult prophylaxis (on‐treatment). </p> </div> </div> </div> </section> <section id="CD008965-sec-0116"> <h6 class="title">Psychiatric effects</h6> <p><a href="#CD008965-fig-0011">Figure 11</a> (<a href="./references#CD008965-fig-0151" title="">Analysis 2.54</a>) shows that in prophylaxis trials of oseltamivir there was a significant increase in patients with psychiatric adverse events over the on‐ and off‐treatment periods (RR 1.80, 95% CI 1.05 to 3.08, I<sup>2</sup> statistic = 0%; RD 1.06%, 95% CI 0.07 to 2.76; NNTH = 94, 95% CI 36 to 1538). Initial analysis of patients with psychiatric adverse events in the on‐treatment period showed a borderline statistically significant result (P = 0.06), hence we conducted sensitivity analysis using Peto's method (P = 0.05) as well as the analysis reported in <a href="#CD008965-fig-0011">Figure 11</a>. </p> <div class="figure" id="CD008965-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.54 Adverse events: psychiatric body system in adult prophylaxis (on‐ and off‐treatment)." data-id="CD008965-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.54 Adverse events: psychiatric body system in adult prophylaxis (on‐ and off‐treatment). </p> </div> </div> </div> <p><a href="#CD008965-tbl-0015">Table 15</a> shows a summary of all psychiatric adverse events in oseltamivir prophylaxis trials. Of particular note was an oseltamivir patient in study <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a> who had severe confusion on day 27 and was hospitalised. On day 28 the patient was taken off medication and the event resolved. On day 29 the patient was discharged from hospital and subsequently resumed medication. However, confusion reappeared on day 32. The initial event was misclassified in the clinical study report as "mental impairment" but has since been corrected in an erratum published in the same journal that published the original trial manuscript (<a href="./references#CD008965-bbs2-0233" title="GravensteinS , PetersP . Erratum. Journal of the American Geriatrics Society2013;61:478. ">Gravenstein 2013</a>; <a href="./references#CD008965-bbs2-0278" title="PetersPHJr , GravensteinS , NorwoodP , DeBockV , VanCouterA , GibbensM , et al. Long‐term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatrics Society2001;49(8):1025‐31. [PUBMED: 11555062] ">Peters 2001</a>). </p> <div class="table" id="CD008965-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Psychiatric adverse events in oseltamivir prophylaxis trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Event type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hallucinations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bipolar disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restlessness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide ideation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paranoia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol related</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.92</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Of the 66 events, 12 were classified as severe intensity (10 oseltamivir, 2 placebo)</p> </div> </div> </section> <section id="CD008965-sec-0117"> <h6 class="title">Renal effects</h6> <p>There was a non‐significant increase in renal events on‐treatment (RR 3.17, 95% CI 0.96 to 10.49, I<sup>2</sup> statistic = 0; RD 0.67%, 95% CI ‐2.93 to 0.01; NNTH = 150, 95% CI NNTH 35 to ∞ to NNTB &gt; 1000) (<a href="./references#CD008965-fig-0135" title="">Analysis 2.38</a>). However, in sensitivity analysis using Peto's method the result for renal events was statistically significant (P = 0.02). </p> </section> </section> <section id="CD008965-sec-0118"> <h5 class="title">Zanamivir</h5> <section id="CD008965-sec-0119"> <h6 class="title">Serious adverse events</h6> <p>There was no significant effect on serious adverse events in adult treatment trials (RR 0.86, 95% CI 0.49 to 1.50, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0163" title="">Analysis 3.11</a>). </p> </section> <section id="CD008965-sec-0120"> <h6 class="title">Nausea, vomiting and diarrhoea</h6> <p>In treatment trials, there was no significant effect on diarrhoea in adults (RR 0.87, 95% CI 0.66 to 1.14, I<sup>2</sup> statistic = 5%) (<a href="./references#CD008965-fig-0185" title="">Analysis 3.33</a>) or headache (RR 0.84, 95% CI 0.60 to 1.18, I<sup>2</sup> statistic = 0) (<a href="./references#CD008965-fig-0187" title="">Analysis 3.35</a>). However, during the on‐treatment phase, nausea and vomiting were significantly less frequent in the zanamivir arm (RR 0.60, 95% CI 0.39 to 0.94, I<sup>2</sup> statistic = 0%; RD 1.63%, 95% CI 0.24 to 2.48%; NNTB = 62, 95% CI 41 to 411) (<a href="./references#CD008965-fig-0184" title="">Analysis 3.32</a>). </p> </section> <section id="CD008965-sec-0121"> <h6 class="title">Renal, psychiatric and other harms</h6> <p>There was no significant effect observed on the renal system (RR 0.84, 95% CI 0.41 to 1.72, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0197" title="">Analysis 3.45</a>), or the psychiatric system (RR 1.16, 95% CI 0.57 to 2.38, I<sup>2</sup> statistic = 0%) (<a href="./references#CD008965-fig-0200" title="">Analysis 3.48</a>). In adult treatment trials of zanamivir, there was no significantly increased risk of any other reported adverse events and there was no significant increase in adverse effects observed in prophylaxis trials, including psychiatric (<a href="./references#CD008965-fig-0250" title="">Analysis 4.29</a>) and renal effects (<a href="./references#CD008965-fig-0251" title="">Analysis 4.30</a>) on‐treatment. There was no significant increase in harms associated with zanamivir treatment of children but data were sparse. </p> </section> <section id="CD008965-sec-0122"> <h6 class="title">Effect on antibodies</h6> <p>There was no significant effect of zanamivir treatment on influenza diagnosis (<a href="./references#CD008965-fig-0160" title="">Analysis 3.8</a>) or probability of a four‐fold increase in antibody titre (<a href="./references#CD008965-fig-0161" title="">Analysis 3.9</a>; <a href="./references#CD008965-fig-0162" title="">Analysis 3.10</a>). </p> </section> </section> </section> <section id="CD008965-sec-0123"> <h4 class="title">Deaths</h4> <p>In oseltamivir treatment trials, there was one death overall. This event occurred due to acute respiratory syndrome in a placebo patient without influenza in study <a href="./references#CD008965-bbs2-0043" title="McCarvilM . A double‐blind, stratified, randomised, placebo controlled study of Ro 64‐0796 (also known as GS4104) in the treatment of influenza in chronically ill adults. Data on file. ">WV15812/WV15872</a>. In prophylaxis trials, there were four deaths in total, all in elderly patients, with two in the placebo group and two in the oseltamivir group. Causes of death were reported as two cancers, one myocardial infarction and one intestinal perforation. However, for both deaths in the oseltamivir arms the participants experienced acute renal failure on‐treatment prior to death. </p> <p>There were eight deaths in total in the zanamivir trials. Six of the deaths were caused by neoplasias or cardiovascular events in elderly patients with multiple pathologies. However, two deaths were reported as due to influenza A pneumonia. One participant was on inhaled rimantadine plus placebo and the other on zanamivir. </p> <p>The results of post‐protocol hypotheses are in <a href="./appendices#CD008965-sec-0150">Appendix 10</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008965-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008965-sec-0124"></div> <p>Oseltamivir and zanamivir have small, non‐specific effects on reducing time to alleviation of influenza‐like illness symptoms in adults, but not in asthmatic children. Using either drug as prophylaxis reduces the risk of developing symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question of whether complications of influenza such as pneumonia are reduced, because of a lack of diagnostic definitions. Use of oseltamivir increases the risk of adverse effects such as nausea, vomiting, psychiatric effects and renal events in adults and the risk of vomiting in children. The lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir. The influenza virus‐specific mechanism of action proposed by the producers does not fit the clinical evidence. </p> <section id="CD008965-sec-0125"> <h3 class="title" id="CD008965-sec-0125">Reconstructing trial lists and indexing regulatory comments</h3> <p>Calls for incorporating unpublished data to supplement published trial data in systematic reviews and meta‐analyses highlight deficiencies in the current methods for obtaining the most complete understanding of a drug's effects (<a href="./references#CD008965-bbs2-0231" title="GodleeF , LoderE . Missing clinical trial data: setting the record straight. BMJ2010; Vol. 341:c5641. [PUBMED: 20940217] ">Godlee 2010</a>). Our methodological approach entailed comprehensive searching of unpublished sources, with a particular emphasis on obtaining unpublished and internal reports from drug manufacturers intended for regulatory submission and comments from national regulatory bodies. Our decision not to use published evidence as a basis for trial appraisal and data extraction meant that we had to reconcile and synthesise information from multiple unpublished sources. We had to devise a new method of searching, indexing, retrieving and reviewing trial data and to combine this understanding with regulatory comments to produce an informative review. The first step in this process entailed the need to develop our own reconstruction of the trial programme without initial help from outside sources. The reconstructed list of trials and then programmes took a whole‐time‐equivalent (WTE) researcher 20 days to compile. Due to the complexity of the task we suggest that in the future some of the essential phases, such as trial ID checking, be conducted in pairs. </p> <p>One of the comments received on our protocol suggested that discrepancies between published and unpublished versions of the same data set could be due to mistakes in the non‐peer reviewed, unedited clinical study reports (which may be corrected by the time of publication). Our experience, especially with the non‐reporting of serious adverse events, points to the opposite being the case (<a href="./references#CD008965-bbs2-0252" title="JeffersonT , DoshiP , ThompsonM , HeneghanC . Ensuring safe and effective drugs: who can do what it takes?. BMJ2011;342:c7258. [PUBMED: 21224325] ">Jefferson 2011b</a>). Considering the fact that unintentional errors can occur, we believe the response should not be a resort to published papers as 'most accurate' and best unit of analysis, but rather that clinical study reports ‐ as by far the most comprehensive record of a trial ‐ remain the key unit of analysis, with the expectation that they be amended and kept as accurate as possible over time, with complete documentation of reasons for any amendments. We believed that the results of our review would be undermined without accessing a more complete body of evidence that we knew to be outside the public domain. </p> <p>In theory, trial registers would be expected to provide a comprehensive picture of a drug's trial programme. However, registers were not our primary instruments to reconstruct zanamivir and oseltamivir trial programmes. Both drugs' programmes were mainly run in the late 1990s, before trial registration became the norm. In addition, registers may suffer from some of the problems that we were trying to address. <a href="./references#CD008965-bbs2-0191" title="BourgeoisFT , MurthyS , MandlKD . Outcome reporting among drug trials registered in ClinicalTrials.gov. Annals of Internal Medicine2010;153:158‐66. ">Bourgeois 2011</a> audited entries for 546 trials of five major classes of drugs on ClinicalTrials.gov, the biggest prospective register of clinical trials, and found evidence of risk of reporting bias and delay in reporting of results. Another review of 152 trials found that the description of 123 (or 81%) of the trials in the sample had been changed in at least one key element in the time between registration and publication. The most frequent changes regarded outcomes (<a href="./references#CD008965-bbs2-0242" title="HuicM , MarusicM , MarusicA . Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS ONE2011;6(9):e25258. [DOI: 10.1371/journal.pone.0025258] ">Huic 2011</a>). Despite the current limits of registers, both specifically to this review and in the way they are run and updated, we believe that registers are an obvious first choice to start reconstruction of trials programmes. Searching for unpublished material has not yet become standard practice in conducting Cochrane reviews (<a href="./references#CD008965-bbs2-0292" title="VanDrielML , DeSutterA , DeMaeseneerJ , ChristiaensT . Searching for unpublished trials in Cochrane reviews may not be worth the effort. Journal of Clinical Epidemiology2009;62:838‐44. ">Van Driel 2009</a>), and is currently variably reported (<a href="./references#CD008965-bbs2-0229" title="GhersiD , ClarkeMJ , ReveizL . Do Cochrane reviews search databases of ongoing trials, and how well do they report these searches? Oral presentation at the Joint Cochrane and Campbell Collaboration. http://www.cochrane.org/sites/default/files/uploads/abstract_book_keystone_2010.pdf. 2010, issue Suppl CD000002:45‐6. [DOI: 10.1002/14651858] ">Ghersi 2010</a>). </p> <p>The indexing and review of regulatory files was also a very laborious task. It took a WTE researcher three days to review the US Food and Drug Administration (FDA) regulator's comments and gain a basic understanding of the content. Four additional days were needed to read and annotate the FDA zanamivir files and 28 days for reading and annotating the oseltamivir files and building the Table of Contents‐Evidence (TOCE). The exercise had to be repeated several times to cross‐check content and expand annotations. Construction of the Table of Contents (TOC) was laborious. A first attempt at electronic mapping the TOC content took 12 and 8 hours respectively for the FDA and National Institute for Health and Clinical Excellence (NICE) regulatory documents. This was carried out using the Adobe Acrobat Optical Character Recognition (OCR) search facility, which enabled mapping of citation counts by document and by trial ID. Initially we used the trial prefix followed by the serial number ('WV15670') as ID. This procedure, however, had one major drawback linked to the nature of regulatory documents. As regulatory documents consist of notes, correspondence and reviews, the same trial is cited in a non‐standardised way. For example, trial <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a> is cited as 'WV15670' 15 times, as 'WV_15670' 12 times and simply as '15670' 19 times). Thorough searches must be conducted using all the different terms. As this can be very time‐consuming, we decided to compare an Acrobat search with a Boolean string strategy containing all possible citation formats (for example, <a href="./references#CD008965-bbs2-0040" title="No authorslisted . A double‐blind, randomized, stratified, placebo‐controlled study of Ro 64‐0796 (also known as GS 4104) in the treatment of children with influenza. Data on file. ">WV15758</a> OR WV 15758 OR Trial 15758 OR Trial15758 OR Trials 15758 OR Trials15758 OR 15758 OR study 15758 OR study15758) (this is logically equivalent to 'WV 15758 OR WV 15758') with a term‐by‐term search (i.e. separately searching for WV15758 and then for WV 15758 and so on). We reasoned that if the yield were comparable, the Boolean strategy would have been faster. The yield of citations of the two strategies was the same for six of seven 'tracker' studies but use of a Boolean string was considerably faster (an average of 3 versus 14 hours) than the term‐by‐term strategy. The National Institute of Clinical Excellence (NICE) submission citations took two hours to list in a TOC using a Boolean strategy. We adopted the Boolean search strategy to construct our TOC. Ultimately it is possible that a search with the trial numerals ('15670') may be sufficient to identify the vast majority of citations. To validate this method of searching further our methods should be repeated on other sets of regulatory documents. </p> <p>Once we had reconstructed the trial programmes we submitted the results to GlaxoSmithKline (GSK) and Roche for their input. We received detailed feedback from both but as late as 2011 Roche's list of trials was incomplete. Despite the laboriousness of the methods, we believe we ended up with a far more comprehensive and less biased set of evidence than that available through the current system of journal‐based publications. This shift in our data synthesis paradigm was made necessary by the numerous and documented discrepancies between regulatory and published evidence and by the sizeable risk of publication bias of the oseltamivir trial programme. The importance of reconstructing the trial programme by first generating a complete trial list was further reinforced upon discovering bias and oversights in regulators' handling of the trial programme. Regulators focus on a few mutually agreed "pivotal" trials whose data analyses are replicated by the FDA but not by the European Medicines Agency (EMA). Both largely ignored trial <a href="./references#CD008965-bbs2-0007" title="McGartyT . A randomized, double‐blind, placebo‐controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64‐0796 (also known as GS 4104). Data on file. ">M76001</a>, the largest oseltamivir treatment trial conducted prior to initial registration of the drug (and still unpublished). While the manufacturer may not have offered it as a "pivotal" trial, far smaller and even ongoing studies were included in the evidence base to support Roche's year 1999 New Drug Application number 021087 (Treatment of uncomplicated acute illness due to influenza infections in adults who have been symptomatic for no more than two days). The depth of the EMA scrutiny is harder to assess as we could find no reports of trial site visits or of data analysis replication, but we identified a pooled analysis of treatment trials, very similar to the <a href="./references#CD008965-bbs2-0254" title="KaiserL , WatC , MillsT , MahoneyP , WardP , HaydenF . Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine2003;163:1667‐72. ">Kaiser 2003</a> analysis which formed the basis for the EMA conclusion that oseltamivir affected complications reported, for example, on EMA's 4 October 2012 Summary of product characteristics (SmPC) (<a href="http://www.bmj.com/tamiflu/ema" target="_blank">http://www.bmj.com/tamiflu/ema</a>). We requested Modules 3, 4 and 5 (individual listings, demographic data and the statistical analysis report) from the EMA. However, for most oseltamivir trials, the EMA do not have the relevant documents and neither apparently do National Competent Authorities (email from the EMA, 24 May 2011; email from Dutch regulator MEB, 20 July 2011). This means that the Modules do not appear to have been either submitted to or requested by regulators, raising questions as to the extent of scrutiny of the clinical trials during the regulatory review of oseltamivir in Europe. </p> </section> <section id="CD008965-sec-0126"> <h3 class="title" id="CD008965-sec-0126">Our new method</h3> <p>Reviewing huge quantities of complicated data and linked comments is a very difficult and delicate process. The main problem is not so much the appraisal following standard rules and possible synthesis of data (as when we review published information), but the reconstructions and logical threading of a trial programme generating huge amounts of data needing appraisal. Also the manufacturer's full regulatory submission, which may have even more information than a full clinical study report, remains confidential. Most of the essential data required are available in clinical study reports, together with masses of less important data, but as we have explained even in this case there may be important omissions, such as mislaid diary cards for follow‐up. Manufacturers are under obligation to provide regulators with all data requested to enable them to reach a decision: in doing so they produce vast submissions. None of the authors (all experienced systematic reviewers) had any experience of reviewing regulatory information. Given the laborious and painstaking process we tried to identify a quicker and equally reliable way of reviewing regulatory information but could not find any obvious shortcuts. However, we believe that providing a critical overview of a trial programme rather than minute dissection of each trial is necessary. This can be done by identifying the important topics in the trial programme (such as the effects of the drug on symptoms, infection, complications, transmission and well‐being) and following them throughout the programme, knitting the evidence into a coherent narrative. This includes carrying out a high‐level overview of the mode of action of the drug in different populations for different indications. Understanding any drug's mode of action is core to correct reporting of its strengths and limitations. In addition, a large part of the regulatory submission is made up of chemistry, microbiological, animal model pharmacodynamic and pharmacokinetic studies, which are important for shedding light on the trial programme but which seldom feature in systematic reviews. We are unsure as to whether this information could be considered as core information but an exhaustive review of a trial programme should include reviews dedicated to such topics. </p> <p>These methods were crucial in discovering major concerns in trial conduct and validity, including the lack of comparability between arms induced by subset analysis and by the randomisation‐analysis fork, high positivity rate of influenza, high gastrointestinal events in the placebo arms, possibly active placebo content and possible procedural breaches several trials, which are concerning. Overall, the safest and more conservative option appears to carry out analyses on the basis of the intention‐to‐treat (ITT) population, in which units of randomisation and analysis are the same and many of the potential problems listed are either not present or minimised. </p> <p>Our novel methodology remains a work in progress.</p> </section> <section id="CD008965-sec-0127"> <h3 class="title" id="CD008965-sec-0127">Regulatory comments</h3> <p>Reviewing regulatory comments was an essential way to deepen our understanding of the trial programme. From early on in our review we hoped that a close reading of regulatory material would allow us to understand the reason for discrepancies between US and European regulators' conclusions regarding the effects of oseltamivir, particularly (but not limited to) their purported effect on complications (<a href="./references#CD008965-bbs2-0203" title="DoshiP . Neuraminidase inhibitors ‐ the story behind the Cochrane review. BMJ2009;339:b5164. ">Doshi 2009</a>). We were interested in what led the FDA to have far more cautious and conservative statements ‐ as witnessed in the Tamiflu product label and FDA letters ‐ in comparison to European regulators. Our access to huge amounts of FDA regulatory data allowed for many insights but gave us little visibility of manufacturers' responses.  </p> <p>Some of the statements made by the manufacturer in the clinical study reports, and subsequently in contemporaneous publications and advertisements, appeared unsupported by the evidence provided at the time. The FDA drug regulatory reviewers' comments, although laborious to summarise and contextualise (because of the non‐availability of the whole pharmaceutical submission), were confirmed by our reading of the clinical study reports. However, we were unable to find a statement explaining how the FDA reviewed each New Drug Application (NDA). FDA reviewing methods appeared to be a mixture of spot checks, re‐run of statistical analyses and on‐site inspections. An FDA methods volume or standard operational procedure may be among the documents not available from the web but accessible through a Freedom of Information (FOI) request. Neither the FDA nor the EMA have inventories of held documents, making it very difficult to know what to ask for under FOI rules. We concentrated on downloading or asking for specific clinical study reports and related documents or reviewers' comments on a particular NDA. The quantity of information held by regulators is likely to be large. For example, New Drug Application 21‐246, the use of Tamiflu in the treatment of influenza in children submitted to the FDA on 15 June 2000 consisted of 137 volumes of study documents and possibly several electronic files. Although we do not know exactly how long a volume was, we have seen references to up to hundreds of pages in each volume. </p> <p>Requesting specific documents and packages of information is especially important to allow a more efficient and timely reviewing process when confronted with a large volume of evidence, most of which could be of peripheral value. A request for a specific document is likely to be dealt with far more efficiently than a generic request for "all documentation relating to oseltamivir". This is one of the reasons why developing a TOC for any drug or family of drugs (no matter how time‐consuming) is an absolute prerequisite for any serious attempt at reviewing regulatory evidence. This introduces another very difficult problem: how to handle huge quantities of structured information and the ethics of drawing conclusions from what is still a fragmentary (albeit sizeable) evidence base. </p> <p>Overall the FDA assessment of the performance of oseltamivir was "modest". This adjective appears six times in a 50‐page review document (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>). For example, in the Division Director Memorandum dated 25 October 1999, under the heading "Public health role of antiviral treatment" the FDA states: "The clinical relevance of the modest treatment benefit is a highly subjective question" (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>, PDF page 3). The FDA refused to accept claims of oseltamivir's effects on influenza complications as "false or misleading" statements in promotional materials (<a href="./references#CD008965-bbs2-0221" title="Food , DrugAdministration . Faxed letter to Roche (file UCM166329) [NDA 21‐087TAMIFLU (oseltamivir phosphate) MACMIS ID#8675]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166329.pdf 2000 (accessed 19 October 2010). ">FDA 2000f</a>). An FDA warning letter seems to imply, for example, that oseltamivir's mode of action is "proposed" or "possibly" [that proposed by the manufacturers] i.e. not certain (<a href="./references#CD008965-bbs2-0221" title="Food , DrugAdministration . Faxed letter to Roche (file UCM166329) [NDA 21‐087TAMIFLU (oseltamivir phosphate) MACMIS ID#8675]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166329.pdf 2000 (accessed 19 October 2010). ">FDA 2000f</a>). However, FDA reviewers appear to have missed important problems in Roche's clinical trials (such as the imbalance in the numbers of individuals classified as influenza‐infected in oseltamivir treatment trials). Most of all, no one seems to have questioned the coherence of the evidence with the proposed mode of action of the drug. </p> </section> <section id="CD008965-sec-0128"> <h3 class="title" id="CD008965-sec-0128">Summary of main results</h3> <p>For the first time a Cochrane review is based on all relevant full clinical study reports of a class of drugs integrated by regulatory comments. Also for the first time, all clinical study reports of trials in a manufacturer's programme (regardless of their relevance to the review) are available to readers without any restriction (apart from minimal redactions to protect anonymity further). The role of Roche and GSK in making this possible should be recognised, as well as that of the <i>BMJ</i>, which kept the issue in the public eye until it was resolved. </p> <p>The evidence we have presented and synthesised shows that both neuraminidase inhibitors (NIs) in this review have symptom‐relieving effects, especially for self reported outcomes. They appear to have symptom‐relieving properties that make people with influenza‐like illness and self reported, investigator‐mediated, unverified pneumonia feel better by shortening symptom duration and reducing the frequency of symptoms such as cough. For oseltamivir, this effect perhaps extends to cardiac symptoms, despite the short duration of treatment (five days). We are unsure what to make of this finding but we think it deserves further investigation. </p> <p>The issue which triggered our change of evidence‐seeking methods is partly resolved: no definitions of secondary illnesses were given anywhere in the clinical study reports (for example "pneumonia" was defined as "pneumonia" in the case report forms (<a href="#CD008965-tbl-0001">Table 1</a>) and diagnostic criteria were not given); clinical diagnosis in the absence of criteria and without X‐ray has only a moderate chance of being correct. </p> <p>We could not decide the level of diagnostic ascertainment of diagnosis of pneumonia and other complications, as it is unclear from the clinical study reports. Definitions of pneumonia were not given and the algorithm for classification of an event as pneumonia was not supplied. In oseltamivir trials, the case report form trigger for recording of adverse events and secondary illness was a question to the participant posed by the investigator. A typical phrasing is as follows: "Secondary illness reminder: Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline?" This was followed by a yes/no box to be ticked and an additional form was to be filled out by the investigator for collecting details on the secondary illness. A record of medications outside trial allocation was elicited in addition to the participant's diary card. The original and Medical Dictionary for Regulatory Activities (MedDRA) terms suggest diagnoses for all secondary illnesses and adverse events but there is no indication how the original and preferred terms were assigned. We therefore considered these outcomes to be "self reported, investigator‐mediated, unverified" outcomes. For a subset of trials, secondary/intercurrent illness and adverse event data were collected on a single, one‐page form. In our meta‐analyses, we called this sub‐analysis "Trials which collected data on non‐specific adverse events or secondary/intercurrent illness form". For a different subset of trials, case report forms contained space to record diagnostic tests such as chest X‐rays, tympanometry and sinus X‐rays for all secondary illness but there was no reporting of such variables in the clinical study reports (<a href="#CD008965-fig-0012">Figure 12</a>; <a href="#CD008965-fig-0013">Figure 13</a>; <a href="#CD008965-fig-0014">Figure 14</a>; <a href="#CD008965-fig-0015">Figure 15</a>). In our meta‐analyses, we called this sub‐analysis "Trials which collected data on specific 'Diagnosis of Secondary Illness' form". None of the complications were defined as primary outcomes in any trial, which may explain the poverty of data definition. </p> <div class="figure" id="CD008965-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt='Sample "Adverse event or intercurrent illness" form (oseltamivir study M76001)' data-id="CD008965-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sample "Adverse event or intercurrent illness" form (oseltamivir study M76001)</p> </div> </div> </div> <div class="figure" id="CD008965-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt='Sample "Secondary illness" form (oseltamivir study WV15670)' data-id="CD008965-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sample "Secondary illness" form (oseltamivir study WV15670)</p> </div> </div> </div> <div class="figure" id="CD008965-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt='Sample "Diagnosis of secondary illness" form, page 1/2 (oseltamivir study WV15978)' data-id="CD008965-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sample "Diagnosis of secondary illness" form, page 1/2 (oseltamivir study WV15978)</p> </div> </div> </div> <div class="figure" id="CD008965-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt='Sample "Diagnosis of secondary illness" form, page 2/2 (oseltamivir study WV15978)' data-id="CD008965-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sample "Diagnosis of secondary illness" form, page 2/2 (oseltamivir study WV15978)</p> </div> </div> </div> <p>In meta‐regression of all 32 included studies that reported on "pneumonia", we found evidence that treatment effects for pneumonia are statistically different depending on the method of diagnosis. Unclear objective diagnosis was associated with an apparent 46% reduction in pneumonia due to treatment with neuraminidase inhibitors, whereas the use of objective criteria in the data collection showed no evidence of effect, with a risk ratio (RR) of 1.0. Age group (adults versus children), drug (oseltamivir versus zanamivir) and indication (treatment versus prophylaxis) showed no evidence of association with treatment effect. </p> <p>Meaningful conclusions on the effect of either NI on complications of influenza are difficult to draw based on the trial evidence. In part this was due to the lack of standardised definitions. In addition, meta‐analyses of these outcomes that lacked definitions were based on few events and therefore not robust. Caution is therefore urged in interpreting the meta‐analysis result, which suggests that 100 patients (67 to 451) need to be treated with oseltamivir for one less self reported, investigator‐mediated, unverified pneumonia. The same applies to the zanamivir treatment result, which suggests a reduced risk of self reported, investigator‐mediated, unverified bronchitis in adults (number needed to treat to benefit (NNTB) 56, 95% confidence interval (CI) 36 to 155). The evidence suggested oseltamivir had a similar effect, although the result was non‐significant. </p> <p>As stated above, there is no evidence that definitions of complications in either paediatric, elderly or adult trials were ever prepared and incorporated in the trials' design. Therefore, the reporting of cases of 'otitis media', 'pneumonia', 'sinusitis' or 'bronchitis' are of unclear significance and importance, making it impossible to attribute a cause and draw conclusions (<a href="./references#CD008965-bbs2-0219" title="Food , DrugAdministration . Review. Tamiflu (oseltamivir). NDA 021087 Supplement 002. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21‐087SE1‐002_review.pdf 2000 (accessed 26 August 2009). ">FDA 2000d</a>). This is probably why the US Food and Drug Administration (FDA)‐approved oseltamivir package insert, since 17 November 2000, has consistently stated: "serious bacterial infections may begin with influenza‐like symptoms or may coexist with or occur as complications during the course of influenza. TAMIFLU has not been shown to prevent such complications." The original product label did not contain such a statement but on 14 April 2000, after oseltamivir was approved for sale in the United States, the FDA sent Roche an untitled letter about "Misleading Efficacy Claims" that the FDA had noted in Roche's promotional materials (<a href="./references#CD008965-bbs2-0216" title='Food , DrugAdministration . Letter from FDA to Hoffman‐La Roche Inc. re "NDA 21‐087 TAMIFLU (oseltamivir phosphate) MACMIS ID#8675. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166329.pdf 2000 (accessed 14 April 2000). '>FDA 2000a</a>, PDF page 3). One of the statements that Roche made was: "Tamiflu reduces incidence of secondary complications (i.e. bacterial infections) by 45%." The FDA commented: "Further, you have claimed reductions in severity and incidence of secondary infections with Tamiflu that are misleading because they are not supported by substantial evidence" (<a href="./references#CD008965-bbs2-0216" title='Food , DrugAdministration . Letter from FDA to Hoffman‐La Roche Inc. re "NDA 21‐087 TAMIFLU (oseltamivir phosphate) MACMIS ID#8675. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166329.pdf 2000 (accessed 14 April 2000). '>FDA 2000a</a>, PDF page 3). We do not know how Roche responded to the FDA but in subsequently available Roche promotional material information, Roche's statements were consistent with the FDA's demands (<a href="./references#CD008965-bbs2-0203" title="DoshiP . Neuraminidase inhibitors ‐ the story behind the Cochrane review. BMJ2009;339:b5164. ">Doshi 2009</a>). </p> <p>There is uncertainty in the "complications" and "secondary illnesses" outcome definition therefore we carried out an analysis on the data from adult treatment trials on those complications classified as serious or those which led to study withdrawal. For oseltamivir, there was no evidence that treatment affected such complications (risk difference (RD) 0.07%, 95% CI ‐0.78 to 0.44) (<a href="./references#CD008965-fig-0035" title="">Analysis 1.20</a>; <a href="./references#CD008965-fig-0070" title="">Analysis 1.55</a>). This outcome could not be assessed in oseltamivir prophylaxis due to an insufficient number of events. For zanamivir, there was no significant evidence of a treatment effect on such complications (RD ‐0.04%, 95% CI ‐0.64 to 0.24) (<a href="./references#CD008965-fig-0159" title="">Analysis 3.7</a>; <a href="./references#CD008965-fig-0229" title="">Analysis 4.8</a>). This outcome could not be assessed in children due to an insufficient number of events. </p> <p>Contrary to the FDA, the European Medicines Agency (EMA)'s oseltamivir 'Summary of Product Characteristics' states that oseltamivir significantly reduces the incidence of "specified lower respiratory tract complications (mainly bronchitis) treated with antibiotics" in individuals of 13 years of age and older. This claim is based on "a pooled analysis of all influenza‐positive adults and adolescents (N = 2413) enrolled into treatment studies", of which 1063 were in the placebo group and 1350 were in the oseltamivir‐treated population (<a href="./references#CD008965-bbs2-0209" title="European Medicines Agency. Annex I. Summary of product characteristics (Tamiflu 30 mg hard capsule). http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500033106 (accessed 21 January 2010). ">EMA 2010</a>). This statement appears in the EMA files as early as 2001 (<a href="./references#CD008965-bbs2-0210" title="European Agency for the Evaluation of Medicinal Products. Tamiflu. Oseltamivir phosphate. (EMEA/H/C/402) CPMP recommendation &amp; scientific discussion consolidated list of questions (June 28, 2001). http://www.ema.europa.eu/. ">EMEA 2001</a>). These exact denominators appear in the <a href="./references#CD008965-bbs2-0254" title="KaiserL , WatC , MillsT , MahoneyP , WardP , HaydenF . Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine2003;163:1667‐72. ">Kaiser 2003</a> meta‐analysis. </p> <p>The design of the trials, as defined in the protocol with amendments, statistical analysis plan and case report forms, does not allow any further inferences. The effect on outcomes that were originally considered of secondary or tertiary importance (such as bronchitis and pneumonia) would have been clarified with better clinical definitions and investigations, as some of the serious adverse events were. These benefited from a paragraph‐length narrative, which reported most of the salient features of the event. </p> <p>Our previous decision to analyse the effects of oseltamivir and zanamivir on the ITT population has been confirmed for oseltamivir with the demonstration of the effect on antibody responses in participants in treatment trials, although no such effect is discernible for zanamivir. This effect leads to the introduction of selection bias with a significantly reduced probability of being diagnosed with influenza and an imbalance in the two arms if the intention‐to‐treat‐influenza‐infected (ITTI) population is analysed. The effect of oseltamivir on antibodies appears to be carried over to children with influenza‐like illness. Its finding contradicts statements made by the manufacturer. </p> <p>The seeming incomparability between arms of the influenza‐infected subpopulations in the oseltamivir trials raises the question of how an appropriate analysis should be conducted. If influenza‐infected groups are comparable (as appears to be the case in zanamivir treatment trials) then an appropriate analysis strategy (based on <a href="./references#CD008965-bbs2-0282" title="SennSJ . Added values: controversies concerning randomization and additivity in clinical trials. Statistics in Medicine2004;23:3729‐53. ">Senn 2004</a>) would be to determine first the effect of treatment in the ITT population. If there is evidence of a treatment effect, then treatment by infected status interaction could be tested. If there was evidence of an interaction, then estimates of treatment effect could be derived separately for the influenza‐infected and non‐influenza‐infected subpopulations. However, this analysis should be conducted on the ITT population using a single appropriate statistical model, obviating the need to conduct separate analysis on the influenza‐infected subpopulation. Roche used geometric mean titres indicating antibody responses in the ITTI population to support their statement that oseltamivir does not affect antibody responses (for example, in <a href="#CD008965-tbl-0016">Table 16</a> and linked text of Module 1 of trial <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a>). However, the use of such measures can be misleading. What are required for such an analysis are data on how many ITT population participants responded by arm, at what level of antibody response and how many were tested. Such data could not be identified with certainty. A further effect of choosing a subpopulation analysis (ITTI in treatment trials and ITTIINAB (ITT influenza‐infected index cases who had negative virology at baseline) in prophylaxis trials) as the primary analysis is the restriction of the generalisability of results. This is especially so in the case of design flaws (for example, in the case of the post‐exposure prophylaxis trial <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a>, where all index cases were not treated and around 55% of participants were dropped from the ITTIINAB analysis). In this cluster‐trial design households should be included as random‐effects in the analysis to take account of within‐household correlations. </p> <div class="table" id="CD008965-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Proportions of contacts with positive serology data (WV15799 ITTIINAB population)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Positive </b> </p> <p><b>serology</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>N</b> </p> <p><b>% </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tamiflu</b> </p> <p><b>N</b> </p> <p><b>% </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> 83.0 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192<br/> 93.7 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Yes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> 17.0 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<br/> 6.3 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITTIINAB population: ITT influenza‐infected index cases who had negative virology at baseline </p> <p>Chi² P = 0.001</p> </div> </div> <p>A significant but slight reduction of the proportion with serum antibody (mostly haemagglutination inhibition (HAI) antibody) titre rise by four‐fold or more among those who were tested was shown in this review. This was consistent with the evidence from animal tests using a sub‐clinical dose of oseltamivir in influenza A/H1N1‐infected mice (<a href="./references#CD008965-bbs2-0286" title="TakahashiE , KataokaK , FujiiK , ChidaJ , MizunoD , FukuiM , et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes and Infection / Institut Pasteur2010;12(10):778‐83. [PUBMED: 20452454] ">Takahashi 2010</a>). <a href="./references#CD008965-bbs2-0286" title="TakahashiE , KataokaK , FujiiK , ChidaJ , MizunoD , FukuiM , et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes and Infection / Institut Pasteur2010;12(10):778‐83. [PUBMED: 20452454] ">Takahashi 2010</a> reported a non‐significant slight reduction of haemagglutinin (HA) specific IgG antibody in serum and spleen, while they reported about an 80% significant reduction of HA specific secretory IgA antibody (s‐IgA Ab) in nasal wash and bronchoalveolar fluids (BALF) on day 12. From this evidence, they warned that the risk of re‐infection may increase in patients showing a low mucosal IgA antibody response following oseltamivir administration. These experiments were done because they had the unexpected finding that paediatric influenza patients treated orally with oseltamivir for five days had significantly low levels (about 60% reduction on day five) of anti‐influenza S‐IgA nasopharyngeal fluids compared to levels in patients not treated with oseltamivir (<a href="./references#CD008965-bbs2-0281" title="SawabuchiT , SuzukiS , IwaseK , ItoC , MizunoD , TogariH , et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology2009;14(8):1173‐9. ">Sawabuchi 2009</a>). Their findings are consistent with our findings that serum HA inhibition (HAI) antibody response was decreased by oseltamivir administration, though s‐IgG Ab could not be analysed in our study because the data were not reported in the clinical study reports (<a href="./references#CD008965-bbs2-0281" title="SawabuchiT , SuzukiS , IwaseK , ItoC , MizunoD , TogariH , et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology2009;14(8):1173‐9. ">Sawabuchi 2009</a>; <a href="./references#CD008965-bbs2-0286" title="TakahashiE , KataokaK , FujiiK , ChidaJ , MizunoD , FukuiM , et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes and Infection / Institut Pasteur2010;12(10):778‐83. [PUBMED: 20452454] ">Takahashi 2010</a>). These findings are also consistent with the evidence on the mode of action of oseltamivir from animal models (Module 2 of <a href="./references#CD008965-bbs2-0266" title="MendelDB , TaiCY , EscarpePA , LiW , SidwellRW , HuffmanJH , et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrobial Agents and Chemotherapy1998;42(3):640‐6. ">Mendel 1998</a>; <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>) and from viral challenge, randomised, placebo‐controlled studies in humans (<a href="./references#CD008965-bbs2-0237" title="HaydenFG , TreanorJJ , FritzRS , LoboM , BettsRF , MillerM , et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA1999;282(13):1240‐6. ">Hayden 1999</a>). </p> <p>Pro‐inflammatory cytokines, including interleukin 6 (IL‐6), tumour necrosis factor alpha (TNF‐α) and interferon gamma (IFN‐γ), were completely suppressed by oseltamivir administered 28 hours after the experimental inoculation of influenza virus, while the reduction of viral titre in nasal lavages was partial (<a href="./references#CD008965-bbs2-0237" title="HaydenFG , TreanorJJ , FritzRS , LoboM , BettsRF , MillerM , et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA1999;282(13):1240‐6. ">Hayden 1999</a>). </p> <p>There is decisive evidence that administration of oseltamivir in animals challenged by respiratory syncytial virus (RSV) that lacks a neuraminidase gene showed a symptom‐relieving effect (decreased weight loss) and inhibition of viral clearance (<a href="./references#CD008965-bbs2-0267" title="MooreML , ChiMH , ZhouW , GoleniewskaK , O'NealJF , HigginbothamJN , et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. Journal of Immunology2007;178(5):2651‐4. ">Moore 2007</a>). These effects were accompanied by a decreased CD+8 T cell surface sialoglycosphingolipid GM1 level, which is regulated by the endogenous sialidase/neuraminidase in response to viral challenge along with suppression of cytokine expression (<a href="./references#CD008965-bbs2-0267" title="MooreML , ChiMH , ZhouW , GoleniewskaK , O'NealJF , HigginbothamJN , et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. Journal of Immunology2007;178(5):2651‐4. ">Moore 2007</a>). They are consistent with those findings from the pharmaceutical company and their investigators. The findings of the study by <a href="./references#CD008965-bbs2-0267" title="MooreML , ChiMH , ZhouW , GoleniewskaK , O'NealJF , HigginbothamJN , et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. Journal of Immunology2007;178(5):2651‐4. ">Moore 2007</a> suggest a risk of infection and exacerbation of infection by pathogens other than influenza virus in spite of the apparent reduction of symptoms from infection. </p> <p>Sufficient plasma concentration of oseltamivir carboxylate from orally administered oseltamivir phosphate may act directly on the host endogenous neuraminidase to reduce (or suppress) the immune response even at the dose of 20 mg twice a day for five days. However, the bioavailability of inhaled zanamivir seems to be very broad: about 10% to 70%, as estimated by the area under the curve (AUC) data from the inhalation and intravenous study from the Japanese Summary Basis of Approval (JSBA). The difference in peak concentration (Cmax) was much larger (6 to 37‐fold). This means that inhaled zanamivir could reach a high enough concentration to reduce the immune response, if it is administered at a high dose or a for long period, or if the patient is very susceptible. In fact, a double‐blind, placebo‐controlled trial using healthy volunteers to investigate the effect of zanamivir treatment (20 mg/day for 14 days) on the humoral immune response to influenza vaccine showed that the zanamivir group responded with significantly lower antibody titres to the H1N1 (<a href="./references#CD008965-bbs2-0202" title="CoxRJ , MykkeltvedtE , SjursenH , HaaheimLR . The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine2001;19(32):4743‐9. ">Cox 2001</a>). Pro‐inflammatory cytokines, including IL‐6, TNF‐α, IFN‐γ and other chemokines, were almost completely suppressed in the viral challenge randomised controlled trial (RCT) using a very high dose (600 mg) of intravenous zanamivir before inoculation of the influenza virus in human adults (<a href="./references#CD008965-bbs2-0227" title="FritzRS , HaydenFG , CalfeeDP , CassLM , PengAW , AlvordWG , et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo‐controlled trial of intravenous zanamivir treatment. Journal of Infectious Diseases1999;180(3):586‐93. ">Fritz 1999</a>). </p> <p>These findings all suggest that the low immune response, with a low level of pro‐inflammatory cytokines, induced by the action of oseltamivir carboxylate may reduce the symptoms of influenza irrespective of an inhibition of influenza virus replication, which is widely believed to be the main mode of action of NIs. </p> <p>In addition, the potential hypothermic or antipyretic effect of oseltamivir (but not zanamivir) as a central nervous system depressant may also contribute to the apparent reduction of host symptoms (<a href="./references#CD008965-bbs2-0275" title="OnoH , NaganoY , MatsunamiN , SugiyamaS , YamamotoS , TanabeM . Oseltamivir, an anti‐influenza virus drug, produces hypothermia in mice. Biological and Pharmaceutical Bulletin2008;31(4):638‐42. ">Ono 2008</a>; <a href="./references#CD008965-bbs2-0276" title="OnoH , IwajimaY , NaganoY , ChazonoK , MaedaY , OhsawaM , et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti‐influenza virus drug, in normal mice. Basic &amp; Clinical Pharmacology &amp; Toxicology2013;113(1):25‐30. ">Ono 2013</a>). </p> <p>Zanamivir had no effect on pneumonia symptoms in treatment trials, even when the diagnosis was supported by a chest X‐ray; nor did it affect antibody responses, but it did affect bronchitis. We think that this shows an undeniable symptom‐relieving effect of both drugs, which also applies to more severe, if undefined, syndromes. Both drugs relieve influenza‐like illness symptoms by around 0.6 to 0.7 of a day, although this is first relief and not necessarily complete relief. In the case of oseltamivir, the mix up with the follow‐up cards does not allow us to draw any conclusions on a possible length of the duration of symptom relief. Also of note is the fact that this important information came to light from the FDA reports and not from the clinical study reports of the relevant trials (<a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a>; <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a>). This points to the incomplete nature of reporting in the clinical study reports and the important role of Summary Basis of Approval (SBA) regulatory information. </p> <p>In a subgroup analysis we found no evidence of a difference in treatment effect for zanamivir on time to first alleviation of symptoms in adults in the influenza‐infected and non‐influenza‐infected subgroups. Both subgroups showed strong evidence of treatment effect of 0.5 to 0.7 days reduction in time to first alleviation of symptoms. This strongly supports our hypothesis that these drugs do not have an influenza‐specific effect. </p> <p>Oseltamivir relieves symptoms in otherwise healthy children, but no effect was noted with zanamivir, which may be due to the limited power of the two eligible trials with just over 700 children in total. However, oseltamivir does not have any effect on asthmatic children with influenza‐like illness, a population which should benefit most from its use. One explanation for this finding is in the nature of the young asthmatic population, which is well cared for and used to regular powerful medications and close follow‐up. The incremental benefit of oseltamivir is thus likely to be undetectable in such a population. An alternative explanation could be the higher susceptibility of the immune system to suppression by oseltamivir carboxylate in asthmatic children compared with those in the placebo group. The finding that oseltamivir administered to asthmatic children reduces symptoms faster than in placebo recipients at the beginning of the study, but during the off‐treatment period more recovered later than those administered placebo, gives some support to this explanation. </p> <p>There is no evidence of an effect of oseltamivir on hospitalisations. Hospitalisations are an important but poorly defined outcome in the oseltamivir protocols, inconsistently reported in the clinical study reports and overlooked in the zanamivir protocols and reports. </p> <p>The oseltamivir trials did not detect any influenza‐related deaths, reflecting the relatively benign nature of influenza in the study populations. The zanamivir trials detected eight deaths, of which only two were likely to be due to influenza and both occurred in the intervention arms. All the trials were likely to be underpowered to detect differential effects on mortality, but the absence of deaths in placebo recipients again underlines the benign nature of influenza. In fact mortality in Japan during the 2009A/H1N1 influenza outbreak was 198 among about 20 million influenza patients (one in 100,000 infected). Early deterioration leading to death was observed more frequently in oseltamivir compared to zanamivir or no antivirals recipients (<a href="./references#CD008965-bbs2-0236" title="Hama R. JonesM , HayashiK , SakaguchiK . Oseltamivir and early deterioration leading to death. International Journal of Risk &amp; Safety in Medicine2011;23:201‐15. [http://iospress.metapress.com/content/5257410g24403m68/fulltext.pdf] ">Hama 2011</a>). </p> <p>Overall the two drugs have similar benefits but quite different toxicity profiles.</p> <p>On average, for every 28 (14 to 112) adults treated with oseltamivir there will be one more report of nausea and for every 22 (14 to 42) adults and 19 (10 to 57) children there will be one more report of vomiting. Oseltamivir seems to have an apparent protective effect on diarrhoea, contrary to the other evidence of gastrointestinal disturbance. This finding might be as an effect of a placebo containing dehydrocholic acid or it might be one of the results of the influenza‐like illness symptom‐relieving effects (similar to relief of tachycardia and palpitation). The other apparent gastrointestinal events, such as nausea and vomiting, may be the results of central nervous disorders indicated by "only day 1 increase of vomiting" in treatment trials in children. </p> <p>For every 62 (41 to 411) adults exposed to zanamivir there will be one less case of nausea and vomiting, but no such effect was visible in children, probably because of a lack of power. Zanamivir does not appear to affect the frequency of bowel movements. </p> <p>In the prophylaxis data set, "influenza without laboratory confirmation" (i.e. influenza‐like illness) was only partially reported in the oseltamivir clinical study reports and not reported in the zanamivir clinical study reports, except for <a href="./references#CD008965-bbs2-0018" title="No authorslisted . A double‐blind, randomized, placebo‐controlled, parallel‐group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community‐dwelling high‐risk populations. Data on file. ">NAI30034</a> in which no significant reduction was observed (9% versus 10%). As a consequence we are unable to report on that outcome. The size of the reduction in influenza symptoms in oseltamivir prophylactic trials is inferior in magnitude to that seen in hand washing to prevent severe acute respiratory syndrome (SARS), based on seven case‐control studies (odds ratio (OR) 0.77, 95% CI 0.70 to 0.84, I<sup>2</sup> statistic = 68%, RD ‐0.12, ‐0.16 to 0.08, I<sup>2</sup> statistic = 26%), the NNTB being approximately 50 for prophylaxis with oseltamivir and eight with hand washing (<a href="./references#CD008965-bbs2-0251" title="JeffersonT , DelMarCB , DooleyL , FerroniE , Al‐AnsaryLA , BawazeerGA , et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD006207.pub4] ">Jefferson 2011a</a>). </p> <p>There is a significant reduction in the proportion of patients with symptomatic influenza with both NIs. However, these findings do not reflect the true efficacy for prevention of influenza, because they conceal the positivity of laboratory testing (measured through tests of viral shedding and four‐fold antibody titre rise). </p> <p>We found an apparent prophylactic effect of zanamivir on pneumonia (which was not defined in case report forms) when it was used for 14 to 28 days. However, we found no evidence of significant effects on other complications and no evidence of an effect of oseltamivir on complications or hospitalisations. </p> <p>Oseltamivir induced nausea in people undergoing prophylaxis but there was insufficient evidence to show an association with vomiting. </p> <p>On‐treatment renal adverse events were three times more common in the oseltamivir arms compared to the placebo arms, with 150 treated patients leading to one additional event. The two participants who died in the oseltamivir arms both experienced acute renal failure while on‐treatment, although only one of those events was listed as an adverse event. The unlisted event was in a 91‐year old female who was "withdrawn from the study on Study Day 15 because her estimated creatinine clearance was less than 30 mL/min. The screening laboratory examinations, that were carried out 10 days before the start of study treatment, were normal". Hyperglycaemic adverse events (aggravated diabetes mellitus or hyperglycaemia) were also more common in the oseltamivir arms, with eight events in total (one in <a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a>, two in <a href="./references#CD008965-bbs2-0038" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Data on file. ">WV15708</a> and five in <a href="./references#CD008965-bbs2-0045" title="No authorslisted . A double‐blind, randomised, placebo‐controlled study of Ro 64‐0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season. Data on file. ">WV15825</a>) compared to none in the corresponding placebo arms. These data are only presented descriptively as they are too few (&lt; 10) to meta‐analyse formally, as prespecified in our analysis plan. </p> <p>Finally, oseltamivir caused headaches and psychiatric harms in adult prophylaxis trials. Headaches are one of the most prominent harms of oseltamivir. There is evidence of a dose‐response effect in prophylaxis trials <a href="./references#CD008965-bbs2-0036" title="No authorslisted . Efficacy of Ro 64‐0796 when used as chemoprophylaxis against natural influenza infection. Data on file. ">WV15673/WV15697</a> (P = 0.013), in which headaches were observed in 202/519, 225/520 and 242/520 participants in the placebo, oseltamivir 75 mg once daily and 75 mg twice daily arms, respectively. </p> <p>In the psychiatric category, several rare and severe single events (nervousness, aggression, hallucinations, psychosis, suicide ideation and paranoia) were reported significantly more frequently in the intervention arm. Added to other more frequently reported but not significantly different events (such as depression and confusion) this gave a large effect and a relatively small number needed to treat to harm of 94 (36 to 1538). The importance of such a finding lies in the distribution of oseltamivir to large numbers of asymptomatic individuals following pandemic plans. There were no prophylaxis trials in children that met our inclusion criteria, therefore we cannot report on prophylaxis harms in this important population. </p> <p>The question of why oseltamivir treatment trials failed to identify a clear association between oseltamivir and psychiatric harms, although a weak dose‐dependent association was observed, is a moot point. It is possible that influenza‐like illness and influenza symptoms masked the harms in those who were already symptomatic and therefore recruited in the treatment trials (and influenza‐type symptoms were excluded as adverse events to be reported). The reporting issue of compliharms may have helped to mask such events. Alternatively, it could be that these events are rare in the populations studied and that there was insufficient power to detect an association. The CI was wide (0.43 to 2.03) and does not rule out a doubling in risk due to treatment ‐ as was found in the prophylaxis trials. It is also possible that the risk of psychiatric harm increases with increasing dose (as the data from trials <a href="./references#CD008965-bbs2-0034" title="DorkingsJ . Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Data on file. ">WV15670</a> and <a href="./references#CD008965-bbs2-0035" title="DorkingsJ . Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Data on file. ">WV15671</a> suggest) and increasing duration of treatment (as the prophylaxis trials suggest). </p> <p><a href="./references#CD008965-bbs2-0288" title="TooveyS , RaynerC , PrinssenE . Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir. A comprehensive review. Drug Safety2008;31(12):1097‐114. ">Toovey 2008</a> assessed the issue and failed to find an association between neurological and psychiatric adverse events and oseltamivir exposure. The outcomes studied were not based on the a priori definition of psychiatric adverse events as defined in the clinical study reports. The definition was constructed post hoc based on a selected group of adverse events taken from the psychiatric, neurological and injury body systems in the reports. The issues are described fully in <a href="./references#CD008965-bbs2-0253" title="JonesM , HamaR , JeffersonT , DoshiP . Neuropsychiatric adverse events and oseltamivir for prophylaxis. Drug Safety2012;35(12):1187‐8. ">Jones 2012</a> and Toovey's response is in <a href="./references#CD008965-bbs2-0289" title="TooveyS . The author's reply. Drug Safety2012;35(12):1188‐90. ">Toovey 2012</a>. <a href="./references#CD008965-bbs2-0288" title="TooveyS , RaynerC , PrinssenE . Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir. A comprehensive review. Drug Safety2008;31(12):1097‐114. ">Toovey 2008</a> reviewed only retrospective observational studies and did not review three prospective cohort studies conducted in Japan. </p> <p>A meta‐analysis of three prospective cohort studies of neuropsychiatric adverse events (NPAEs) in Japanese children show a pooled odds ratio for abnormal behaviours due to oseltamivir exposure of 1.55 (95% CI 1.21 to 1.98; P = 0.0005) without significant heterogeneity (<a href="./references#CD008965-bbs2-0235" title="HamaR , JonesM , HayashiK , YanagiK , SakaguchiK . Oseltamivir: a systematic review and meta‐analysis of adverse effects in prospective cohort studies. Presentation at the 16th Japanese Society for Pharmaco‐epidemiology (JSPE) and 5th Activities and Co‐operation for Drug Safety in Asia (ACPE) Joint Meeting. Tokyo, 2010. ">Hama 2010</a>). In one prospective study of several thousand children with influenza carried out to test the hypothesis of a causal relation between oseltamivir and neuropsychiatric events, abnormal behaviour was observed more frequently in oseltamivir recipient children than in controls (RR 1.57, 95% CI 1.34 to 1.83). Abnormal behaviour was observed in 3.4 per 100 person day (or 13.8%) in the oseltamivir group, compared to 2.2 per 100 person‐days (or 8.8%) in the control group (<a href="./references#CD008965-bbs2-0304" title="YorifujiT , SuzukiE , TsudaT . Oseltamivir and abnormal behaviors: true or not?. Epidemiology2009;20(4):619‐21. ">Yorifuji 2009</a>). Reanalysis of this study population, focusing on delirium and unconsciousness, also showed a significant association between oseltamivir and neuropsychiatric events, especially in the very early phase of the illness within a day of commencement of fever (<a href="./references#CD008965-bbs2-0228" title="FujitaT , FujiiY , WatanabeY , MoriM , YokotaS . A pharmacoepidemiological study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection. Japanese Journal of Pharmacoepidemiology2010;15:73‐92. ">Fuiita 2011</a>). These indicate that prospective and intentional collection with this scale of participants may be necessary in treatment RCTs. </p> <p>Animal toxicity study results firmly support the effect of oseltamivir on the central nervous system. One of these is the hypothermic effect of oseltamivir (but not zanamivir) administered orally, intraperitoneally (<a href="./references#CD008965-bbs2-0275" title="OnoH , NaganoY , MatsunamiN , SugiyamaS , YamamotoS , TanabeM . Oseltamivir, an anti‐influenza virus drug, produces hypothermia in mice. Biological and Pharmaceutical Bulletin2008;31(4):638‐42. ">Ono 2008</a>; <a href="./references#CD008965-bbs2-0276" title="OnoH , IwajimaY , NaganoY , ChazonoK , MaedaY , OhsawaM , et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti‐influenza virus drug, in normal mice. Basic &amp; Clinical Pharmacology &amp; Toxicology2013;113(1):25‐30. ">Ono 2013</a>) and intracerebroventricularly (<a href="./references#CD008965-bbs2-0276" title="OnoH , IwajimaY , NaganoY , ChazonoK , MaedaY , OhsawaM , et al. Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti‐influenza virus drug, in normal mice. Basic &amp; Clinical Pharmacology &amp; Toxicology2013;113(1):25‐30. ">Ono 2013</a>). The other is that intra‐duodenal or intravenous administration of oseltamivir to mature rats induced respiratory arrest shortly followed by cardiac arrest. These studies clearly show central depressant effects of oseltamivir (<a href="./references#CD008965-bbs2-0255" title="KimuraS , NiwaY , IwajimaY , NaganoY , YamamotoS , OhiY , et al. High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats. Basic &amp; Clinical Pharmacology &amp; toxicology2012;111(4):232‐9. ">Kimura 2012</a>). Moreover in the post‐marketing toxicology phase studies by Roche, many symptoms that the manufacturer considered "item‐related" were observed: alterations in respiration including decreased respiratory rate/gasping and altered mucous membrane/skin colour (pale) prior to death. Although the manufacturer denied the causality (<a href="./references#CD008965-bbs2-0226" title="FreichelC , PrinssenE , HoffmannG , GandL , BeckM , WeiserT , et al. Oseltamivir is devoid of specific behavioral and other central nervous system effects in juvenile rats at supratherapeutic oral doses. International Journal of Virology2009;5(3):119‐30. ">Freichel 2009</a>), symptoms at two hours after administration that showed dose‐related increase were lack of olfactory orientation, lack of cliff aversion and low or very low arousal. Twenty‐four of 52 pups that did not exhibit cliff aversion were later found dead. Fourteen of 17 animals with low or very low arousal died thereafter. These findings are consistent with the clinically observed psychiatric symptoms in the RCTs and post‐marketing spontaneous reports. </p> <p>Zanamivir was well tolerated. However, a potentially active placebo may have masked the occurrence of bronchospasm in zanamivir trials. </p> <p>Treatment trials were mostly under‐recruited and often their results pooled post hoc in two or even three trials, and yet they showed very high influenza positivity rates. One possible explanation for this lies in the intensive surveillance carried out in the predefined trial centre areas and the restricted time span of recruitment during high likelihood of positivity periods. This may be why many centres with low levels of recruitment are listed in the clinical study reports; this limits the generalisability of the results to everyday life. </p> <p>In a primary or secondary prophylaxis indication the postulated central effect of oseltamivir is confined to suppressing symptoms, as infection was not prevented even when oseltamivir was administered prior to the inoculation of influenza virus both in animals (<a href="./references#CD008965-bbs2-0266" title="MendelDB , TaiCY , EscarpePA , LiW , SidwellRW , HuffmanJH , et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrobial Agents and Chemotherapy1998;42(3):640‐6. ">Mendel 1998</a>) and in humans (<a href="./references#CD008965-bbs2-0237" title="HaydenFG , TreanorJJ , FritzRS , LoboM , BettsRF , MillerM , et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA1999;282(13):1240‐6. ">Hayden 1999</a>) and the prophylaxis trials. However, the central problem remains the incompatibility of the two contrasting claims of its activity against antibody production. If, as reported in many documents, oseltamivir does not interfere with antibody production (see, for example, <a href="./references#CD008965-bbs2-0222" title="F. Hoffman‐LaRoche . Tamiflu label (for FDA NDA no. 021087). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf 2011 (accessed 7 February 2011). ">FDA 2011a</a>; <a href="./references#CD008965-bbs2-0279" title="Roche . Investigators Guide. http://www.roche.be/fmfiles/re7189007/CU056/10_Investigators_brochure.pdf. ">Roche Investigators' Guide</a>), how is it possible that oseltamivir prevents cases of influenza when part of the definition of prevented cases in oseltamivir trials was based on absence of antibody response? </p> <p>The apparent ability of oseltamivir to interfere with antibody response calls into question the mode of action of the drug and puts in doubt the proposed effects of oseltamivir. One possibility in treatment trials is that oseltamivir administration, by interfering with antibody production, has the effect of selecting the strongest antibody responders in the ITTI subpopulation. These individuals are classified as influenza cases and are included in the oseltamivir arm of the ITTI population. This selected subpopulation probably represents the healthiest or those least likely to experience complications. An alternative consequence could be that interference with antibody production in the oseltamivir arm led to active arm participants being more likely to develop complications due to impaired immune function. </p> <p>Evidence from prophylaxis and secondary prophylaxis trials suggests that in addition to the apparent similar mode of action as in the treatment studies, suppression of viral shedding in nasal swab may be of importance. In the former, participants who become positive (i.e. who are subsequently classified as cases of influenza) in the oseltamivir arms are the few who mount a strong response despite oseltamivir interference. The remainder (who are significantly more than in the placebo arm) are classified as prevented or avoided cases. However, as prophylaxis clinical study reports do not report antibody responses and viral isolate results for the ITT populations either, it is impossible to tell whether this proposed mode of action fits all the evidence. The effect of oseltamivir on nasal shedding is consistent with the proposed mode of action of NIs in preventing the virus from leaving the host respiratory epithelial cells, which are covered by a mucous layer. Compared with the rather small reduction of symptoms of influenza‐like illness and reduction in antibody rise (up to 10%) by both oseltamivir and zanamivir, the extent of the reduction of symptomatic influenza is almost half. This may be due to reduction of influenza viruses in the nasal swab sample. </p> <p>In prophylaxis there is no evidence that oseltamivir reduces symptomatic influenza‐like illness. Oseltamivir reduces the number of prophylaxis participants testing positive (based on antibody rise and/or culture test). However, this finding is weakened by oseltamivir’s interference with the viral replication on the swab and effect on antibody production. In addition oseltamivir does not affect asymptomatic influenza and there is no evidence that it interferes with person‐to‐person spread. </p> <p>Similarly to the FDA (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>; <a href="./references#CD008965-bbs2-0218" title="Food , DrugAdministration . Drug approval package. Tamiflu (oseltamivir). Application No.: 021087‐SE1‐002. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21‐087SE1‐002_review.pdf 2000 (accessed 27 August 2009). ">FDA 2000c</a>) because of the problems with the design of study <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> we could not draw any conclusions on the ability of oseltamivir to interrupt viral transmission. </p> <p>This is important as the results of trial <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a> formed part of the WHO3 rationale for use of the drug to interrupt transmission from person to person and allow time before the arrival of vaccines in the event of a pandemic furnishing a seemingly powerful rationale for stockpiling oseltamivir. </p> <p>This shows the importance of availability of full clinical study reports, something the WHO did not have. </p> <p>Antibody suppression seems stronger for oseltamivir than zanamivir, probably due to the difference in bioavailability. It may be that evidence of other effects, such as hyperglycaemia and renal impairment (though significance was marginal) in the prophylaxis trials may be due to inhibition of the host's endogenous neuraminidase, which impairs the cell function of various organs (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>). Overall, the significance of oseltamivir for nasal shedding is unclear but problems with sampling and culture undermine any claims as to its secondary prophylactic properties, as the FDA made clear in its response (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>). </p> <p>The dose‐response increase in psychiatric events in the "pivotal" oseltamivir treatment trials and the increase in vomiting only on day one in treatment trials in children may be due to the sudden onset of the central action of unchanged oseltamivir (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>). Brain concentration of unchanged oseltamivir increases during the early phase of influenza in juvenile animals (<a href="./references#CD008965-bbs2-0226" title="FreichelC , PrinssenE , HoffmannG , GandL , BeckM , WeiserT , et al. Oseltamivir is devoid of specific behavioral and other central nervous system effects in juvenile rats at supratherapeutic oral doses. International Journal of Virology2009;5(3):119‐30. ">Freichel 2009</a>), due to a reduced or low function of p‐glycoprotein, a major transporter of oseltamivir at the blood‐brain barrier (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>; <a href="./references#CD008965-bbs2-0255" title="KimuraS , NiwaY , IwajimaY , NaganoY , YamamotoS , OhiY , et al. High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats. Basic &amp; Clinical Pharmacology &amp; toxicology2012;111(4):232‐9. ">Kimura 2012</a>). The likely centrally mediated mode of action of oseltamivir is supported by the finding of adverse events in healthy people in prophylaxis trials. However, these effects may also be derived from a delayed action associated with host endogenous neuraminidase inhibition by oseltamivir (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>), because this appeared after more than a week's exposure the drug and lasted for more than two weeks. Other effects, such as pain in the limbs, hyperglycaemia or diabetic events, reduction of antibody rise and reduction of cytokine induction, may also be due to the suppression of the host's endogenous neuraminidase by oseltamivir (<a href="./references#CD008965-bbs2-0267" title="MooreML , ChiMH , ZhouW , GoleniewskaK , O'NealJF , HigginbothamJN , et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. Journal of Immunology2007;178(5):2651‐4. ">Moore 2007</a>). Pain in the limbs and metabolic control events (mainly hyperglycaemia) were in excess in the oseltamivir arms, but we did not carry out a formal meta‐analysis, as they were not prespecified in our analysis plan and the number of events was below 10 for metabolic events. </p> <p>Statements made about the capacity of oseltamivir to interrupt viral transmission and reduce complications are not supported by any data we have been able to access. </p> <p>We have not reviewed other NIs, such as laninamivir and peramivir, or other antivirals, such as the adamantanes (amantadine and rimantadine), or antipyretic/anti‐inflammatory agents either. Laninamivir and peramivir may be more potent as NIs, because their bioavailability is far higher than zanamivir and may affect the host's endogenous neuraminidase. Adamantanes are well known centrally active agents and may be more harmful than oseltamivir and zanamivir. Anti‐inflammatory antipyretics (except paracetamol) may be more toxic than NIs (<a href="./references#CD008965-bbs2-0234" title="HamaR . Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. International Journal of Risk and Safety in Medicine2008;20:5‐36. ">Hama 2008</a>). Hence, the other NIs, adamantanes and anti‐inflammatory antipyretics may not be alternatives to oseltamivir and zanamivir. </p> </section> <section id="CD008965-sec-0129"> <h3 class="title" id="CD008965-sec-0129">Overall completeness and applicability of evidence</h3> <p>We used the Cochrane seven‐domain 'Risk of bias' instrument to assess bias. The availability of partial or complete clinical study reports decreased the uncertainty and allowed definitive judgements to be made. Previous unclear risk of bias became certainty of bias or certainty of absence of bias. Certainty or low levels of uncertainty are due to our expectations regarding the complete clinical study reports. We were expecting to have all relevant and consistent information available for our reviews, but when it was not, our judgements changed because we found gaps in the availability of information and inconsistent information. We are still uncertain whether the complete study reports represent an exhaustive and coherent source of trial narrative and data. </p> <p>In the case of treatment trials, conclusions and generalisations are drawn from a subpopulation in which the two arms do not appear comparable due to the apparent ability of oseltamivir to interfere with influenza antibody production. The effect of oseltamivir on the gastrointestinal tract appears to be notable, although a definitive statement will only be possible once the mode of action and dosage of dibasic calcium phosphate dihydrate and dehydrocholic acid have been clarified. The high percentage of influenza infections appears to be in contrast with the need to pool or delay several trials and the small recruitment size of others because of a lack of influenza circulation. In the case of post‐exposure prophylaxis trials, the selection of the infected population has the effect of excluding from the analysis large percentages (in some cases over 50%) of participants. This brings the generalisability of the results of these trials into question. </p> <p>Much has been made in the trial programmes of viral nasal voidance as a marker of effect. However, its measurement was unreliable in treatment trials as this verbatim quote from the FDA review shows: "Duration of viral shedding was measured from treatment initiation to the time of the first negative virus culture with no subsequent positive cultures. Upon reviewing a list of viral shedding patterns provided by the applicant on 8/16/99, two problems emerged: (1) the pattern of virus shedding was fluctuating in at least 33 subjects (i.e. pos‐neg‐pos‐neg, with or without a subsequent negative result). (2) In at least 100 subjects, the last virus shedding sample was the first negative sample in sequence, meaning there was not a subsequent negative confirmation. Given the fluctuating pattern of virus shedding, to estimate the duration of viral shedding based on the occurrence of a single first negative data poses a high level of uncertainty" (<a href="./references#CD008965-bbs2-0215" title="Food , DrugAdministration . Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.: 021087). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf 1999 (accessed 26 August 2009). ">FDA 1999c</a>). </p> <p>In all programmes, the effect on complications was based on unclear and potentially unreliable definitions, often at the discretion of local clinicians and confirmation (e.g. radiological confirmation of pneumonia) was not consistently reported when it did occur. In the ITT population, the correct population for analysis, there is no credible effect of oseltamivir against pneumonia as the significance of the term "pneumonia" is not clarified. </p> <p>In the case of post‐exposure prophylaxis trial <a href="./references#CD008965-bbs2-0042" title="No authorslisted . A double‐blind randomised placebo controlled study of Ro 64‐0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families. Data on file. ">WV15799</a>, nasal voidance was measured only in symptomatic subjects as an adjunct to protocol version H. However, this does not prevent the manufacturers from making claims of effect for all these outcomes. </p> <p>Other general requirements, such as presentation within 36 to 48 hours, raise questions about the generalisability of the research evidence. However, underlying all our doubts is the conflicting evidence on the mode of action of the drug. </p> <p>Most of the trials were substantially under‐recruited and so had insufficient power individually to answer the research question. </p> </section> <section id="CD008965-sec-0130"> <h3 class="title" id="CD008965-sec-0130">Quality of the evidence</h3> <p>We assessed all full clinical study reports of relevant trials. An example of the kind of detail available in complete clinical study reports and the importance of the trial timeline in assessing the presence of bias is the observation that of the clinical study reports for the included trials, only one contained a protocol that predated the beginning of participant enrolment, only two had statistical analysis plans that clearly predated participant enrolment and three had clearly dated protocol amendments. No oseltamivir clinical study report included a clear date of unblinding. </p> <p>All reports in our review were sponsored by the manufacturers. It is known that published studies sponsored by the pharmaceutical industry are more likely to have outcomes favouring the sponsor compared to studies which have other sponsors (<a href="./references#CD008965-bbs2-0256" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326(7400):1167‐70. ">Lexchin 2003</a>; <a href="./references#CD008965-bbs2-0260" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>). As the evidence relates to published studies, we do not know whether the findings are applicable to clinical study reports. </p> </section> <section id="CD008965-sec-0131"> <h3 class="title" id="CD008965-sec-0131">Potential biases in the review process</h3> <p>The main limitation of our study is our relative inexperience in dealing with large quantities of information and our lack of familiarity with certain trial documents, such as randomisation lists. Randomisation lists appeared to be of two types. The first was a pre‐randomisation list of random codes with which participants' IDs cannot be matched with the participant IDs used within other sections of the clinical study report. The second was a post hoc randomisation list to which individual participants can be matched but the original generated codes are not shown. In both cases the truly random generation of the sequence could not be properly assessed because either the original codes are not provided or original codes cannot be matched to patients. </p> <p>We have created methods and procedures to address the risk of reporting bias that we identified in published trials, but remain uncertain about the success of these new methods. </p> </section> <section id="CD008965-sec-0132"> <h3 class="title" id="CD008965-sec-0132">Agreements and disagreements with other studies or reviews</h3> <p>Several reviews of NIs are now available (<a href="./references#CD008965-bbs2-0193" title="BurchJ , CorbettM , StockC , NicholsonK , ElliotAJ , DuffyS , et al. Prescription of anti‐influenza drugs for healthy adults: a systematic review and meta‐analysis. Lancet2009;9(9):537‐45. ">Burch 2009</a>; <a href="./references#CD008965-bbs2-0201" title="CooperNJ , SuttonAJ , AbramsKR , WailooA , TurnerD , NicholsonKG . Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta‐analyses of randomised controlled trials. BMJ2003;326(7401):1235. ">Cooper 2003</a>; <a href="./references#CD008965-bbs2-0212" title="FalagasME , KoletsiPK , VouloumanouEK , RafailidisPI , KapaskelisAM , RelloJ . Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta‐analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy2010;65:1330‐46. [DOI: 10.1093/jac/dkq158] ">Falagas 2010</a>; <a href="./references#CD008965-bbs2-0287" title="TappendenP , JacksonR , CooperK , ReesA , SimpsonE , ReadR , et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technology Assessment2009;11(iii, ix‐xii):1‐246. ">Tappenden 2009</a>; <a href="./references#CD008965-bbs2-0291" title="TurnerD , WailooA , NicholsonK , CooperN , SuttonA , AbramsK . Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment2003;7(35):iii‐iv, xi‐xiii, 1‐170. ">Turner 2003</a>), including several separate versions of our previous reviews (<a href="./references#CD008965-bbs2-0248" title="JeffersonTO , DemicheliV , DiPietrantonjC , JonesM , RivettiD . Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001265.pub2] ">Jefferson 2006</a>; <a href="./references#CD008965-bbs2-0249" title="JeffersonT , JonesM , DoshiP , DelMarC . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta‐analysis. BMJ2009;339:b5106. ">Jefferson 2009a</a>; <a href="./references#CD008965-bbs2-0262" title="MathesonNJ , HarndenAR , PereraR , SheikhA , Symmonds‐AbrahamsM . Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002744.pub2] ">Matheson 2007</a>; <a href="./references#CD008965-bbs2-0283" title="Shun‐ShinM , ThompsonM , HeneghanC , PereraR , HarndenA , MantD . Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta‐analysis of randomised controlled trials. BMJ2009;339:b3172. ">Shun‐Shin 2009</a>). All are mainly based on published information and reach similar conclusions to our 2006 review, which sparked the reader's comment and subsequent investigation and change of methods. </p> <p>Following publication of our review update in December 2009, Roche asked the Harvard‐based academics Hernan and Lipsitch to repeat the Kaiser analysis to confirm or reject Kaiser's conclusions (<a href="./references#CD008965-bbs2-0239" title="HernanMA , LipsitchM . Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta‐analysis of eleven randomized clinical trials. Clinical Infectious Diseases2011;53(3):277‐9. [PUBMED: 21677258] ">Hernan 2011</a>). They were not provided with any funding to carry out this analysis and Roche ultimately provided them with patient‐level data sets and Module 1 for the 10 Kaiser trials and one more treatment trial (<a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>). An important methodological difference between Hernan and Lipsitch's analysis and that of Kaiser was Hernan and Lipsitch's decision to privilege a true ITT analysis over the sub‐population analysis featured in the Kaiser analysis. Our Cochrane review also analyses the ITT population. </p> <p>The Kaiser analysis concluded that oseltamivir provided two statistically significant reductions: in lower respiratory tract complications and in hospitalisations. </p> <p>Hernan and Lipsitch evaluated lower respiratory tract complications and found a statistically significant, but smaller, reduction in the risk of these complications. </p> <p>Hernan and Lipsitch omitted evaluating the Kaiser paper's conclusion that oseltamivir reduced the risk of hospitalisation. They wrote, "it was not possible to assess the potential benefit for high‐risk participants who are hospitalised, because the sample size of most studies was too small to consider hospitalisation as an outcome." </p> <p>Hernan and Lipsitch do not elaborate on or highlight their apparent methodological disagreement with the <a href="./references#CD008965-bbs2-0254" title="KaiserL , WatC , MillsT , MahoneyP , WardP , HaydenF . Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine2003;163:1667‐72. ">Kaiser 2003</a> analysis and it is not reflected in the news article published on the Harvard website entitled "Oseltamivir effect on complications confirmed by reanalysis" (<a href="http://ccdd.hsph.harvard.edu/NewsEvents/Oseltamivir-reanalysis" target="_blank">http://ccdd.hsph.harvard.edu/NewsEvents/Oseltamivir‐reanalysis</a>). In fact, Hernan and Lipsitch did not confirm one of the key conclusions of the Kaiser paper (<a href="./references#CD008965-bbs2-0254" title="KaiserL , WatC , MillsT , MahoneyP , WardP , HaydenF . Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine2003;163:1667‐72. ">Kaiser 2003</a>). </p> <p>Unfortunately, the Hernan‐Lipsitch analysis has been cited by influential bodies such as the European Centre for Disease Prevention and Control (ECDC) as "confirmation of the original Kaiser meta‐analysis" (<a href="http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?ID=561%26List=a3216f4c%2Df040%2D4f51%2D9f77%2Da96046dbfd72" target="_blank">http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?ID=561&amp;List=a3216f4c%2Df040%2D4f51%2D9f77%2Da96046dbfd72</a>) despite the fact that Hernan and Lipsitch did not confirm one of the key conclusions of the Kaiser paper (<a href="./references#CD008965-bbs2-0254" title="KaiserL , WatC , MillsT , MahoneyP , WardP , HaydenF . Impact of oseltamivir treatment on influenza‐related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine2003;163:1667‐72. ">Kaiser 2003</a>). </p> <p>For complications, while Hernan and Lipsitch clearly produced similar results to Kaiser, we do not think that this means the result is more credible. In view of our findings, we suggest that these results should be interpreted with caution. We have published our preliminary comments (<a href="./references#CD008965-bbs2-0199" title="Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza?. Clinical Infectious Diseases2011;53(12):1302–3. ">Cochrane Neuraminidase Inhibitors Review Team 2011</a>). The approach Hernan and Lipsitch took in analysing data was insufficient to provide a credible, independent check on validity and reinforces the importance of detailed, critical assessment of entire trial programmes, with access to full‐length study reports. Our analysis questions the coherence between the evidence and the proposed mode of action of oseltamivir. </p> <p>The <a href="./references#CD008965-bbs2-0208" title="EbellMH , CallM , ShinholserJ . Effectiveness of oseltamivir in adults: a meta‐analysis of published and unpublished clinical trials. Family Practice2012;30(2):125‐33. [DOI: 10.1093/fampra/cms059] ">Ebell 2012</a> review concluded that there was "no evidence that oseltamivir reduces the likelihood of hospitalisation, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population". This conclusion was based on Module 1 of the 10 Kaiser trials plus <a href="./references#CD008965-bbs2-0046" title="No authorslisted . A double‐blind, randomised, stratified, placebo‐controlled study of oseltamivir in the treatment of influenza infection in patients. Data on file. ">WV16277</a>. These are the same 11 trials as <a href="./references#CD008965-bbs2-0239" title="HernanMA , LipsitchM . Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta‐analysis of eleven randomized clinical trials. Clinical Infectious Diseases2011;53(3):277‐9. [PUBMED: 21677258] ">Hernan 2011</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008965-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.  'Other bias' includes potentially active placebos." data-id="CD008965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.<br/> 'Other bias' includes potentially active placebos. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.  'Other bias' includes potentially active placebos." data-id="CD008965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.<br/> 'Other bias' includes potentially active placebos. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram describing the number of studies identified, inclusion, exclusion and progression from identification to stage 1 to stage 2 of the review.NB Because of the absence of trial programmes for both drugs listing all sponsored trials completed or underway, we had to rely on a variety of sources for the reconstruction of the trial programmes and retrieval of relevant clinical study reports. This complexity is reflected in the flowchart, illustrating the study selection process for this review. The two main pathways were the spontaneous release of 77 clinical full clinical study reports by Roche and the requests to regulatory authorities and GSK for all the relevant reports. There was overlap in trial reports retrieved following the different pathways" data-id="CD008965-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Flow diagram describing the number of studies identified, inclusion, exclusion and progression from identification to stage 1 to stage 2 of the review. </p> <p><b>NB</b> Because of the absence of trial programmes for both drugs listing all sponsored trials completed or underway, we had to rely on a variety of sources for the reconstruction of the trial programmes and retrieval of relevant clinical study reports. This complexity is reflected in the flowchart, illustrating the study selection process for this review. The two main pathways were the spontaneous release of 77 clinical full clinical study reports by Roche and the requests to regulatory authorities and GSK for all the relevant reports. There was overlap in trial reports retrieved following the different pathways </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.1 Time to first alleviation of symptoms in adult treatment (ITT population) [hours]." data-id="CD008965-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.1 Time to first alleviation of symptoms in adult treatment (ITT population) [hours]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.1 Time to first alleviation of symptoms in adult treatment (days)." data-id="CD008965-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.1 Time to first alleviation of symptoms in adult treatment (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.68 Time to first alleviation of symptoms in adults with/without relief medication [days]." data-id="CD008965-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Zanamivir versus placebo for treatment, outcome: 3.68 Time to first alleviation of symptoms in adults with/without relief medication [days]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.17 Complications: pneumonia in adult treatment." data-id="CD008965-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oseltamivir versus placebo for treatment, outcome: 1.17 Complications: pneumonia in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Example Diary card from case‐report form for Zanamivir trial" data-id="CD008965-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Example Diary card from case‐report form for Zanamivir trial</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Example Diary card from case‐report form for Zanamivir trial (cont)" data-id="CD008965-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Example Diary card from case‐report form for Zanamivir trial (cont)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.19 Adverse events: headache in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.19 Adverse events: headache in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.54 Adverse events: psychiatric body system in adult prophylaxis (on‐ and off‐treatment)." data-id="CD008965-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oseltamivir versus placebo for prophylaxis, outcome: 2.54 Adverse events: psychiatric body system in adult prophylaxis (on‐ and off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt='Sample "Adverse event or intercurrent illness" form (oseltamivir study M76001)' data-id="CD008965-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Sample "Adverse event or intercurrent illness" form (oseltamivir study M76001)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt='Sample "Secondary illness" form (oseltamivir study WV15670)' data-id="CD008965-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Sample "Secondary illness" form (oseltamivir study WV15670)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt='Sample "Diagnosis of secondary illness" form, page 1/2 (oseltamivir study WV15978)' data-id="CD008965-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Sample "Diagnosis of secondary illness" form, page 1/2 (oseltamivir study WV15978)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt='Sample "Diagnosis of secondary illness" form, page 2/2 (oseltamivir study WV15978)' data-id="CD008965-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Sample "Diagnosis of secondary illness" form, page 2/2 (oseltamivir study WV15978)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 1 Time to first alleviation of symptoms in adult treatment (ITT population)." data-id="CD008965-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 1 Time to first alleviation of symptoms in adult treatment (ITT population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 2 Hospital admission in adult treatment (safety population)." data-id="CD008965-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 2 Hospital admission in adult treatment (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 3 Defined as influenza‐infected at baseline in adult treatment." data-id="CD008965-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 3 Defined as influenza‐infected at baseline in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 4 Antibody rise four‐fold or greater in adult treatment." data-id="CD008965-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 4 Antibody rise four‐fold or greater in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 5 Adverse events ‐ nausea in adult treatment (on‐treatment)." data-id="CD008965-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 5 Adverse events ‐ nausea in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 6 Adverse events ‐ vomiting in adult treatment (on‐treatment)." data-id="CD008965-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 6 Adverse events ‐ vomiting in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 7 Adverse events ‐ diarrhoea in adult treatment (on‐treatment)." data-id="CD008965-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 7 Adverse events ‐ diarrhoea in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 8 Withdrawal from adult treatment trial due to adverse events." data-id="CD008965-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 8 Withdrawal from adult treatment trial due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 9 All withdrawals from adult treatment." data-id="CD008965-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 9 All withdrawals from adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 10 Adverse events ‐ cough in adult treatment (on‐treatment)." data-id="CD008965-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 10 Adverse events ‐ cough in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 11 Adverse events ‐ abdominal pain in adult treatment (on‐treatment)." data-id="CD008965-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 11 Adverse events ‐ abdominal pain in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 12 Adverse events: dizziness in adult treatment (on‐treatment)." data-id="CD008965-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 12 Adverse events: dizziness in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 13 Adverse events: headache in adult treatment (on‐treatment)." data-id="CD008965-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 13 Adverse events: headache in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 14 Serious adverse events: overall in adult treatment (on‐treatment)." data-id="CD008965-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 14 Serious adverse events: overall in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 15 Serious adverse events: overall in adult treatment (off‐treatment)." data-id="CD008965-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 15 Serious adverse events: overall in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 16 Complications: bronchitis in adult treatment." data-id="CD008965-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 16 Complications: bronchitis in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-17.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 17 Complications: pneumonia in adult treatment." data-id="CD008965-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 17 Complications: pneumonia in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 18 Complications: sinusitis in adult treatment." data-id="CD008965-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 18 Complications: sinusitis in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 19 Complications: otitis media in adult treatment." data-id="CD008965-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 19 Complications: otitis media in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 20 Complications in adult trials classified as serious or leading to study withdrawal." data-id="CD008965-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 20 Complications in adult trials classified as serious or leading to study withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 21 Culture‐positive at baseline in adult treatment." data-id="CD008965-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 21 Culture‐positive at baseline in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 22 Adverse events: general body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 22 Adverse events: general body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 23 Adverse events: neurological body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 23 Adverse events: neurological body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 24 Adverse events: respiratory body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 24 Adverse events: respiratory body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 25 Adverse events: infection body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 25 Adverse events: infection body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 26 Adverse events: gastrointestinal body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 26 Adverse events: gastrointestinal body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 27 Adverse events: cardiac body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 27 Adverse events: cardiac body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 28 Adverse events: ear body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 28 Adverse events: ear body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 29 Adverse events: eye body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 29 Adverse events: eye body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 30 Adverse events: metabolism body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 30 Adverse events: metabolism body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 31 Adverse events: musculoskeletal body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 31 Adverse events: musculoskeletal body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 32 Adverse events: psychiatric body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 32 Adverse events: psychiatric body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 33 Adverse events: skin body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 33 Adverse events: skin body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 34 Adverse events: cardiac body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 34 Adverse events: cardiac body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 35 Adverse events: ear body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 35 Adverse events: ear body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 36 Adverse events: gastrointestinal body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 36 Adverse events: gastrointestinal body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 37 Adverse events: general body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 37 Adverse events: general body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 38 Adverse events: infection body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 38 Adverse events: infection body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 39 Adverse events: musculoskeletal body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 39 Adverse events: musculoskeletal body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 40 Adverse events: neurological body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 40 Adverse events: neurological body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 41 Adverse events: respiratory body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 41 Adverse events: respiratory body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 42 Adverse events: skin body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 42 Adverse events: skin body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 43 Adverse events: cough in adult treatment (off‐treatment)." data-id="CD008965-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 43 Adverse events: cough in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 44 Adverse events: headache in adult treatment (off‐treatment)." data-id="CD008965-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 44 Adverse events: headache in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 45 Adverse events: nausea in adult treatment (off‐treatment)." data-id="CD008965-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 45 Adverse events: nausea in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 46 Time to first alleviation of symptoms in child treatment [hours]." data-id="CD008965-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 46 Time to first alleviation of symptoms in child treatment [hours]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 47 Hospital admission in child treatment (safety population)." data-id="CD008965-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 47 Hospital admission in child treatment (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 48 Defined as influenza‐infected at baseline in child treatment." data-id="CD008965-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 48 Defined as influenza‐infected at baseline in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 49 Antibody rise four‐fold or greater in child treatment." data-id="CD008965-fig-0064" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 49 Antibody rise four‐fold or greater in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 50 Complications: bronchitis in child treatment." data-id="CD008965-fig-0065" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 50 Complications: bronchitis in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 51 Complications: otitis media in child treatment." data-id="CD008965-fig-0066" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 51 Complications: otitis media in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 52 Complications: pneumonia in child treatment." data-id="CD008965-fig-0067" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 52 Complications: pneumonia in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 53 Complications: sinusitis in child treatment." data-id="CD008965-fig-0068" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 53 Complications: sinusitis in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 54 Complications: pneumonia in child treatment by on‐ and off‐treatment." data-id="CD008965-fig-0069" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 54 Complications: pneumonia in child treatment by on‐ and off‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 55 Complications in trials of children classified as serious or leading to study withdrawal." data-id="CD008965-fig-0070" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 55 Complications in trials of children classified as serious or leading to study withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 56 Withdrawal from child treatment trial due to adverse events." data-id="CD008965-fig-0071" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 56 Withdrawal from child treatment trial due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 57 All withdrawals from child treatment." data-id="CD008965-fig-0072" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 57 All withdrawals from child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 58 Serious adverse events: overall in child treatment (on‐treatment)." data-id="CD008965-fig-0073" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 58 Serious adverse events: overall in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 59 Serious adverse events: overall in child treatment (off‐treatment)." data-id="CD008965-fig-0074" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 59 Serious adverse events: overall in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 60 Adverse events: abdominal pain in child treatment (on‐treatment)." data-id="CD008965-fig-0075" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 60 Adverse events: abdominal pain in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 61 Adverse events: diarrhoea in child treatment (on‐treatment)." data-id="CD008965-fig-0076" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 61 Adverse events: diarrhoea in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 62 Adverse events: nausea in child treatment (on‐treatment)." data-id="CD008965-fig-0077" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 62 Adverse events: nausea in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 63 Adverse events: vomiting in child treatment (on‐treatment)." data-id="CD008965-fig-0078" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.63</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 63 Adverse events: vomiting in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 64 Adverse events: abdominal pain in child treatment (off‐treatment)." data-id="CD008965-fig-0079" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.64</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 64 Adverse events: abdominal pain in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 65 Adverse events: cough in child treatment (off‐treatment)." data-id="CD008965-fig-0080" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.65</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 65 Adverse events: cough in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 66 Adverse events: diarrhoea in child treatment (off‐treatment)." data-id="CD008965-fig-0081" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.66</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 66 Adverse events: diarrhoea in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 67 Adverse events: headache in child treatment (off‐treatment)." data-id="CD008965-fig-0082" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.67</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 67 Adverse events: headache in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-68" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-68.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 68 Adverse events: vomiting in child treatment (off‐treatment)." data-id="CD008965-fig-0083" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-68.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.68</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 68 Adverse events: vomiting in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-68.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-69" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-69.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 69 Adverse events: ear body system in child treatment (on‐treatment)." data-id="CD008965-fig-0084" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-69.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.69</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 69 Adverse events: ear body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-69.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-70" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-70.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 70 Adverse events: gastrointestinal body system in child treatment (on‐treatment)." data-id="CD008965-fig-0085" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-70.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.70</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 70 Adverse events: gastrointestinal body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-70.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-71" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-71.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 71 Adverse events: general body system in child treatment (on‐treatment)." data-id="CD008965-fig-0086" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-71.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.71</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 71 Adverse events: general body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-71.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-72" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-72.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 72 Adverse events: infection body system in child treatment (on‐treatment)." data-id="CD008965-fig-0087" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-72.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.72</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 72 Adverse events: infection body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-72.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-73" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-73.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 73 Adverse events: neurological body system in child treatment (on‐treatment)." data-id="CD008965-fig-0088" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-73.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.73</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 73 Adverse events: neurological body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-73.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-74" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-74.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 74 Adverse events: respiratory body system in child treatment (on‐treatment)." data-id="CD008965-fig-0089" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-74.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.74</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 74 Adverse events: respiratory body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-74.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-75" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-75.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 75 Adverse events: skin body system in child treatment (on‐treatment)." data-id="CD008965-fig-0090" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-75.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.75</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 75 Adverse events: skin body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-75.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-76" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-76.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 76 Adverse events: ear body system in child treatment (off‐treatment)." data-id="CD008965-fig-0091" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-76.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.76</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 76 Adverse events: ear body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-76.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-77" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-77.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 77 Adverse events: gastrointestinal body system in child treatment (off‐treatment)." data-id="CD008965-fig-0092" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-77.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.77</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 77 Adverse events: gastrointestinal body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-77.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-78" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-78.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 78 Adverse events: general body system in child treatment (off‐treatment)." data-id="CD008965-fig-0093" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-78.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.78</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 78 Adverse events: general body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-78.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-79" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-79.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 79 Adverse events: infection body system in child treatment (off‐treatment)." data-id="CD008965-fig-0094" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-79.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.79</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 79 Adverse events: infection body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-79.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-80" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-80.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 80 Adverse events: neurological body system in child treatment (off‐treatment)." data-id="CD008965-fig-0095" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-80.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.80</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 80 Adverse events: neurological body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-80.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-81" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-81.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 81 Adverse events: respiratory body system in child treatment (off‐treatment)." data-id="CD008965-fig-0096" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-81.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.81</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 81 Adverse events: respiratory body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-81.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-001-82" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-001-82.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oseltamivir versus placebo for treatment, Outcome 82 Culture‐positive at baseline in child treatment." data-id="CD008965-fig-0097" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-82.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.82</div> <div class="figure-caption"> <p>Comparison 1 Oseltamivir versus placebo for treatment, Outcome 82 Culture‐positive at baseline in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-001-82.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 1 Symptomatic influenza in adult prophylaxis of individuals." data-id="CD008965-fig-0098" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 1 Symptomatic influenza in adult prophylaxis of individuals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 2 Asymptomatic influenza in adult prophylaxis of individuals." data-id="CD008965-fig-0099" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 2 Asymptomatic influenza in adult prophylaxis of individuals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 3 Symptomatic influenza in household prophylaxis." data-id="CD008965-fig-0100" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 3 Symptomatic influenza in household prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 4 Asymptomatic influenza in household prophylaxis." data-id="CD008965-fig-0101" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 4 Asymptomatic influenza in household prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 5 Influenza‐like illness reported as adverse event (on‐treatment)." data-id="CD008965-fig-0102" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 5 Influenza‐like illness reported as adverse event (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 6 Influenza‐like illness reported as adverse event (off‐treatment)." data-id="CD008965-fig-0103" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 6 Influenza‐like illness reported as adverse event (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 7 Hospitalisation in adult prophylaxis (safety population)." data-id="CD008965-fig-0104" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 7 Hospitalisation in adult prophylaxis (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 8 Complications: bronchitis in adult prophylaxis." data-id="CD008965-fig-0105" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 8 Complications: bronchitis in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 9 Complications: sinusitis in adult prophylaxis." data-id="CD008965-fig-0106" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 9 Complications: sinusitis in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 10 Adverse events leading to study withdrawal in adult prophylaxis." data-id="CD008965-fig-0107" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 10 Adverse events leading to study withdrawal in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 11 All withdrawals in adult prophylaxis." data-id="CD008965-fig-0108" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 11 All withdrawals in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 12 Serious adverse events in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0109" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 12 Serious adverse events in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 13 Serious adverse events in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0110" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 13 Serious adverse events in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 14 Adverse events: abdominal pain in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0111" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 14 Adverse events: abdominal pain in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 15 Adverse events: cough in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0112" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 15 Adverse events: cough in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 16 Adverse events: diarrhoea in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0113" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 16 Adverse events: diarrhoea in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 17 Adverse events: dizziness in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0114" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 17 Adverse events: dizziness in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 18 Adverse events: fatigue in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0115" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 18 Adverse events: fatigue in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-19.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 19 Adverse events: headache in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0116" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 19 Adverse events: headache in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 20 Adverse events: nausea in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0117" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 20 Adverse events: nausea in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 21 Adverse events: vomiting in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0118" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 21 Adverse events: vomiting in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 22 Adverse events: cough in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0119" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 22 Adverse events: cough in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 23 Adverse events: fatigue in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0120" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 23 Adverse events: fatigue in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 24 Adverse events: headache in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0121" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 24 Adverse events: headache in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 25 Adverse events: blood body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0122" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 25 Adverse events: blood body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 26 Adverse events: cardiac body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0123" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 26 Adverse events: cardiac body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 27 Adverse events: ear body system in adult prophylaxis (on treatment)." data-id="CD008965-fig-0124" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 27 Adverse events: ear body system in adult prophylaxis (on treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 28 Adverse events: eye body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0125" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 28 Adverse events: eye body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 29 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0126" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 29 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 30 Adverse events: general body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0127" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 30 Adverse events: general body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 31 Adverse events: infection body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0128" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 31 Adverse events: infection body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 32 Adverse events: immune body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0129" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 32 Adverse events: immune body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 33 Adverse events: injury body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0130" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 33 Adverse events: injury body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 34 Adverse events: metabolism body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0131" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 34 Adverse events: metabolism body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 35 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0132" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 35 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 36 Adverse events: neurological body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0133" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 36 Adverse events: neurological body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 37 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0134" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 37 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 38 Adverse events: renal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0135" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 38 Adverse events: renal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 39 Adverse events: reproductive body system in adult prophylaxis (on treatment)." data-id="CD008965-fig-0136" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 39 Adverse events: reproductive body system in adult prophylaxis (on treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 40 Adverse events: respiratory body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0137" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 40 Adverse events: respiratory body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 41 Adverse events: skin body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0138" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 41 Adverse events: skin body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 42 Adverse events: surgical events in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0139" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 42 Adverse events: surgical events in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 43 Adverse events: vascular body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0140" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.43</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 43 Adverse events: vascular body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 44 Adverse events: cardiac body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0141" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.44</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 44 Adverse events: cardiac body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 45 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0142" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.45</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 45 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 46 Adverse events: general body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0143" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.46</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 46 Adverse events: general body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 47 Adverse events: infection body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0144" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.47</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 47 Adverse events: infection body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 48 Adverse events: injury body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0145" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.48</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 48 Adverse events: injury body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 49 Adverse events: musculoskeletal body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0146" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.49</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 49 Adverse events: musculoskeletal body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 50 Adverse events: neurological body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0147" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.50</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 50 Adverse events: neurological body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 51 Adverse events: reproductive body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0148" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.51</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 51 Adverse events: reproductive body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 52 Adverse events: respiratory body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0149" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.52</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 52 Adverse events: respiratory body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 53 Adverse events: skin body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0150" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.53</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 53 Adverse events: skin body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-54.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 54 Adverse events: psychiatric body system in adult prophylaxis (on and off‐treatment)." data-id="CD008965-fig-0151" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.54</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 54 Adverse events: psychiatric body system in adult prophylaxis (on and off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-002-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-002-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 55 Adverse events: renal body system in adult prophylaxis (on and off‐treatment)." data-id="CD008965-fig-0152" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.55</div> <div class="figure-caption"> <p>Comparison 2 Oseltamivir versus placebo for prophylaxis, Outcome 55 Adverse events: renal body system in adult prophylaxis (on and off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-002-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 1 Time to first alleviation of symptoms in adult treatment (days)." data-id="CD008965-fig-0153" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 1 Time to first alleviation of symptoms in adult treatment (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 2 Complications: pneumonia in adult treatment." data-id="CD008965-fig-0154" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 2 Complications: pneumonia in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 3 Complications: pneumonia confirmed with X‐ray in adult treatment." data-id="CD008965-fig-0155" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 3 Complications: pneumonia confirmed with X‐ray in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 4 Complications: bronchitis in adult treatment." data-id="CD008965-fig-0156" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 4 Complications: bronchitis in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 5 Complications: sinusitis in adult treatment." data-id="CD008965-fig-0157" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 5 Complications: sinusitis in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 6 Complications: otitis media in adult treatment." data-id="CD008965-fig-0158" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 6 Complications: otitis media in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 7 Complications in adult trials classified as serious or leading to study withdrawal." data-id="CD008965-fig-0159" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 7 Complications in adult trials classified as serious or leading to study withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 8 Proportion diagnosed as influenza‐infected in adult treatment." data-id="CD008965-fig-0160" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 8 Proportion diagnosed as influenza‐infected in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 9 Proportion with four‐fold rise in antibody titre in adult treatment." data-id="CD008965-fig-0161" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 9 Proportion with four‐fold rise in antibody titre in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 10 Proportion with positive culture at baseline in adult treatment." data-id="CD008965-fig-0162" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 10 Proportion with positive culture at baseline in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 11 Serious adverse events in adult treatment." data-id="CD008965-fig-0163" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 11 Serious adverse events in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 12 Adverse events leading to study withdrawal in adult treatment." data-id="CD008965-fig-0164" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 12 Adverse events leading to study withdrawal in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 13 All withdrawals in adult treatment." data-id="CD008965-fig-0165" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 13 All withdrawals in adult treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 14 Time to first alleviation of symptoms in children (days)." data-id="CD008965-fig-0166" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 14 Time to first alleviation of symptoms in children (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 15 Complications: pneumonia in child treatment." data-id="CD008965-fig-0167" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 15 Complications: pneumonia in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 16 Complications: bronchitis in child treatment." data-id="CD008965-fig-0168" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 16 Complications: bronchitis in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 17 Complications: sinusitis in child treatment." data-id="CD008965-fig-0169" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 17 Complications: sinusitis in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 18 Complications: otitis media in child treatment." data-id="CD008965-fig-0170" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 18 Complications: otitis media in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 19 Proportion diagnosed as influenza‐infected in child treatment." data-id="CD008965-fig-0171" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 19 Proportion diagnosed as influenza‐infected in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 20 Proportion with four‐fold increase in antibodies in child treatment." data-id="CD008965-fig-0172" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 20 Proportion with four‐fold increase in antibodies in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 21 Proportion with positive culture at baseline in child treatment." data-id="CD008965-fig-0173" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 21 Proportion with positive culture at baseline in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 22 All withdrawals in child treatment." data-id="CD008965-fig-0174" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 22 All withdrawals in child treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 23 Adverse events: nausea and vomiting in child treatment (on‐treatment)." data-id="CD008965-fig-0175" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 23 Adverse events: nausea and vomiting in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 24 Adverse events: diarrhoea in child treatment (on‐treatment)." data-id="CD008965-fig-0176" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 24 Adverse events: diarrhoea in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 25 Adverse events: gastrointestinal body system in child treatment (on‐treatment)." data-id="CD008965-fig-0177" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 25 Adverse events: gastrointestinal body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 26 Adverse events: respiratory body system in child treatment (on‐treatment)." data-id="CD008965-fig-0178" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 26 Adverse events: respiratory body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 27 Adverse events: neurological body system in child treatment (on‐treatment)." data-id="CD008965-fig-0179" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 27 Adverse events: neurological body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 28 Adverse events: ear, nose and throat body system in child treatment (on‐treatment)." data-id="CD008965-fig-0180" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 28 Adverse events: ear, nose and throat body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 29 Adverse events: skin body system in child treatment (on‐treatment)." data-id="CD008965-fig-0181" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 29 Adverse events: skin body system in child treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 30 Adverse events: gastrointestinal body system in child treatment (off‐treatment)." data-id="CD008965-fig-0182" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 30 Adverse events: gastrointestinal body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 31 Adverse events: ear nose and throat body system in child treatment (off‐treatment)." data-id="CD008965-fig-0183" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 31 Adverse events: ear nose and throat body system in child treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 32 Adverse events: nausea/vomiting in adult treatment (on‐treatment)." data-id="CD008965-fig-0184" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 32 Adverse events: nausea/vomiting in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 33 Adverse events: diarrhoea in adult treatment (on‐treatment)." data-id="CD008965-fig-0185" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 33 Adverse events: diarrhoea in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 34 Adverse events: dizziness in adult treatment (on‐treatment)." data-id="CD008965-fig-0186" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.34</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 34 Adverse events: dizziness in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 35 Adverse events: headache in adult treatment (on‐treatment)." data-id="CD008965-fig-0187" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.35</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 35 Adverse events: headache in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 36 Adverse events: cough in adult treatment (on‐treatment)." data-id="CD008965-fig-0188" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.36</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 36 Adverse events: cough in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 37 Adverse events: gastrointestinal body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0189" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.37</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 37 Adverse events: gastrointestinal body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 38 Adverse events: respiratory body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0190" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.38</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 38 Adverse events: respiratory body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 39 Adverse events: neurological body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0191" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.39</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 39 Adverse events: neurological body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 40 Adverse events: ear, nose and throat body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0192" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.40</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 40 Adverse events: ear, nose and throat body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 41 Adverse events: skin body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0193" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.41</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 41 Adverse events: skin body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 42 Adverse events: musculoskeletal body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0194" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.42</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 42 Adverse events: musculoskeletal body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 43 Adverse events: eye body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0195" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.43</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 43 Adverse events: eye body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 44 Adverse events: hepato body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0196" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.44</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 44 Adverse events: hepato body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 45 Adverse events: renal body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0197" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.45</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 45 Adverse events: renal body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 46 Adverse events: cardiovascular body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0198" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.46</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 46 Adverse events: cardiovascular body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 47 Adverse events: blood body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0199" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.47</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 47 Adverse events: blood body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 48 Adverse events: psychiatric body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0200" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.48</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 48 Adverse events: psychiatric body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 49 Adverse events: reproduction body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0201" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.49</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 49 Adverse events: reproduction body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 50 Adverse events: endocrine and metabolic body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0202" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.50</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 50 Adverse events: endocrine and metabolic body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 51 Adverse events: injury body system in adult treatment (on‐treatment)." data-id="CD008965-fig-0203" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.51</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 51 Adverse events: injury body system in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 52 Adverse events: non‐site specific events in adult treatment (on‐treatment)." data-id="CD008965-fig-0204" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.52</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 52 Adverse events: non‐site specific events in adult treatment (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 53 Adverse events: nausea/vomiting in adult treatment (off‐treatment)." data-id="CD008965-fig-0205" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.53</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 53 Adverse events: nausea/vomiting in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 54 Adverse events: cough in adult treatment (off‐treatment)." data-id="CD008965-fig-0206" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.54</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 54 Adverse events: cough in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 55 Adverse events: respiratory body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0207" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.55</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 55 Adverse events: respiratory body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 56 Adverse events: headache in adult treatment (off‐treatment)." data-id="CD008965-fig-0208" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.56</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 56 Adverse events: headache in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 57 Adverse events: diarrhoea in adult treatment (off‐treatment)." data-id="CD008965-fig-0209" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.57</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 57 Adverse events: diarrhoea in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 58 Adverse events: fatigue in adult treatment (off‐treatment)." data-id="CD008965-fig-0210" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.58</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 58 Adverse events: fatigue in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 59 Adverse events: gastrointestinal body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0211" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.59</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 59 Adverse events: gastrointestinal body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 60 Adverse events: neurological body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0212" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.60</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 60 Adverse events: neurological body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 61 Adverse events: ear, nose and throat in adult treatment (off‐treatment)." data-id="CD008965-fig-0213" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.61</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 61 Adverse events: ear, nose and throat in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 62 Adverse events: skin body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0214" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.62</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 62 Adverse events: skin body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 63 Adverse events: musculoskeletal body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0215" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.63</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 63 Adverse events: musculoskeletal body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 64 Adverse events: non‐site specific in adult treatment (off‐treatment)." data-id="CD008965-fig-0216" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.64</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 64 Adverse events: non‐site specific in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 65 Adverse events: injury body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0217" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.65</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 65 Adverse events: injury body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 66 Adverse events: endocrine and metabolic body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0218" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.66</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 66 Adverse events: endocrine and metabolic body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 67 Adverse events: eye body system in adult treatment (off‐treatment)." data-id="CD008965-fig-0219" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.67</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 67 Adverse events: eye body system in adult treatment (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-68" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-68.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 68 Time to first alleviation of symptoms in adults with/without relief medication [days]." data-id="CD008965-fig-0220" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-68.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.68</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 68 Time to first alleviation of symptoms in adults with/without relief medication [days]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-68.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-003-69" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-003-69.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zanamivir versus placebo for treatment, Outcome 69 Time to first alleviation of symptoms in adults by infection status [days]." data-id="CD008965-fig-0221" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-69.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.69</div> <div class="figure-caption"> <p>Comparison 3 Zanamivir versus placebo for treatment, Outcome 69 Time to first alleviation of symptoms in adults by infection status [days]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-003-69.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 1 Symptomatic influenza in prophylaxis of individuals." data-id="CD008965-fig-0222" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 1 Symptomatic influenza in prophylaxis of individuals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 2 Asymptomatic influenza in prophylaxis of individuals." data-id="CD008965-fig-0223" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 2 Asymptomatic influenza in prophylaxis of individuals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 3 Symptomatic influenza in post‐exposure prophylaxis." data-id="CD008965-fig-0224" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 3 Symptomatic influenza in post‐exposure prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 4 Asymptomatic influenza in post‐exposure prophylaxis." data-id="CD008965-fig-0225" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 4 Asymptomatic influenza in post‐exposure prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 5 Complications: pneumonia in adult prophylaxis." data-id="CD008965-fig-0226" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 5 Complications: pneumonia in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 6 Complications: bronchitis in adult prophylaxis." data-id="CD008965-fig-0227" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 6 Complications: bronchitis in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 7 Complications: sinusitis in adult prophylaxis." data-id="CD008965-fig-0228" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 7 Complications: sinusitis in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 8 Complications classified as serious or leading to study withdrawal." data-id="CD008965-fig-0229" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 8 Complications classified as serious or leading to study withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 9 Serious adverse events in adult prophylaxis." data-id="CD008965-fig-0230" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 9 Serious adverse events in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 10 Adverse events leading to study withdrawal in adult prophylaxis." data-id="CD008965-fig-0231" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 10 Adverse events leading to study withdrawal in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 11 All withdrawals in adult prophylaxis." data-id="CD008965-fig-0232" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 11 All withdrawals in adult prophylaxis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 12 Adverse events: abdominal pain in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0233" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 12 Adverse events: abdominal pain in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 13 Adverse events: cough in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0234" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 13 Adverse events: cough in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 14 Adverse events: diarrhoea in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0235" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 14 Adverse events: diarrhoea in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 15 Adverse events: dizziness in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0236" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 15 Adverse events: dizziness in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 16 Adverse events: fatigue in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0237" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 16 Adverse events: fatigue in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 17 Adverse events: headache in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0238" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 17 Adverse events: headache in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 18 Adverse events: blood body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0239" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 18 Adverse events: blood body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 19 Adverse events: nausea/vomiting in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0240" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 19 Adverse events: nausea/vomiting in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 20 Adverse events: cardiovascular body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0241" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 20 Adverse events: cardiovascular body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 21 Adverse events: ear, nose and throat body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0242" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 21 Adverse events: ear, nose and throat body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0243"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 22 Adverse events: endocrine and metabolic body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0243" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 22 Adverse events: endocrine and metabolic body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0243">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0244"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 23 Adverse events: eye body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0244" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 23 Adverse events: eye body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0244">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0245"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 24 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0245" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 24 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0245">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0246"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 25 Adverse events: injury body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0246" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 25 Adverse events: injury body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0246">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0247"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 26 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0247" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 26 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0247">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0248"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 27 Adverse events: neurological body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0248" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 27 Adverse events: neurological body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0248">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0249"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 28 Adverse events: non‐site specific in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0249" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 28 Adverse events: non‐site specific in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0249">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0250"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 29 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0250" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 29 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0250">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0251"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 30 Adverse events: renal body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0251" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.30</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 30 Adverse events: renal body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0251">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0252"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 31 Adverse events: reproductive body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0252" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.31</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 31 Adverse events: reproductive body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0252">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0253"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 32 Adverse events: respiratory body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0253" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.32</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 32 Adverse events: respiratory body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0253">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0254"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 33 Adverse events: skin body system in adult prophylaxis (on‐treatment)." data-id="CD008965-fig-0254" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.33</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 33 Adverse events: skin body system in adult prophylaxis (on‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0254">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0255"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 34 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0255" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.34</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 34 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0255">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0256"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 35 Adverse events: respiratory body system in adult prophylaxis (off‐treatment)." data-id="CD008965-fig-0256" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.35</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 35 Adverse events: respiratory body system in adult prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0256">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0257"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 36 Adverse events: nausea/vomiting in prophylaxis (off‐treatment)." data-id="CD008965-fig-0257" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.36</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 36 Adverse events: nausea/vomiting in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0257">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0258"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 37 Adverse events: diarrhoea in prophylaxis (off‐treatment)." data-id="CD008965-fig-0258" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.37</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 37 Adverse events: diarrhoea in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0258">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0259"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 38 Adverse events: headache in prophylaxis (off‐treatment)." data-id="CD008965-fig-0259" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.38</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 38 Adverse events: headache in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0259">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0260"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 39 Adverse events: cough in prophylaxis (off‐treatment)." data-id="CD008965-fig-0260" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.39</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 39 Adverse events: cough in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0260">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0261"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 40 Adverse events: fatigue in prophylaxis (off‐treatment)." data-id="CD008965-fig-0261" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.40</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 40 Adverse events: fatigue in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0261">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0262"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 41 Adverse events: neurological body system in prophylaxis (off‐treatment)." data-id="CD008965-fig-0262" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.41</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 41 Adverse events: neurological body system in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0262">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0263"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 42 Adverse events: ear, nose and throat in prophylaxis (off‐treatment)." data-id="CD008965-fig-0263" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.42</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 42 Adverse events: ear, nose and throat in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0263">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0264"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 43 Adverse events: musculoskeletal body system in prophylaxis (off‐treatment)." data-id="CD008965-fig-0264" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.43</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 43 Adverse events: musculoskeletal body system in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0264">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0265"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 44 Adverse events: non‐site specific in prophylaxis (off‐treatment)." data-id="CD008965-fig-0265" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.44</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 44 Adverse events: non‐site specific in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0265">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0266"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 45 Adverse events: injury in prophylaxis (off‐treatment)." data-id="CD008965-fig-0266" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.45</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 45 Adverse events: injury in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0266">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0267"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-004-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-004-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 46 Adverse events: endocrine and metabolic in prophylaxis (off‐treatment)." data-id="CD008965-fig-0267" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.46</div> <div class="figure-caption"> <p>Comparison 4 Zanamivir versus placebo for prophylaxis, Outcome 46 Adverse events: endocrine and metabolic in prophylaxis (off‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0267">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-004-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008965-fig-0268"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/urn:x-wiley:14651858:media:CD008965:CD008965-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_t/tCD008965-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Neuraminidase inhibitor versus placebo for treatment or prophylaxis, Outcome 1 Complications: pneumonia." data-id="CD008965-fig-0268" src="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Neuraminidase inhibitor versus placebo for treatment or prophylaxis, Outcome 1 Complications: pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-fig-0268">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/media/CDSR/CD008965/image_n/nCD008965-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008965-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blank case report forms' data capture for secondary illnesses in oseltamivir trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Where in CRF (PDF pg #)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data captured</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Person reporting</b> </p> <p><b>(participant/investigator)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Where reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific field for recording confirmatory assessment (e.g. CXR)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confirmation (including px)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes/no answer to question: "Is this event a secondary illness related to influenza?"</p> <p>Secondary illness is defined: sinusitis, otitis, bronchitis, pneumonia + other chest infections that are not diagnosed as bronchitis and/or pneumonia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In form for "Adverse events or intercurrent illness"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV16871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361, 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Form states:</p> <p>Have there been any changes in the patient’s health including any new conditions or worsening of existing conditions since day 1 (please include secondary illnesses)? </p> <p>Yes/No. If "Yes", please record the details on the "Adverse events or secondary illness" form in the Additional Forms section of the CRF on pg 30.0. All serious adverse events must be reported within 1 working day of occurrence to Roche </p> <p>Pg 30.0 of CRF (PDF pg 389) defines secondary illnesses as sinusitis, otitis media, bronchitis and pneumonia, and asks additional questions such as relationship to test drug and outcome, and leaves space for investigator's comments on the adverse event </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not listed as efficacy outcomes</p> <p>Recording of secondary illnesses was to occur in a form titled "Adverse event or secondary illness" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>732, 754, 791, 832</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRF form (PDF pg 732) states:</p> <p>Secondary illness reminder</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [ ] Complete secondary illness page (not the adverse event page)</p> <p>no [ ]</p> <p>Secondary illness page CRF (PDF pg 754) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose, and start/end date of treatment or medical procedure </p> <p>In addition, participants could fill in information related to a secondary illness in their diary card in the free‐text box called "Notes" which prompts participants: "Please can you record below any extra information about your flu which may be of interest to us, (for example: did your flu symptoms re‐occur, and if so when?), and have you taken any other treatments. If so please record the treatment name and the dates you took it." (PDF pg 791) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For investigators, on "Secondary illness" form</p> <p>For participants, on "Notes" section of diary card</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15671</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740, 889, 1018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRF form (PDF pg 740) states:</p> <p>Secondary illness reminder</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [ ] Complete secondary illness page (not the adverse event page)</p> <p>no [ ]</p> <p>Secondary illness page CRF (PDF pg 889) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose and start/end date of treatment or medical procedure </p> <p>Secondary illnesses are listed as sinusitis, otitis, bronchitis, pneumonia and other chest infections that are not diagnosed as bronchitis and/or pneumonia </p> <p>In addition, participants could fill in information related to a secondary illness in their diary card in the free‐text box called "Notes" which prompts participants: "Please can you record below any extra information about your flu which may be of interest to us, (for example: did your flu symptoms re‐occur, and if so when?), and have you taken any other treatments. If so please record the treatment name and the dates you took it." (PDF pg 1018) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mentioned in M1 and RAP as tertiary outcomes not mentioned in protocol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673/WV15697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 483</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No mention of pneumonia, secondary illness, complications in the CRFs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illnesses not listed in protocol as endpoints. They are listed as safety endpoints in the RAP which states that "pre‐defined" secondary illnesses were "sinusitis, otitis, bronchitis, pneumonia, and other chest infections that are not diagnosed as bronchitis and/or pneumonia, plus recurrence of symptoms from the diary card once alleviation had occurred." (PDF pg 479) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pg 117 Secondary illness reminder: Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [] ‐ Complete secondary illness page (not the adverse event page)</p> <p>no []</p> <p>Pg 131: <b>Diagnostic procedures</b> </p> <p>1) Were there any diagnostic procedures or tests carried out since day 1 as a result of influenza or secondary illness that were not scheduled as part of protocol?<br/> Yes </p> <p>Type of diagnostic procedure or test</p> <p>1 Chest X‐rays, 2 ECG, 3 Bacterial culture, 4 Bronchoscopy, 5 Pulmonary function test, 6 Viral culture (other than influenza), 7 Blood tests (other than antibody sample), 8 Other <i>specify</i> </p> <p>No</p> <p>Secondary illness page CRF (PDF pg 158) requests information on date of onset, date resolved, whether treatment was given and, if so, what treatment or medical procedures, total daily dose and start/end date of treatment or medical procedure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mentioned in RAP as tertiary endpoints pg 57‐8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 460</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness reminder at pg 474:</p> <p>Has the patient reported any new episodes of sinusitis, otitis, bronchitis, other chest infection or pneumonia since screening? </p> <p>yes [] ... <i>Complete adverse event page</i> </p> <p>no []</p> <p>"Adverse events" CRF collected data on date of onset, initial intensity, test drug adjustment, whether treatment was given (if so, what), most extreme intensity, relationship to test drug, outcome, whether it led to hospitalisation and a free‐text line for recording "Comments on AE" (e.g. PDF pg 479) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not mentioned in protocol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15730</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 340</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness reminder:</p> <p>Has the patient reported any sinusitis, otitis, bronchitis, other chest infection or pneumonia since baseline? </p> <p>yes [] ... <i>Complete secondary illness page (not the adverse event page)</i> </p> <p>no []</p> <p>The secondary illness page is descriptive of dates and px</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as tertiary endpoints in RAP at pg 297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15758</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 637</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses and secondary illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>Diagnostic confirmation of otitis media from pg 648 onwards</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as secondary illnesses in core report Module 1‐2 (pg 36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15759/871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 665</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the subject reported any adverse events including secondary and intercurrent illnesses?</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illnesses not mentioned in protocol, but secondary outcome in core report</p> <p>Note: worth looking at comparisons 1.49 to 1.51 in RM5. No effect but in bronchitis this study has a more conservative effect than NV 16871 which has no definitions and no diagnostics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 642</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness defined as in M76001. There is a generic physical examination form at pg 704 including "lungs" normal/abnormal specify_______ </p> <p>At pg 709 has the patient reported any new AE including intercurrent or secondary illnesses yes/no. If y record the adverse events/intercurrent illness section of the CRF (noted at pf 746 on to be at the back of the CRF) with FULL HISTORY, PHYSICAL EXAMINATION AND DIAGNOSTIC WORK UP QUESTIONS FOR BRON+PNUM+LRTI+SIN+OM including questions about CXR, MRI, sputum etc. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of contacts who are classified as having a secondary illness subsequent to a confirmed episode of influenza listed as tertiary endpoints </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15812/872</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 285</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses and secondary illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>At pg 450‐74 is <b>DIAGNOSIS OF SECONDARY ILLNESS</b> page which is very similar to the one at serial 10 </p> <p>EXHAUSTIVE list of diagnostic procedures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Listed as secondary tertiary in protocol at pg 252</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15819/978/876</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pg 437 (adverse event reminder):</p> <p>Has the patient reported any new adverse events or symptoms (including intercurrent illnesses)? </p> <p>yes [] record in the adverse events/intercurrent illness section of the case</p> <p>no [] report form</p> <p>In CRF pg 447 and 443 usual secondary illness reminder</p> <p>From pg 471 <b>DIAGNOSTIC OF SECONDARY ILLNESS. This is a one page list of diagnostics similar to that at serial 10.</b> The question is: "Were there any diagnostic procedures or tests carried out since day 1 as a result of influenza or secondary illness that were not scheduled as part of protocol?" If yes list per serial 10 </p> <p>From pg 486 is a list of diagnostic tests</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness listed as secondary (required antibiotics) and tertiary outcomes in core report and as an addition in protocol amendment at pg 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is a usual note: please go to diagnosis of secondary illness at back of CRF. Pg 487: </p> <p>Is this event a secondary illness related to influenza?</p> <p><b>DIAGNOSTIC OF SECONDARY ILLNESS</b> </p> <p>From pg 510‐40 with exhaustive list of diagnostics as per serial 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant mediated through investigator</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness listed as secondary outcomes in protocol pg 346</p> <p>Secondary illnesses recorded on "Adverse events" CRF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Px</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV16277</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not found</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not found</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary illness not listed as efficacy outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>#Events within the first 2 days of the study were excluded<br/> *Note that some events are reported as secondary illness and adverse event (AE) but some events are reported as secondary illness only and some events are reported as adverse event only<br/> BRON = bronchitis<br/> CRF = case report form<br/> CXR = chest x‐ray<br/> ECG = electrocardiogram<br/> LRTI = lower respiratory tract infection<br/> MRI = magnetic resonance imaging<br/> OM = otitis media<br/> PNUM = pneumonia<br/> px = prescription<br/> ˜RAP = reporting analysis plan<br/> SIN = sinusitis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blank case report forms' data capture for secondary illnesses in oseltamivir trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from the FDA (USA)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mentioned study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113502</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113625</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113678</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI108166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105934</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI106784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107485</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112311</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GCP/95/045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10902</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 14 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19, 19, 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 3, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/21036ltr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 110 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 10, 12, 13, 13, 14, 14, 17, 29, 42, 61, 62, 64, 64, 65, 65, 68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 34, 36, 43, 43, 43, 43, 52, 52, 52, 53, 53, 56, 57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 5, 6, 6, 8, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 3, 3, 3, 3, 4, 4, 5, 8, 9, 9, 10, 10, 11, 11, 11, 14, 14, 15, 16, 17, 19, 19, 19, 20, 20, 22, 23, 23, 23, 24, 24, 24, 25, 25, 25, 25, 25, 25, 26, 26, 26, 27, 27, 28, 28, 28, 29, 29, 31, 31, 31, 31 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MICROBR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 4, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 2, 4, 7, 12, 18, 18, 18, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 65 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 12, 13, 14, 14, 15, 17, 62, 62, 62, 64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34, 34, 36, 43, 53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 3, 3, 4, 5, 18, 19, 21, 21, 22, 23, 23, 23, 23, 24, 25, 25, 25, 26, 26, 26, 26, 27, 27, 27, 28, 28, 29, 29, 29, 30, 31, 31, 31, 32 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 13, 13, 13, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30028</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30034</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI40012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIA1009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 17 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 48, 49, 52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_MEDR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 6, 7, 20, 31, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_STATR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>NAIA3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 documents with 122 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 7, 7, 14, 15, 22, 22, 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 4, 4, 12, 12, 12, 12, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 14, 14, 14, 14, 14, 15, 15, 15, 15, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 2, 3, 4, 4, 5, 6, 6, 6, 8, 8, 9, 9, 9, 12, 12, 15, 16, 16, 16, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 6, 6, 6, 7, 7, 7, 8, 8, 9, 9, 9, 10, 11, 12, 13, 13, 14, 15, 15, 17, 18, 18, 19, 20, 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 1, 2, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 2, 2, 2, 2, 3, 3, 4, 4, 5, 5, 7, 8, 10, 11, 12, 14, 16, 16, 16, 16, 16, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 6, 6, 8, 8, 9, 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐stats.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIA3003</p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17, 17, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NAIA3004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 18, 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 4, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NAIA3005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12, 12, 12, 13, 14, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_ADMINCORRES_P2.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 documents with 99 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 14, 14, 14, 14, 14, 14, 14, 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9, 9, 9, 9, 9, 9, 10, 11, 12, 12, 12, 12, 13, 13, 13, 14, 14, 14, 15, 15, 16, 16, 16, 17 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 6, 6, 6, 7, 7, 7, 8, 8, 8, 9, 9, 11, 12, 12, 13, 13, 14, 15, 17, 18, 18, 19, 20, 21 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 1, 1, 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 3, 3, 7, 8, 10, 11, 14, 15, 16, 16, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 8, 8, 8, 9, 9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐stats.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAIB2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 18 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15, 16, 16, 17, 17, 17, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8, 10, 10, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>C94‐085</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview9.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NAIB1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/20000426_001/21‐036‐S001_RELENZA_BIOPHARMR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIA2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 44 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 17, 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin3.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 2, 3, 3, 3, 3, 5, 6, 6, 6, 6, 8, 8, 8, 9, 11, 12, 12, 13, 14, 14, 14, 14, 14, 15, 18 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 9, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐microbiology.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIB2005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 43 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐admin2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17, 20, 20, 22, 23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview4.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 3, 7, 8, 8, 8, 9, 10, 11, 11, 11, 11, 11, 12, 12, 12, 13, 14, 14, 14, 14, 14, 14, 14, 15 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview7.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 9, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview8.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐microbiology.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA/B2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview6.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036‐medreview5.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA/B2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PE‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167T3‐11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Zanamivir trials citation by trial ID and source FDA file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which regulatory file. Blank spaces indicate no citation for known trials. </p> <p>All the studies have been searched in the folder "Tamiflu and Relenza/Relenza/Relenza ‐ NDA 021036/19990726_000/021036". File name is left blank when the study was not present in that folder. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from the FDA (USA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from the FDA (USA)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Referenced study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NP15717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 13 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14, 15, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 8, 10, 13, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15718</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NP15728 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45, 46, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92, 93, 104, 122, 126, 131, 144, 144, 145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NP15826 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 26 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4, 5, 5, 8, 8, 8, 10, 17, 29, 30, 30, 30, 30, 30, 31, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NP15827 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 7 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15525 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21, 25, 26, 27, 27, 27, 27, 42, 42, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 document with 13 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WP15647</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 27, 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15648 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94, 128, 153, 153, 154</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WP15676 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15670 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 44, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 45 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 19, 37, 38, 39, 39, 39, 39, 40, 41, 41, 42, 43, 44, 48, 48, 49, 49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 25, 25, 35, 35, 39, 39, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 3, 4, 4, 5, 5, 5, 8, 9, 10, 17, 17, 21, 22,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15671 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 44, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 50 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 16, 19, 24, 24, 25, 25, 26, 27, 27, 28, 32, 34, 35, 36, 37, 38, 39, 39, 39, 40, 41, 46, 49, 49 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 25, 25, 35, 38, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 4, 5, 5, 5, 5, 9, 10, 10, 15, 17, 21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15673 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 50 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18, 18, 18, 20, 21, 21, 21, 22, 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58, 59, 71, 71, 71, 71, 71, 72, 72, 73, 73, 76, 76, 76, 76, 76, 77, 77, 79, 82, 83, 83, 84, 122, 124, 125, 126, 128, 131, 131, 132, 133, 134, 134, 145, 145, 156, 169, 177, 189 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15697 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 40 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58, 59, 71, 71, 71, 71, 71, 72, 72, 73, 73, 76, 76, 76, 76, 76, 77, 77, 79, 82, 83, 83, 84, 122, 126, 128, 131, 131, 131, 132, 133, 134, 145, 145, 152, 153, 156, 162, 189 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15708 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 39 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23, 35, 39, 41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71, 71, 71, 71, 71, 72, 72, 72, 72, 75, 75, 75, 75, 77, 77, 78, 79, 79, 82, 82, 122, 125, 125, 126, 131, 134, 134, 135, 135, 149, 151, 152, 152, 153 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15708D </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>WV15730 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_bior.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 15 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 9, 19, 49, 50, 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 1, 25, 25, 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15731 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 30, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 30, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>WV15758 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12, 19, 19, 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 92 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 8, 17, 39, 39, 57, 57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_BioPharmr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 4, 5, 5, 5, 8, 10, 17, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Corres.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 9, 9, 10, 11, 12, 12, 16, 18, 18, 18, 19, 19, 31, 31, 31, 33, 33, 35, 36, 37, 37, 37, 37, 37, 37, 37, 40, 43 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 5, 9, 9, 10, 11, 12, 12, 16, 18, 18, 18, 19, 19, 31, 31, 31, 33, 33, 35, 36, 37, 37, 37, 37, 37, 37, 37, 40, 43 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15759 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 44 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 10, 30, 30, 30, 30, 31, 32, 32, 33, 34, 37, 37, 37, 40, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 4, 4, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 10, 30, 30, 30, 30, 31, 32, 32, 33, 34, 37, 37, 37, 40, 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 6, 9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15799 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 28, 28, 28, 29, 29, 30, 30, 30, 30, 30, 31, 31, 31, 31, 32, 32, 32, 32, 32, 33, 33, 34, 34, 35, 35, 35, 36, 37, 37, 37, 37, 37, 38, 38, 38, 39, 39, 40, 40, 40, 40, 40, 58, 60, 71, 71, 71, 71, 71, 72, 72, 73, 76, 76, 76, 77, 78, 79, 84, 85, 122, 125, 125, 126, 126, 128, 131, 140, 140, 140, 143, 147, 149, 156, 162, 169, 175, 187, 203, 208, 208 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 89 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15812 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, 10, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 9 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 8, 10, 25, 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15819 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6, 10, 12, 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/19991027_000/21087_Tamiflu_medr_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 6, 6, 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20001117_002/21‐087SE1‐002_review.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41, 41, 41, 41, 42, 42, 42, 42, 42, 42, 43, 44, 58, 59, 71, 71, 71, 71, 71, 72, 72, 72, 72, 73, 73, 75, 75, 77, 77, 78, 79, 79, 79, 80, 80, 80, 81, 82, 85, 125, 125, 126, 126, 128, 131, 134, 134, 135, 135, 137, 137, 138, 145, 150, 151, 152, 152, 155, 156, 162, 169, 180, 204, 211 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 64 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15871 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 42 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Admindocs_P2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 11, 30, 31, 31, 32, 32, 32, 33, 34, 37, 37, 37, 37, 37, 37, 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Microbr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 11, 30, 31, 31, 32, 32, 32, 33, 34, 37, 37, 37, 37, 37, 37, 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021087/20040624_016/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_ADMINCORRES.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20040624_010/021087_S016_TAMIFLU CAPSULES ‐ DRY POWDER_BIOPHARMR.pdf </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15872 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Medr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 4 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamiflu and Relenza/Tamiflu/Tamiflu ‐ NDA 021246/20001214_000/21‐246_Tamiflu_Statr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Oseltamivir trials citation by trial ID and source FDA file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which regulatory file. Blank spaces indicate no citation for known trials. </p> <p>Search strategy:<br/> WV15758 OR WV 15758 OR Trial 15758 OR Trial15758 OR Trials 15758 OR Trials15758 OR 15758 OR study 15758 OR study15758 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from the FDA (USA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from NICE (UK)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mentioned study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI106784</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107485</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112311</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GCP/95/045</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI10902</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission executive summary.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 10 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 26, 146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 461 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\suptables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\tables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 19, 27, 30, 31,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 19, 27, 30, 31, 76, 128, 130, 132, 134, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report\Final NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 399 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\NAI30010 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\suptables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\tables.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 8, 11, 12, 19, 20, 21, 23, 24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 27, 30, 31, 76, 135, 137, 139, 141, 143, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission executive summary.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 8 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26, 146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5, 26, 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30028</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30031</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30034</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI40012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NAIA1009</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>NAIA3002</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 documents with 513 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 supporting tables 2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 47, 49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31, 63, 63, 63, 76, 106, 106, 107, 107, 109, 109, 112, 112, 114, 114, 115, 115, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3003</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NAIA3005</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 94, 94, 94, 95, 96, 96, 101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 documents with 310 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\NAI30010 HO FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\TABS.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza prophylaxis submission.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2, 5, 6, 12, 13, 13, 15, 15, 16, 16, 17, 17, 18, 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>NAIB3001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34, 50, 95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 documents with 374 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf \NAI30010 HO FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 supporting tables 1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 27, 30, 31, 32, 63, 63, 63, 76, 99, 99, 101, 101, 103, 103, 105, 105, 144, 162 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 18, 18, 27, 30, 31, 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 579 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010 study report pdf\FINAL NAI30010 for sign‐off.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 48, 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002supporting tables 1.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002supporting tables 2.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31, 63, 63, 63, 76, 117, 117, 117, 118, 118, 120, 120, 122, 122, 124, 124, 125, 125, 127, 127, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 17, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>NAIB2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 documents with 379 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\TABLES.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 19, 27, 30, 31, 76, 91, 91, 92, 92, 94, 94, 96, 96, 98, 98, 144</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 17, 18, 18, 19, 27, 30, 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NAIA2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38, 73, 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 6 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIB2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C94‐085</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB_1001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>NAIA2005</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 documents with 895 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\APPS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\TBS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 48, 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\b2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 7, 22, 25, 26, 34, 34, 42, 71, 72, 72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 47, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30, 76, 77, 77, 77, 79, 79, 79, 80, 80, 82, 82, 84, 84, 85, 144, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>NAIB2005</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 documents with 838 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2005 study report pdf\a2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 8, 8, 24, 24, 25, 43, 70, 74, 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 48, 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\APPSNEW.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\b2005cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2005 study report pdf\TBS_ALL.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB2007 study report pdf\b2007cr.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 47, 47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission full document.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30, 76, 77, 79, 79, 85, 85, 85, 86, 86, 88, 88, 90, 90, 144, 144 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relenza treatment submission main text.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16, 16, 16, 16, 17, 18, 27, 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NAIA/B2008</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\CSR30009.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 documents with 16 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009 study report pdf\NAI 30009 HO final FSR.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3001 study report pdf\NAIB3001 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25, 26, 26, 26, 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28, 28, 29, 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NAIA/B2009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002 study report pdf\NAIA3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 3 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3005 study report pdf\A3005cr01.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002 study report pdf\NAIB3002 full study report.pdf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐03</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JNAI‐04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PE‐01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167‐101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167T3‐11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Zanamivir trials citation by trial ID and source NICE file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which file. Blank spaces indicate no citation for known trials </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of contents for studies of zanamivir described in regulatory documentation from NICE (UK)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from NICE (UK)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Referenced study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>File name volume*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pages where study is mentioned (separated by commas)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Note</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS97‐802</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS‐97‐801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JP15734</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JP15735</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV15823</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV15824</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JV16284</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 67, 68, 94, 95, 224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML20910</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML22789</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML22879</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MV21118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MV22841</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00298233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00555893</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00707941</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00799760</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00830323</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML25018</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00867139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00873886</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01002729</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NP15717</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32, 75, 76, 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15718</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15728</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15826</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32, 75, 75, 75, 76, 76, 77, 78, 79, 80, 98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 11 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP15827</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP22770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP25138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NP25139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV16871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20234</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20235 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV20237</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV22155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV25118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV25182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PP16351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15517</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.245</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15525</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185.245</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15647</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15648</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15676</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP15901</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP22849</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV144181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>WV15670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 48, 48, 49, 49, 50, 53, 54, 54, 55, 163, 171, 188, 207, 209, 224, 245, 245, 252, 253, 253 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 1193 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20, 20, 20, 20, 20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>WV15671</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 48, 49, 49, 50, 53, 54, 54, 55, 163, 171, 188, 207, 209, 224, 245, 245 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 documents with 1222 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15697D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 67, 68, 224, 245, 245, 245, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708D</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15730</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 38, 39, 47, 53, 54, 55, 186, 207, 224, 245, 245, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 22 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7, 36, 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15731</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 1 instance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>WV15758</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 82, 83, 84, 85, 86, 92, 94, 95, 97, 106, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 documents with 424 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15759</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 94, 95, 95, 109, 113, 114, 121, 122, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 12 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>WV15799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137, 139, 139, 232, 233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 documents with 499 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15812</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107, 107, 108, 108, 121, 121, 122, 123, 224, 246 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 197 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WV15819</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33, 36, 37, 37, 38, 58, 58, 59, 59, 60, 61, 62, 62, 65, 65, 67, 68, 224, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 documents with 173 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15825</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66, 66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15872</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36, 37, 37, 38, 38, 39, 67, 68, 68, 107, 107, 108, 108, 121, 121, 122, 123, 224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 18 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15876</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 2 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15978</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67, 70, 175, 246, 246</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 document with 5 instances</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV16193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ML16369</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Oseltamivir trials citation by trial ID and source NICE file. Page numbers separated by commas (where applicable) indicate which trial is cited where in which file. Blank spaces indicate no citation for known trials. </p> <p>All the studies have been searched in the folder "Roche submission".</p> <p>When there is the number of the volume but no pages are mentioned, it means that the code of the study is cited more than 100 times. </p> <p>*Number of the volume of the Tamiflu NICE submission.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of contents for studies of oseltamivir described in regulatory documentation from NICE (UK)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to alleviation* of clinically significant symptoms of influenza‐like illness (in all participants and participants with no use of relief medication)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Sample size </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Median days to alleviation for all participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference in days </b> </p> <p><b>(P value)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Median days to alleviation and no use of relief medication</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference in days (P value)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.123)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> <p>(0.037)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30009</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.011)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.002)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.033)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25</p> <p>(0.150)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> <p>(0.495)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> <p>(0.623)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.159)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.131)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAI30015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.166)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> <p>(0.058)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIA3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> <p>(0.228)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> <p>(0.054)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAIB3002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> <p>(&lt; 0.001)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 (&lt; 0.001)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>*Alleviation defined as no fever (temperature &lt; 37.8 °C), cough recorded as none or mild and muscle/joint aches and pains, sore throat, feverishness/chills and headache recorded as absent/minimal </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to alleviation* of clinically significant symptoms of influenza‐like illness (in all participants and participants with no use of relief medication)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treating influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults with influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> oseltamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in adult treatment (ITT population) (hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (hours) to first alleviation of symptoms adults in the intervention groups was<br/> <b>16.76 lower</b><br/> (25.1 to 8.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 hours (8.4 to 25.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3954<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (1.14 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐3.66% (‐7.39 to ‐0.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 28 (14 to 112)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/> (73 to 138) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.43</b> <br/> (1.75 to 3.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐4.56% (‐7.58 to ‐2.39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 22 (14 to 42)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/> (56 to 108) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: diarrhoea in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> <br/> (0.46 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2.33% (0.14 to 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 43 (27 to 709)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/> (32 to 69) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: self reported, investigator‐mediated, unverified pneumonia in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.55</b> <br/> (0.33 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4452<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.00% (0.22 to 1.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 100 (67 to 451)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>(7 to 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: cardiac body system in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> <br/> (0.25 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3943<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.68% (0.04 to 1.00)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 148 (101 to 2509)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/> (3 to 13) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: hospital admission in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.57 to 1.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4394</p> <p>(7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.15% (‐0.78 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 687 (NNTB 110 to ∞ to NNTH 128)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> <p>(11 to 28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treating influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children with influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> oseltamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in child treatment (hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (hours) to first alleviation of symptoms in children in the intervention groups was<br/> <b>8.04 lower</b><br/> (33.34 lower to 17.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1329<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospital admission in child treatment (safety population)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b> <br/> (0.7 to 5.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.81% (‐3.72 to 0.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 124 (NNTB 379 to ∞ to NNTH 27)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/> (6 to 46) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b> <br/> (0.27 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.08% (‐1.69 to 2.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 93 (NNTB 45 to ∞ to NNTH 59)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (8 to 48) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: otitis media in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.8</b> <br/> (0.62 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3.26% (‐0.33 to 6.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 31 (NNTB 17 to ∞ to NNTH 308)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/> (101 to 166) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> <br/> (0.62 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1359<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.22% (‐3.07 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 450 (NNTB 71 to ∞ to NNTH 33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/> (23 to 68) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: diarrhoea in child treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b> <br/> (0.58 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1358<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.93% (‐2.01 to 3.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB 108 (NNTB 34 to ∞ to NNTH 50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b><br/> (42 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in child treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.7</b> <br/> (1.23 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1358<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5.34% (1.75 to 10.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 19 (10 to 57)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/> (94 to 179) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harm; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Oseltamivir versus placebo for treating influenza in healthy children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treating influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults with influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> zanamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in adult treatment (days)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (days) to first alleviation of symptoms in adults in the intervention groups was<br/> <b>0.60 lower</b><br/> (0.81 to 0.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 days (0.39 to 0.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5411<br/> (13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia confirmed with X‐ray in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.35 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>946<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.06% (‐6.56 to 2.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 1540 (NNTB 48 to ∞ to NNTH 16)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (11 to 98) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea/vomiting in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.6</b> <br/> (0.39 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6553<br/> (15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.63% (0.24 to 2.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 62 (41 to 411)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/> (16 to 38) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: psychiatric body system in adult treatment (on‐treatment)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/> (0.57 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4732<br/> (10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.09% (‐0.76 to 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH 1132 (NNTB 421 to ∞ to NNTH 132)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (3 to 13) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in adult treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.61 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6072</p> <p>(12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.80% (0.65 to 2.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB 56 (36 to 155)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> <p>(44 to 65)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treating influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children with influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> zanamivir versus placebo for treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first alleviation of symptoms in children (days)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean time (days) to first alleviation of symptoms in children in the intervention groups was<br/> <b>1.08 lower</b><br/> (2.32 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>723<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: sinusitis in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b> <br/> (0.12 to 6.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>737<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.19% (‐8.09 to 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 519 (NNTB 13 to ∞ to NNTH 77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/> (2 to 96) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: otitis media in child treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> <br/> (0.59 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>737<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.00% (‐5.13 to 2.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = &gt; 1000 (NNTB 35 to ∞ to NNTH 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (42 to 122) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zanamivir versus placebo for treating influenza in healthy children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for preventing influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children without influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> oseltamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; RR: risk ratio </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0012"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for preventing influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults without influenza<br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> zanamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for prophylaxis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in prophylaxis of individuals</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.39</b> </p> <p>(0.22 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5275</p> <p>(4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.98% (0.98 to 2.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 51 (40 to 103)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/> (7 to 23) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic influenza in prophylaxis of individuals</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/> (0.76 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5275<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.14% (‐1.1 to 1.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 729 (NNTB 91 to ∞ to NNTH 91)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><br/> (38 to 60) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in household prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.22</b> <br/> (0.13 to 0.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>824<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14.84% (12.18 to 16.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 7 (6 to 9)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (25 to 68) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic influenza in household prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/> (0.6 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>824<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1.32% (‐2.2 to 3.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 76 (NNTB 26 to ∞ to NNTH 46)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>107 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b><br/> (64 to 145) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: pneumonia in adult prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.30</b> <br/> (0.11 to 0.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7662<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.32% (0.09 to 0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 311 (244 to 1086)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.5 per 1000</b><br/> (1 to 4) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications: bronchitis in adult prophylaxis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.49</b> </p> <p>(0.02 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7662</p> <p>(6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.79% (‐0.29 to 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 127 (to NNTB 81 to ∞ to NNTH 341)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> <p>(3 to 18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0013"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy adults</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for preventing influenza in healthy adults</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults without influenza <br/> <b>Settings:</b> community, nursing homes<br/> <b>Intervention:</b> oseltamivir for prophylaxis<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Risk difference (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NNTB or NNTH (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir versus placebo for prophylaxis</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in adult prophylaxis of individuals</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.45</b> <br/> (0.30 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2479<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3.05% (1.83 to 3.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 33 (26 to 55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (17 to 37) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic influenza in household prophylaxis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.2</b> <br/> (0.09 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>405<br/> (1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13.6% (9.52 to 15.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 7 (6 to 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (15 to 75) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: psychiatric body systems in adult prophylaxis (all events on‐ and off‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.80</b> <br/> (1.05 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐1.06% (‐2.76 to ‐0.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 94 (36 to 1538)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b><br/> (14 to 40) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: headache in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.18</b> <br/> (1.05 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐3.15% (‐5.78 to ‐0.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 32 (18 to 115)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b><br/> (184 to 233) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: nausea in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.96</b> <br/> (1.2 to 3.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐4.15% (‐9.51 to ‐0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 25 (11 to 116)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (52 to 138) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: vomiting in adult prophylaxis (on‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.91</b> <br/> (0.7 to 5.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐0.95% (‐4.41 to 0.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTH = 106 (NNTB 319 to ∞ to NNTH 23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (7 to 55) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: headache in adult prophylaxis (off‐treatment)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> <br/> (0.63 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3434<br/> (4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.44% (‐0.89 to 1.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 226 (NNTB 74 to ∞ to NNTH 113)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (23 to 46) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Negative risk differences indicate harms; positive risk differences indicate benefits.<br/> CI: confidence interval; RR: risk ratio; NNTB: number needed to treat to benefit; NNTH: number needed to treat to harm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Oseltamivir versus placebo for preventing influenza in healthy adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0014"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for preventing influenza in healthy children</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy children without influenza<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> zanamivir versus placebo for prophylaxis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zanamivir versus placebo for treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; RR: risk ratio </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Zanamivir versus placebo for preventing influenza in healthy children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0015"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Psychiatric adverse events in oseltamivir prophylaxis trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oseltamivir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Event type</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p># Events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hallucinations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bipolar disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping disorder</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stress symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restlessness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide ideation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paranoia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alcohol related</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.92</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Of the 66 events, 12 were classified as severe intensity (10 oseltamivir, 2 placebo)</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Psychiatric adverse events in oseltamivir prophylaxis trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0016"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Proportions of contacts with positive serology data (WV15799 ITTIINAB population)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Positive </b> </p> <p><b>serology</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>N</b> </p> <p><b>% </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tamiflu</b> </p> <p><b>N</b> </p> <p><b>% </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> 83.0 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192<br/> 93.7 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Yes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> 17.0 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<br/> 6.3 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ITTIINAB population: ITT influenza‐infected index cases who had negative virology at baseline </p> <p>Chi² P = 0.001</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Proportions of contacts with positive serology data (WV15799 ITTIINAB population)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/full#CD008965-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008965-tbl-0022"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Oseltamivir and placebo intervention contents by trial</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description oseltamivir/batch no.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description placebo/batch no.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certified content</b> </p> <p><b>(oseltamivir)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Certified content</b> </p> <p><b>(placebo)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ref (PDF page number)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M76001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size 2 capsules containing 75 mg oseltamivir/V01‐00 (GS 4104), batch number GMZ 0082</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size 2 placebo capsules for oseltamivir/V02‐00 (GS 4104), batch number GMZ 0083</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WP16263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grey opaque body, light yellow opaque cap/PT2247C01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grey opaque body, ivory opaque cap/GMZ 0163</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 97.5 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 and 422</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size 2 capsules containing 75 mg Ro 64‐0796/V01‐00 (GS 4104), batch number GMZ 0067; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size 2 placebo capsules for Ro 64‐0796/V02‐00 (GS 4104), batch number GMZ 0066; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 94.3 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid 6.13 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13, 834‐5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15671</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Capsules (size 2) containing 75 mg Ro 64‐0796 (GS 4104)/V01; batch number GMZ 0067/GMZ 0065. Capsules are caramel opaque body, caramel opaque cap. Also used batch GMZ 0067 capsules caramel opaque body, caramel opaque cap (for oseltamivir 94.3 mg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching placebo capsules (size 2) for Ro 64‐0796 (GS  4104)/V02; batch number GMZ 0066. Capsules are caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 93.1 mg and oseltamivir 94.3 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid 6.13 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13, 764‐7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15673/WV15697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GS 4104 (Ro 64‐0796) provided as size 2 caramel‐coloured capsules containing 75 mg of active drug and packaging material consisting of dehydrocholic acid, dibasic calcium phosphate dihydrate, pregelatinised starch, povidone, talc and sodium stearyl fumarate." Ro 64‐0796/V01‐00 batch GMZ 0067; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo provided as size 2 caramel‐coloured capsules, containing dehydrocholic acid, dibasic calcium phosphate dihydrate, pregelatinised starch, povidone, talc and sodium stearyl fumarate Ro64‐0796/V02‐00 batch GMZ 0066; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.3 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid 6.13 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385, 540‐2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15707</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 64‐0796 was provided as a size 2 capsule containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. Ro 64‐0796 (GS4104)/V01‐00 batch number GMZ 0082 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo was provided as a size 2 capsule containing dehydrocholic acid, dibasic calcium phosphate dihydrate and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. Placebo Ro 64‐0796/V02‐00 batch number GMZ 0066 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 64‐0796/002 100.5 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 517‐9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15708</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Size 2 capsules of 75 mg; Ro 64‐0796/V01‐00 batch no. GMZ 0082; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching size 2 placebo capsules Ro 64‐0796/V02‐00 batch no. GMZ 0083; caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 100.5 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐2, 517‐9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15730</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro  64‐0796 was provided as a caramel, opaque, size 2 capsule containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. Ro 64‐0796 (GS4104)/V01‐00 batch number GMZ 0082 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo was provided as a caramel, opaque, size 2 capsule containing dehydrocholic acid, dibasic (calcium phosphate dihydrate and packaging material consisting of  pregelatinised starch, povidone, talc and sodium  stearyl fumarate. Placebo Ro  64‐0796/V02‐00 batch number GMZ 0083 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 100.5 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 504‐5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15758</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 batches of the paediatric formulation were used in the present study:</p> <p>1. Ro 64‐0796/V20‐01 (0.6% syrup); batch no. G HK 0180/05</p> <p>2. Ro 64‐0796/V20‐01 (0.6% syrup); batch no. G HK 0180/06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 batches of the corresponding placebo formulation were used:</p> <p>1. Ro 64‐0796/V19‐01; batch no. G HK 0179/04</p> <p>2. Ro 64‐0796/V19‐01; batch no. G HK 0179/05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 0.768 g (G HK 0180/05), 0.763 g (G HK 0180/06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27, 1043‐5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15759/15871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 64‐0796 was to be provided as a dry powder for reconstitution with water. The powdered formulation contains the active ingredient, sorbitol and saccharin sodium (sweeteners), betacarotene (colouring agent), permageal 31 tutti frutti (flavour), cellulose, xanthan gum and methylhydroxy/propylhydroxybenzoate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificates of analysis not in our possession)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificates of analysis not in our possession)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 64‐0796 was provided as ivory, opaque, size 2 capsule containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. Ro 64‐0796 (GS4104)/V14‐00 batch numbers GMZ 0124/03 and GMZ 0129/03 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo was provided as an ivory, opaque, size 2 capsule containing dehydrocholic acid, dibasic calcium phosphate dihydrate and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. Placebo Ro 64‐0796/V16‐00 batch number GMZ 0136 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificates of analysis not in our possession)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificates of analysis not in our possession)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15812/WV15872</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ro 64‐0976 was provided as size 2 capsules containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching placebo was provided as size 2 capsules containing dehydrocholic acid, dibasic calcium phosphate dihydrate, pregelatinised starch, povidone, talc, sodium stearyl fumarate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV15876/WV15819/WV15978</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Capsules (size 2) containing 95.8 mg oseltamivir phosphate, equivalent to 75 mg oseltamivir: formulation V14; batch numbers GMZ 0124/03, GMZ 0129/03. Both batches: grey opaque body, ivory opaque cap </p> <p>The following statement appears after the description of the placebo; whether it applies to oseltamivir capsules is unclear: "Excipients for each capsule consisted of dehydrocholic acid, dibasic calcium diphosphate dihydrate, pregelatinized starch, povidone, talc, sodium stearyl fumarate." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching placebo capsules (size 2) for oseltamivir: formulation V16; batch numbers GMZ 0136, GMZ 0163. Both batches: grey opaque body, ivory opaque cap </p> <p>The following statement appears after the description of the placebo; whether it applies to oseltamivir capsules is unclear: "Excipients for each capsule consisted of dehydrocholic acid, dibasic calcium diphosphate dihydrate, pregelatinized starch, povidone, talc, sodium stearyl fumarate." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir 95.7 mg (GMZ 0124/03); 97.9 mg (GMZ 0129/03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dehydrocholic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21, 944‐9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WV16277</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oseltamivir was provided as size 2 capsules containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate.. Oseltamivir: 75 mg capsules, Ro 64‐0796/V14, batch number PT2247C01 </p> <p>Capsules are caramel opaque body, caramel opaque cap</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching placebo was provided as size 2 capsules, containing dehydrocholic acid, dibasic calcium phosphate dihydrate, pregelatinised starch, povidone, talc, sodium stearyl fumarate Matching placebo capsules: Ro 64‐0796/V16, batch number GMZ 0163. Capsules are caramel opaque body, caramel opaque cap </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NV16871</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Capsules containing 75 mg of active drug and packaging material consisting of pregelatinised starch, povidone, talc and sodium stearyl fumarate. All participants over the age of 13 or who weighed &gt; 40 kg received this dosage form. 2. A paediatric suspension containing 12 mg oseltamivir per ml of reconstituted solution and the following excipients: sorbitol, titanium dioxide, sodium benzoate, xanthan gum, monosodium citrate, saccharin sodium and Permaseal 11900‐31 tutti frutti (flavour). All participants of 12 years and under or who weighed ≤ 40 kg received this dosage form or 10 doses </p> <p>Ro 64‐0796/V14 (oseltamivir 75 mg capsules), batch PT2247C01</p> <p>Ro 64‐0796/V37 (oseltamivir powder for oral suspension), batch B1023</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matching placebo was to be provided as capsules and as suspension</p> <p>Ro 64‐0796/V16 (placebo capsules), batch GMZ 0163</p> <p>Ro 64‐0796/VF01 (placebo powder for oral suspension), batch C0318A001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown (certificate of analysis not provided)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13‐14, 24</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NB Most content dosage unavailable at review time‐lock.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Oseltamivir and placebo intervention contents by trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/appendices#CD008965-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008965-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oseltamivir versus placebo for treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to first alleviation of symptoms in adult treatment (ITT population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.76 [‐25.10, ‐8.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admission in adult treatment (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.57, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Defined as influenza‐infected at baseline in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Antibody rise four‐fold or greater in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events ‐ nausea in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.14, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events ‐ vomiting in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.75, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events ‐ diarrhoea in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.46, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal from adult treatment trial due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All withdrawals from adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events ‐ cough in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.41, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events ‐ abdominal pain in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.64, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: dizziness in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: headache in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.72, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serious adverse events: overall in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.51, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serious adverse events: overall in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.39, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Complications: bronchitis in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.56, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Trials which collected data on non‐specific adverse event or secondary/intercurrent illness form </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.42, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Trials which collected data on specific "Diagnosis of secondary illness" form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Complications: pneumonia in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Trials which collected data on non‐specific adverse event or secondary/intercurrent illness form </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.22, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Trials which collected data on specific "Diagnosis of secondary illness" form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.33, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Complications: sinusitis in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.76, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Trials which collected data on non‐specific adverse event or secondary/intercurrent illness form </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.74, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Trials which collected data on specific "Diagnosis of secondary illness" form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.52, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Complications: otitis media in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.57, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Trials which collected data on non‐specific adverse event or secondary/intercurrent illness form </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.46, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Trials which collected data on specific "Diagnosis of secondary illness" form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.41, 6.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Complications in adult trials classified as serious or leading to study withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.40, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Culture‐positive at baseline in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events: general body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events: neurological body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.80, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events: respiratory body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events: infection body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events: gastrointestinal body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.08, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events: cardiac body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.25, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events: ear body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.61, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events: eye body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.52, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events: metabolism body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.46, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events: musculoskeletal body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.59, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events: psychiatric body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.43, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events: skin body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.63, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Adverse events: cardiac body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.55, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Adverse events: ear body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.57, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Adverse events: gastrointestinal body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.74, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Adverse events: general body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.50, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Adverse events: infection body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Adverse events: musculoskeletal body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.54, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Adverse events: neurological body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.87, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Adverse events: respiratory body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Adverse events: skin body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.42, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Adverse events: cough in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.55, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Adverse events: headache in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.83, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Adverse events: nausea in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.50, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Time to first alleviation of symptoms in child treatment [hours] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.04 [‐33.34, 17.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 Otherwise healthy children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.40 [‐47.04, ‐11.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 Children with chronic asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.18 [‐11.06, 21.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Hospital admission in child treatment (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.70, 5.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Defined as influenza‐infected at baseline in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 Antibody rise four‐fold or greater in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 Complications: bronchitis in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.27, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Complications: otitis media in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 Complications: pneumonia in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.62, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 Complications: sinusitis in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 Complications: pneumonia in child treatment by on‐ and off‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 On‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.48, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 Off‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.52, 15.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 Complications in trials of children classified as serious or leading to study withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.58, 6.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 Withdrawal from child treatment trial due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.33, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 All withdrawals from child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.56, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 Serious adverse events: overall in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.59, 6.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 Serious adverse events: overall in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.38, 8.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 Adverse events: abdominal pain in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.62, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 Adverse events: diarrhoea in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 Adverse events: nausea in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.50, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 Adverse events: vomiting in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.23, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 Adverse events: abdominal pain in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.39, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 Adverse events: cough in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 Adverse events: diarrhoea in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Adverse events: headache in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.55, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68 Adverse events: vomiting in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.57, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69 Adverse events: ear body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.30, 4.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70 Adverse events: gastrointestinal body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.96, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71 Adverse events: general body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.47, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72 Adverse events: infection body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73 Adverse events: neurological body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.17, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74 Adverse events: respiratory body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75 Adverse events: skin body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.71, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76 Adverse events: ear body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.52, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77 Adverse events: gastrointestinal body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.69, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78 Adverse events: general body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79 Adverse events: infection body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80 Adverse events: neurological body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.51, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">81 Adverse events: respiratory body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.65, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">82 Culture‐positive at baseline in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oseltamivir versus placebo for treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008965-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oseltamivir versus placebo for prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic influenza in adult prophylaxis of individuals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.30, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asymptomatic influenza in adult prophylaxis of individuals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic influenza in household prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.09, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asymptomatic influenza in household prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.39, 3.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Influenza‐like illness reported as adverse event (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.73, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Influenza‐like illness reported as adverse event (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.34, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hospitalisation in adult prophylaxis (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Complications: bronchitis in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.41, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Complications: sinusitis in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.75, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events leading to study withdrawal in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.57, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All withdrawals in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.82, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serious adverse events in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.53, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serious adverse events in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.57, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: abdominal pain in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.77, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events: cough in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.68, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: diarrhoea in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.64, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: dizziness in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse events: fatigue in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.89, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse events: headache in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.05, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse events: nausea in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.20, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events: vomiting in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.70, 5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events: cough in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.36, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events: fatigue in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.57, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events: headache in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events: blood body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.30, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events: cardiac body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.36, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events: ear body system in adult prophylaxis (on treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.61, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events: eye body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.56, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.17, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events: general body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events: infection body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events: immune body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.45, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events: injury body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Adverse events: metabolism body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.73, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Adverse events: neurological body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.03, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.97, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Adverse events: renal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.96, 10.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Adverse events: reproductive body system in adult prophylaxis (on treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Adverse events: respiratory body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Adverse events: skin body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Adverse events: surgical events in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.42, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Adverse events: vascular body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.45, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Adverse events: cardiac body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.67, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.62, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Adverse events: general body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Adverse events: infection body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Adverse events: injury body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.49, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 Adverse events: musculoskeletal body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.63, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 Adverse events: neurological body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Adverse events: reproductive body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.24, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 Adverse events: respiratory body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.69, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 Adverse events: skin body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.32, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 Adverse events: psychiatric body system in adult prophylaxis (on and off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.05, 3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 Adverse events: renal body system in adult prophylaxis (on and off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.74, 5.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oseltamivir versus placebo for prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008965-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Zanamivir versus placebo for treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to first alleviation of symptoms in adult treatment (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.81, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Complications: pneumonia in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Complications: pneumonia confirmed with X‐ray in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.35, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complications: bronchitis in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complications: sinusitis in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.84, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Complications: otitis media in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Complications in adult trials classified as serious or leading to study withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.46, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proportion diagnosed as influenza‐infected in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.98, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Proportion with four‐fold rise in antibody titre in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proportion with positive culture at baseline in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serious adverse events in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events leading to study withdrawal in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.66, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 All withdrawals in adult treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Time to first alleviation of symptoms in children (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.32, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Complications: pneumonia in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.12, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Complications: bronchitis in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.26, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Complications: sinusitis in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.12, 6.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Complications: otitis media in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Proportion diagnosed as influenza‐infected in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Proportion with four‐fold increase in antibodies in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Proportion with positive culture at baseline in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 All withdrawals in child treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.16, 8.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events: nausea and vomiting in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events: diarrhoea in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.15, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events: gastrointestinal body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events: respiratory body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events: neurological body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.20, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events: ear, nose and throat body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.63, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events: skin body system in child treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.34, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events: gastrointestinal body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.50, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events: ear nose and throat body system in child treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.54, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events: nausea/vomiting in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events: diarrhoea in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Adverse events: dizziness in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.68, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Adverse events: headache in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Adverse events: cough in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Adverse events: gastrointestinal body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Adverse events: respiratory body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Adverse events: neurological body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Adverse events: ear, nose and throat body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Adverse events: skin body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Adverse events: musculoskeletal body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.49, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Adverse events: eye body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.55, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Adverse events: hepato body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.39, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Adverse events: renal body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.41, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Adverse events: cardiovascular body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.50, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Adverse events: blood body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Adverse events: psychiatric body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.57, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 Adverse events: reproduction body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.33, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 Adverse events: endocrine and metabolic body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.58, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Adverse events: injury body system in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.57, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 Adverse events: non‐site specific events in adult treatment (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.78, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 Adverse events: nausea/vomiting in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.67, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 Adverse events: cough in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.71, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 Adverse events: respiratory body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 Adverse events: headache in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 Adverse events: diarrhoea in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.59, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 Adverse events: fatigue in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.37, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 Adverse events: gastrointestinal body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 Adverse events: neurological body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 Adverse events: ear, nose and throat in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 Adverse events: skin body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.68, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 Adverse events: musculoskeletal body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.87, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 Adverse events: non‐site specific in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 Adverse events: injury body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.60, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 Adverse events: endocrine and metabolic body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.49, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Adverse events: eye body system in adult treatment (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.55, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68 Time to first alleviation of symptoms in adults with/without relief medication [days] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.47, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69 Time to first alleviation of symptoms in adults by infection status [days] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.78, ‐0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1 Influenza‐infected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐0.99, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.2 Not influenza‐infected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.86, ‐0.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Zanamivir versus placebo for treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008965-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zanamivir versus placebo for prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic influenza in prophylaxis of individuals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asymptomatic influenza in prophylaxis of individuals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic influenza in post‐exposure prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.18, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Household prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.13, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Other prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.30, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asymptomatic influenza in post‐exposure prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complications: pneumonia in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Complications: bronchitis in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.20, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Complications: sinusitis in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.64, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Complications classified as serious or leading to study withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.36, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.65, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events leading to study withdrawal in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All withdrawals in adult prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: abdominal pain in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.55, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: cough in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: diarrhoea in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.73, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events: dizziness in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.59, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: fatigue in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: headache in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse events: blood body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.62, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse events: nausea/vomiting in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.66, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse events: cardiovascular body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.77, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events: ear, nose and throat body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events: endocrine and metabolic body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events: eye body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events: gastrointestinal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events: injury body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.62, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events: musculoskeletal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events: neurological body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events: non‐site specific in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.85, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events: psychiatric body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.48, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse events: renal body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse events: reproductive body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Adverse events: respiratory body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Adverse events: skin body system in adult prophylaxis (on‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.58, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Adverse events: gastrointestinal body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Adverse events: respiratory body system in adult prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Adverse events: nausea/vomiting in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.39, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Adverse events: diarrhoea in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.54, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Adverse events: headache in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Adverse events: cough in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.99, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Adverse events: fatigue in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Adverse events: neurological body system in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Adverse events: ear, nose and throat in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.84, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Adverse events: musculoskeletal body system in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.77, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Adverse events: non‐site specific in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Adverse events: injury in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.34, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Adverse events: endocrine and metabolic in prophylaxis (off‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.60, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zanamivir versus placebo for prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008965-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Neuraminidase inhibitor versus placebo for treatment or prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Complications: pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Unclear diagnostic confirmation capture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.35, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Clear diagnostic confirmation capture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.69, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Neuraminidase inhibitor versus placebo for treatment or prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008965.pub4/references#CD008965-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008965.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008965-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008965-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008965-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008965-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008965-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008965-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008965-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008965-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008965-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008965\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008965\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008965\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008965\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008965\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008965.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008965.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008965.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008965.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008965.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715101519"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008965.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715101522"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008965.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7ed928051bde',t:'MTc0MDcxNTEwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 